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SUMMARY
The long repeat region of HSV-1 contains the diploid RLl gene which encodes the protein 
ICP34.5, a 43K polypeptide of 263 amino acids in HSV-1 strain F and a 37K polypeptide 
of 248 amino acids in HSV-1 strain 17+ infected cells (Ackermann et aL, 1986; Chou and 
Roizman, 1986, 1990; McKay e ta l, 1993). The role of RLl in virulence of HSV-1 has 
been studied by Chou etal (1990), MacLean, A et al (1991) and McKie et al (1994). The 
discovery of the RLl gene in HSV-1 was followed by sequencing data of the 
corresponding region of HSV-2 strain HG52 which indicated that HG52 possesses a 
counterpart of the HSV-1 RLl gene (McGeoch et al., 1991). The organization of HG52 
RLl differs from that of HSV-1 although both initiation codons are in equivalent positions. 
The coding sequence of HG52 RLl lacks the (PAT)io repeat element and is disrupted by a 
reiterated sequence proposed to be an intron. Removal of this intron results in a second 
exon containing a 63-amino acids HSV-l/HSV-2 conserved region, being in frame. To 
characterise the functional domains of the HSV-2 RLl gene, three mutant viruses have 
been constructed and characterized: (1) 2620, with a stop codon within the conserved 
region, 46 amino acids upstream of the 3' end of RLl (2) 2621, with an in frame stop 
codon 9bp downstream of the initiating ATG and (3) 2622, in which the proposed intron 
has been apparently deleted. The mutant viruses 2620, 2621 and 2622 were characterized 
in vivo following intracerebral inoculation of Balb/c mice and in vitro using BHK21/C13 
and 3T6 mouse embryo fibroblast cells. The mutant 2621 was avirulent with a LD50 >10^ 
p.f.u./mouse compared to 3.16x10^ p.f.u./mouse for 2604 and 10^ p.f.u./mouse for HG52. 
The 2620 mutant was also avirulent with a LD50 of 2.37x10^ p.f.u./mouse. The 2622 
mutant was intermediate with a LD50 of 10  ^p.f.u./mouse. The growth of the mutants 2620 
and 2621 was not impaired in BHK21/C13 but was impaired in 3T6 cells. The growth of 
2622 was comparable to that of the wild-type HG52 in BHK21/C13 cells and intermediate 
between HG52 and the avirulent deletion mutant 2604 in 3T6 cells.
Rescuants of the mutants (R2620, R2621, R2622) were generated by in vitro and in vivo 
marker rescue. Those generated by in vitro marker rescue demonstrated an intermediate
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virulence phenotype. Rescuants, generated by in vivo marker rescue, except for R2620 
were restored to the full virulence phenotype of the wild-type HG52 pi. 17. A secondary 
mutation in the genome of 2620 and its rescuants generated by in vitro marker rescue 
could explain failure of the R2620 rescuants to return to wild-type virulence. The 
secondary mutation could be due to passage of the virus during purification and/or 
virulence heterogeneity within the HG52 pi. 17 stock. Individual plaques of HG52 pi. 17 
demonstrated variable virulence phenotypes. The rescuants generated in vitro and 
individual plaques of HG52 pi. 17 were characterised by growth in 3T6 cells which 
differentiates between ICP34.5 positive and negative virus. The 3T6 growth and plaque 
morphology strongly discount a possible mutation in RLl which should be confirmed 
when an antiserum against ICP34.5 of HG52 becomes available. It seems that the growth 
phenotype of HG52 variants in vitro does not always mimic the in vivo phenotype thus 
emphasising the necessity of the animal model to determine virulence. The demonstrated 
heterogeneity of the HG52 pi. 17 stock emphasises the necessity of in vivo marker rescue 
experiments to confirm the phenotype of constructed mutants.
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CHAPTER 1
INTRODUCTION
CHAPTER 1: INTRODUCTION
Herpes simplex virus (HSV) is a member of the family Herpesviridae which includes 
many viruses of medical and veterinary importance. Herpes simplex virus types 1 and 2 
(HSV-1 and HSV-2) which belong to the subfamily Alphaherpesvirinae are among eight 
human herpes viruses characterised to date. HSV is a neurotropic virus responsible for a 
broad spectrum of clinical diseases ranging from relatively benign recurrent cutaneous 
lesions to fatal encephalitis. The life cycle of HSV includes acute, latent and recurrent 
phases. In acute infection, the genes of HSV are expressed and the extent of disease is 
controlled by the cellular and humoral responses of the host. In latent infection, gene 
expression is repressed except for a limited region of the HSV genome encoding 
latency-associated transcripts (LATs). Latency in HSV represents a challenging problem 
in understanding how a virus which can kill most cell types remains mostly 
asymptomatically in humans for life without destroying the sensory neurons in which it 
resides. HSV can emerge intermittently from sensory neurons to cause a recurrent 
peripheral infection. The mechanism by which the productive pattern of gene expression 
in acutely-infected neurons switches to a latent state and how HSV reactivates remain 
unanswered questions in HSV biology.
In this chapter, HSV infections and the structure of HSV are discussed in sections 1.1-
1.4. Sections 1.5 and 1.6 are devoted to the lytic and latent phases of HSV infection. 
Special attention is given to genes coding for proteins or glycoproteins involved in 
virulence of HSV [section 1.7]. The aims of the project are outlined in section 1.8.
1.1. Herpes simplex virus infections
Two herpes simplex virus (HSV) serotypes have been identified: HSV type 1 (HSV-1) 
and HSV type 2 (HSV-2). Differentiation of HSV-1 and HSV-2 has been based upon 
pock size studies on chorioallantoic membranes (Rodgers, 1973), neutralisation 
(Nahmias and Dowdle, 1968), monoclonal antibody-based assay and restriction enzyme 
analysis (Lonsdale et a l, 1979; Buchman et al., 1981). Serological studies have
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demonstrated that HSV-1 infections are generally acquired during childhood and by 60 
years of age, up to 90% of the population have antibodies to HSV-1 (Nahmias et a l, 
1970). HSV-2 infections are usually not acquired until puberty and are correlated with 
sexual activity. Recent studies (Johnson e ta l, 1989) have shown that the seroprevalence 
of HSV-2 antibody rises with increasing age in the post-adolescent years, an 
epidemiological pattern typical of a sexually transmitted disease (Kinghom, 1993).
HSV causes genital infections, gingivostomatitis, conjunctivitis, herpetic whitlow and 
keratitis. HSV ocular infections affect approximately 500 000 people in the U.S.A. each 
year (Liesengang, 1988; Binder, 1977). HSV encephalitis is the most commonly 
reported viral infection of the CNS, accounting for 10%-20% of all viral encephalitis 
in the U.S.A. (Wiedbrauk and Johnson, 1993). Patients compromised by either immune 
therapy, underlying disease or malnutrition are at increased risk from HSV recurrent 
infection (Whitley, 1990).
Historically, HSV-1 has been associated with oral infections, while HSV-2 has been 
associated with genital infections. This distinction is no longer valid as today, 30-50% of 
genital herpes infections are caused by HSV-1 (Kalinyak eta l, 1977; Smith e ta l, 1977; 
Kinghom, 1993) and 5-20% of oral infections are caused by HSV-2 (Wiedbrauk and 
Johnston, 1993). The increased incidence of genital herpes has caused an increase in the 
incidence of neonatal herpes (Sullivan-Bolyai et a l, 1983; Whitley et a l, 1991). 
Neonatal HSV infection remains life-threatening for the newborn in all countries. 
Genital HSV infection results in 1600 cases of neonatal herpes yearly in the U.S.A. 
(Whitley, 1990).
1.2. Virion structure
HSV virions consist of three morphological structures: an icosahedral nucleocapsid, an 
amorphous tegument surrounding the capsid and an outer envelope which exhibits 
glycoprotein spikes (reviewed by Dargan, 1986 and Rixon, 1993). The HSV capsid is 
approximately 125nm in diameter, exhibiting 5:3:2 axial symmetry and is composed of 
162 capsomeres, of which 150 are hexameric (hexons) and 12 pentameric (pentons) and
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320 triplexes that provide intercapsomeric connections (Wildy et al., 1960; Schrage et 
al., 1989; Zhou et al., 1994). Three capsid forms have been observed and purified from 
wild type virus-infected cells: (i) empty capsids (type A) which lack viral DNA, (ii) 
intermediate capsids (type B) which lack viral DNA and possess 2 proteins not found in 
A capsids, VP21(UL26 C-terminus) and VP22a(UL26.5) which occupy the inner capsid 
space and are thought to act as scaffolding proteins that are released when DNA 
packaging occurs (Rixon et al., 1988) and (iii) full capsids (type C) which contain viral 
genomes and are the immediate precursors of mature virions that undergo tegumentation 
and envelopment before being released from the cell (Gibson and Roizman, 1972; 
Atkinson et al., 1978; Furlong et al., 1972; Rixon, 1993). The capsid is composed of 
seven proteins: VP5 (UL19), VP19C (UL38), VP23 (UL18), and VP26 (UL35),VP22a 
(UL26.5), VP21 (UL26 C-terminus), VP24 (UL26 N-terminus), (Braun etal., 1984a,b; 
Costa et al., 1984; Newcomb and Brown, 1989, 1991; Rixon, 1993) and is surrounded 
by an amorphous layer, the tegument (Roizman and Furlong, 1974). The tegument 
contains proteins which function in very early and in late events in the replication 
cycle. Some of the viral proteins which are contained within the tegument include 
Vmw65(aTIF) (Batterson and Roizman, 1983; Campbell et al., 1984), the virion host 
shutoff {vhs) protein (Fenwick, 1984; Smibert et al., 1992), VP 1/2 (UL36) (Chou and 
Roizman, 1989; McNabb and Courtney, 1992), VP13/14(UL47) (McGeoch etal., 1993; 
McKnight et al., 1987; Zhang et al., 1991), VP22(UL49) (McGeoch et al., 1993; Elliot 
and Meredith, 1992) and the UL37 product which is a yl phosphoprotein (Schmitz et a l, 
1995). Vmw 175 has been localised to the tegument of light particles (Yao and Courtney, 
1989; McLauchlan and Rixon, 1992). Other proteins have been identified as components 
of the virus particle and are assumed to be located within the tegument. These include 
proteins encoded by U Lll (MacLean et a l, 1989; Baines and Roizman, 1992), UL13 
(Rubenstein et a l, 1972; Lemaster and Roizman, 1980; Overton et al., 1992); US9 
(Frame e ta l, 1986) and U Sll (Roller and Roizman, 1992).
The tegument is completely enclosed in a trilaminar membrane envelope (Wildy et a l, 
1960; Darlington and Moss, 1968) of mean diameter 180nm which has surface spikes 8 -
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lOnm long spaced 5nm apart (Wildy et ai, 1960). Use of monoclonal antibodies coupled 
to immunogold labelling allowed identification of some viral glycoproteins (gB, gC and 
gD) projecting from the virion envelope (Stannard et aL, 1987). To date, 10 HSV-1 
glycoproteins have been identified: gB(UL27), gC(UL44), gD(US6 ), gE(US8 ), 
gG(US4), gH(UL22), gI(US7), gK(UL53), gL(ULl) and gM(ULlO) (Spear, 1976; 
Frame et a i, 1986, Buckmaster et a i, 1984; Sullivan and Smith, 1988; Longnecker et 
al., 1987; Hutchinson et a l, 1992a,b; Ramasway and Holland, 1992; Baines and 
Roizman, 1993). An 11th gene, US5 is predicted to encode the glycoprotein gJ 
(McGeoch et a l, 1993). In addition to the glycoproteins, the envelope contains cell 
lipids (Asher et a l, 1969).
1.3. Structure and organisation of the HSV genome
HSV DNA is linear, double-stranded (Becker et a l, 1968) and contains 152 kilobase 
pairs (McGeoch e ta l, 1986; Perry and McGeoch, 1988). The genome of HSV-2 has not 
been completely sequenced, but DNA hybridisation and comparison of DNA sequences 
have demonstrated that it is highly related to HSV-1 with a slightly higher G+C content 
of 68.3% compared to 67% (Kieff et a l, 1972; Davison and Wilkie, 1983; McGeoch et 
al., 1988a). To date, the coding sequences of corresponding genes show in general 70- 
80% identity with one major exception: the coding sequence of HSV-2 US4 (gG2) 
contains an extra sequence of about 1460bp (McGeoch et a l, 1987). Moreover, the 
coding sequence of the HSV-2(HG52) RLl gene is predicted to be interrupted by an 
intron which is absent in that of HSV-1 (McGeoch et al., 1991). The non-coding 
regions, in particular the major repeats, typically show greater differences and in some 
cases have become highly diverged (Davison and Wilkie, 1981; Whitton and Clements, 
1984).
The HSV-1 and HSV-2 genomes consist of two covalently joined segments, designated 
long (L) and short (S). Each component is composed of a unique sequence (U l, Us) 
flanked by terminal and inverted repeat sequences (TR, IR). The repeats of the L- 
component, T R l and IR l are respectively designated a b and a' b\ while those of the S
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component, TRs and IRs, are respectively designated a ’ c’ and c a (Wadsworth et a l, 
1975). The organisation of the HSV genome is illustrated in Fig. 1.1. The genome of 
HSV-1 encodes at least 77 genes, 59 map in U l, 13 map in Us and two copies of 4 
genes map in the repeated sequences (McGeoch e ta l, 1985,1986,1988a, 1993; Liu and 
Roizman, 1991a, Barker and Roizman, 1992; Barnett et a l, 1992, Georgopoulou et al, 
1993). The genes identified to date in HSV-1 are listed in Table 1.1. The most recent 
77th gene designated ORF P, has been identified by Lagunoff and Roizman (1994).
The L and S genome components invert relative to one another giving four equimolar 
isomers (Fig. 1.1) termed P (prototype), I I  (inversion of the L component). Is (inversion 
of the S component) and ISL (inversion of both S and L components) (Sheldrick and 
Berthelot, 1974, Hayward e ta l, 1975; Clements e ta l, 1976; Wilkie and Cortini, 1976; 
Roizman, 1979). Due to isomérisation, restriction enzyme analysis of DNA yields three 
classes of fragments (Clements e ta l, 1976; Skare and Summers, 1977) which occur at 
different frequencies. Fragments derived entirely from the Us and U l regions appear in 
IM quantities relative to the molarity of intact viral DNA. As each terminus is present in 
only 2 of the 4 isomers, terminal sequence fragments are present in 0.5M quantities 
while fragments which consist of the joint sequences are present in only 1 of the 4 
isomers so are in 0.25M quantities (Wilkie and Cortini, 1976; Skare and Summers, 
1977).
1.4. The 'a* sequence
The ‘a ’ sequence which varies in size from 250-550bp is a sequence found as a direct 
repeat at the termini and an inverted repeat at the L/S junction of the HSV genome. 
Tandem reiterations (1-5 copies) of the ‘a ’ sequence are found at the L terminus and the 
L/S junction, but only a single copy is found at the S terminus (Wilkie, 1976; Wagner 
and Summers, 1978). The structure of the ‘a ’ sequence is highly conserved consisting of 
both unique (U) and direct repeat (DR) sequences and is represented as: DRl-Ub-DR2n- 
DR4m-Uc-DRl (Fig. 1.2). Ub and Uc are named by virtue of their proximity to the b' 
and c' repeated regions, respectively. Adjacent ‘a ’ sequences share the intervening DRl
Figure 1.1. Structure of the HSV genome
The HSV genome is shown (A) with unique sequences as solid lines (Ul  and Us). The repeats 
TRl , IRu, IRS and TRg are illustrated as boxes with their component parts a, b, c, and a', b', 
c'. The isomérisation of the HSV-1 genome is illustrated (B). The 4 isomers are: P (prototype), 
IL (L inverted with respect to P), Is (S inverted with respect to P) and IsL (S and L inverted 
with respect to P).
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Table 1.1. The HSV genes identified to date
Gene Protein/ function Status
RLl Neurovirulence factor (ICP34.5) ne
ORF P Encodes a protein of 248 amino acids, function unknown ne
RL2 IE protein; transcriptional regulator (Vmw 110) ne
ULl Glycoprotein L, role in cell entry e?
UL2 Uracil-DNA glycosylase ne
UL3 Function unknown ne
UL4 Function unknown ne
UL5 Component of DNA helicase-primase e
UL6  Associated with virion capsid and involved in
packaging of nascent DNA e
UL7 Function unknown
UL8 Component of DNA helicase primase, DNA replication e
UL8.5 Encodes a protein of 486 amino acids (OBPC),
potential role in HSV DNA replication 
UL9 On-binding protein essential for DNA replication e
ULIO Glycoprotein M (gM) ne
ULl 1 myristylated tegument protein, role in envelopment
and egress of virions ne
UL 12 Deoxyribonuclease, role in maturation/packaging
of nascent DNA e
ULl3 Tegument protein, protein kinase, host shutoff ne
ULl4 Function unknown
ULl5 Role in cleavage of concatemeric DNA e?
ULl6  Function unknown ne
ULl7 Function unknown e
ULl8  Capsid protein triplexes (VP23), involved in cleavage
of concatemeric DNA e
ULl9 Major capsid protein (VP5); constitutes the hexons and
pentons, involved in cleavage of concatemeric DNA e
UL20 Integral membrane protein, role in egress of virions e/ne
UL21 Fimction unknown
UL22 Virion surface glycoprotein H, role in virion entry e
UL23 Thymidine kinase, DNA replication ne
UL24 Function unknown ne
UL25
UL26
UL26.5
UL27
UL28
UL29
UL30
UL31
UL32
UL33
UL34
UL35
UL36
UL37
UL38
UL39
UL40
UL41
UL42
UL43
UL44
UL45
UL46
UL47
UL48
UL49
UL49A
UL50
UL51
UL52
Virion protein; role in capsid maturation and DNA
packaging e
Proteinase, the N-terminal portion is capsid protein
VP24, C-terminal is VP21, involved in capsid assembly e
Scaffolding protein of B capsids (VP22a), processed
by UL26 proteinase, involved in DNA packaging e
Virion surface glycoprotein B, role in cell entry e
Role in capsid maturation/DNA packaging e
ssDNA binding protein (ICP8), essential for DNA
replication e
Catalytic subunit of replicative DNA polymerase e
Nuclear phosphoprotein, function unknown
Role in capsid maturation/DNA packaging
Role in capsid maturation/DNA packaging e
Membrane associated phosphoprotein
Capsid protein (VP26), present on tips of hexons e
Very large tegument protein (ICPl/2; VP 1/2), involved
in cleavage of concatemeric DNA and virion assembly e
Tegument yl phosphoprotein, function unknown, may
have DNA-binding role
Capsid protein (VP19C), component of triplexes e
Ribonucleotide reductase large subunit (Rl) e/ne
Ribonucleotide reductase small subunit (R2) e/ne
Virion protein, host shutoff ne
Subunit of replicative DNA polymerase, increases 
processivity e
Function unknown, probable integral membrane protein ne
Virion surface glycoprotein C, role in cell entry ne
Envelope protein, mediates cell fusion ne
Modulates IE gene transactivation by Vmw65 ne
Tegument protein (VP13/14), modulates IE gene 
transactivation by Vmw65 ne
Major tegument protein (VP16,Vmw65, aTIF), 
transactivate IE genes e
Tegument protein (VP22)
Possible membrane protein ne
Deoxyuridine triphosphatase ne
Function unknown e/ne
Component of DNA helicase-primase e
UL53 Glycoprotein K, role in cell fusion e?
UL54 IE protein, post-translational regulator of gene expression
(ICP27, Vmw63) e
UL55 Function unknown ne
UL56 Function unknown, role in intraperitoneal virulence ne
LAT Family of transcripts expressed during latency, function
unknown, protein-coding capacity uncertain ne
RSI IE protein (ICP4, Vmw 175), transcriptional regulator e
US 1 IE protein (ICP22, Vmw68), transcriptional regulator e/ne
US2 Function unknown ne
US3 Protein kinase ne
US4 Glycoprotein G ne
US 5 Glycoprotein J ne
US6 Glycoprotein D, role in entry e
US7 Glycoprotein I, complex together with gE, role in
cell-to-cell spread and is a receptor for Fc of IgG ne
US 8 Virion surface glycoprotein E, complex together
with gl, role in cell-to-cell spread and is a receptor 
for Fc of IgG ne
US8.5 Function unknown ne
US9 Tegument protein ne
US 10 Virion protein ne
US 11 Virion protein, ribosome associated in infected cells ne
US 12 IE protein, function unknown (ICP47, Vmwl2) ne
e: essential for virus growth in culture cells
ne: non-essential
e/ne: necessity depends on culture conditions or temperature 
e?: the data regarding status is not conclusive
- :  absence of information regarding the status
Adapted from: McGeoch e ta l, 1985,1986,1988a, 1993; Addison e ta l, 1984, 1990; Al- 
Kobaissi eta l, 1991; Liu and Roizman, 1991a; Rosen-Wolff and Darai, 1991; Barker and 
Roizman, 1992; Barnett et aA, 1992; Georgopoulou et a l, 1993, Chang and Roizman, 1993; 
Purves etaL, 1993; Baines and Roizman, 1993; Baradaran e ta l, 1994; Haanes etaL, 1994; 
Lagunoff and Roizman, 1994; Overton et al, 1994; Baines et al, 1995; Schmitz et al.,
1995; Patel and MacLean, 1995.
Figure 1.2. Structure of the HSV-1 ‘a ’ sequence
The HSV genome is shown (A). An expansion of the IRl /IRs junction showing the structure 
of the ‘fl’ sequence (B). The ‘a ’ sequence consists of unique and directly repeated elements. In 
HSV-1 strain F (Mocarski and Roizman, 1981, 1982):
Ub- a unique region located towards the b' region of the genome.
DR lb and DRIq- 20bp elements present as direct repeats at the edge of the ‘a ’ sequence.
DR2- a directly repeated 12bp element present in 19-22 copies.
DR4- a directly repeated 37bp sequence present in 2-3 copies.
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(Mocarski and Roizman, 1981). The size of the ‘a ’ sequence varies from strain to strain 
due to variation in the number of copies of DR2 and DR4. In HSV-l(F), the ‘a ’ 
sequence consists of 20bp of DRl, 65bp of Ub, 12bp of DR2 present in 19-22 copies 
and 37bp of DR4 present in 3 copies, 58bp of Uc and a final copy of DRl (Mocarski and 
Roizman, 1981, 1982). The ‘a ’ sequence appears to be a cw-acting site for inversion as 
insertion of the ‘a ’ sequence elsewhere in the genome (Mocarski et a l, 1980) or deletion 
of the entire internal inverted repeat sequences {a* b* o') leads to additional inversions or 
the loss of the ability of the L and S components to invert respectively (Poffenberger et 
a l ,  1983). Also Chou and Roizman (1985) demonstrated that deletion of DR4 
drastically reduces inversion while deletion of both DR2 and DR4 completely abolishes 
inversion. Deletion of the Ub and Uc domains does not affect the ability of the ‘a ’ 
sequence to mediate inversion. The ‘a ’ sequence was also shown to contain the cis- 
acting sites for the circularisation of the genome after infection, for cleavage of the HSV 
genome into unit length concatamers and for encapsidation of DNA (Mocarski and 
Roizman, 1982; Vlazny eta l, 1982; Varmuza and Smiley, 1985).
In the course of studies on the function of the ‘a ’ sequence, Chou and Roizman (1986) 
reported that the ‘a ’ sequence in HSV-1(F) contains the promoter-regulatory domain and 
transcription initiation site of a diploid gene located in the b sequences of the inverted 
repeats of the L component. A chimeric construct consisting of the ‘a ’ sequence fused to 
a promoterless thymidine kinase gene (tk) was inducible in transfected cells and 
regulated as a yl gene when inserted into the viral genome. The expression of thymidine 
kinase occurred only when the ‘a ’ sequence was oriented with Ub adjacent to tk while 
no expression occurred when Uc was adjacent. Nucleotide sequence analysis revealed 
the presence of an ORF which could potentially encode a protein designated ICP34.5 
[see section 1.7.3.3].
1.5. HSV lytic infection
1.5.1. Adsorption
The entry of HSV virions into cells is preceded by adsorption and binding of the virions
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to a cell surface component. Heparan sulphate acts as the initial receptor for both HSV-1 
and HSV-2 (WuDunn and Spear, 1989; Lycke eta l, 1991; Shieh e ta l,  1992; Shieh and 
Spear, 1994). Enzymatic removal of heparan sulfate from the cell surface significantly 
reduces the binding of virus to cells and renders them resistant to infection (WuDunn 
and Spear, 1989). Binding of HSV is also severely impaired in Chinese hamster ovary 
(CHO) mutant cells defective in biosynthesis of either heparan sulphate alone or in all 
glycosaminoglycans or defective in sulphation of heparan sulphate (Shieh e ta l,  1992). 
The interaction of virions with heparan sulphate is mediated by the viral structural 
glycoprotein gC of which at least two regions form a functional domain involved in 
binding (Trybala et a l, 1994). HSV-1 mutants lacking gC exhibit significant 
impairments in adsorption and penetration (Herold e ta l, 1991). Neutralising antibodies 
specific for HSV-1 gC are able to block the binding of virus to cells (Svennerholm et ah, 
1991; Fuller and Spear, 1985). The glycoproteins gD and gB are essential for secondary 
interactions at the cell surface which lead to virus entry into cells (Fuller and Spear, 
1985; Cai et a l, 1988; Ligas and Johnson, 1988; Kuhn et a l, 1990; Herold et a l, 1994).
1.5.2. Penetration
Herpes simplex virus can enter cells by fusion with plasma membranes (Morgan et a l, 
1968; Fuller and Spear, 1987). A number of glycoproteins present in the virion envelope 
are required for penetration into cells after initial attachment. These include gB, gD, gH, 
gK and gL (Fuller and Spear, 1987; Cai et a l, 1988; Highlander et a l, 1988; Ligas and 
Johnson, 1988; Forrester et a l, 1992; Roop et al, 1993). gB-null viruses can bind to cell 
surfaces but are unable to enter cells unless treated with polyethylene glycol, a 
membrane fusion agent (Cai et a l, 1988). Neutralising monoclonal antibodies specific 
for gB, gD or gH can block viral penetration with little or no effect on adsorption (Fuller 
and Spear, 1987; Fuller et a l  1989; Highlander et a l, 1988; Navarro et a l, 1992). 
Virions lacking gD can adsorb to cells but fail to penetrate (Ligase and Johnson, 1988). 
Truncated soluble forms of both HSV-1 and HSV-2 gD can inhibit HSV entry but not 
adsorption (Johnson et a l, 1990) by interacting with gD receptors thus blocking viral
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penetration but not adsorption. Binding of soluble gD is abolished by treatment of cells 
with pro teases but not by enzymes which remove heparan sulphate (Johnson et al., 
1990) indicating binding to protein receptors.
The glycoproteins gH and gL form a heterodimer which acts during entry of virus into 
cells (Hutchinson et al., 1992a). gL-null mutants fail to incorporate gH into virion 
envelopes (Roop et a l, 1993). Mutant viruses lacking gH and gL (Forrester et a l, 1992; 
Roop et al., 1993) are able to adsorb onto cells but fail to penetrate and initiate infection. 
The precise role of glycoproteins in HSV penetration is not known. Fuller and Lee 
(1992) proposed a model which involves a cascade of virus-cell interactions in which gH 
and gD play a role. The model proposes that gD performs at least two functions (i) it 
contributes to stable virion attachment via interaction with a cellular component or 
receptor, and (ii) it interacts with a viral component which is directly involved in 
initiation of fusion of viron envelopes and cell membranes. For this reason, antibodies to 
gD that block attachment of virus do not bind to the same site as antibodies that block 
penetration. In contrast, gH seems to participate in fusion initiation cooperatively with 
gD and perhaps other viral proteins.
1.5.3. Release and replication of viral DNA
Following fusion of the virion envelope with the cell membrane, viral capsids are 
transported to the nuclear pore (Tognon et a l, 1981; Batterson et al, 1983) and DNA is 
released into the nucleoplasm to allow gene expression [see section 1.5.8]. The cellular 
cytoskeleton probably mediates transport to nuclear pores (Kristensson et a l, 1986). In 
the nucleus, HSV-DNA replication is detected about 3 h post-infection and continues for 
at least 9-14h (Roizman e ta l, 1963; Roizman and Roane, 1964). Head to tail viral DNA 
concatamers accumulate in the nuclei (Jacob and Roizman, 1977; Jacob et a l, 1979). 
HSV-DNA replicates by a rolling circle mechanism (Ben-Porat and Tokazewski, 1977; 
Jacob et a l, 1979; Roizman, 1979) with synthesis initially restricted to a few well- 
defined sites within the nucleus called replication compartments or inclusions (Quinlan 
et a l, 1984; Kops and Knipe, 1994) which are organised in the nuclear interior rather
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than at the periphery (Kops and Knipe, 1994). The number and size of these 
compartments increases throughout infection until the entire nucleus is filled with 
replicating viral DNA (Rixon et a i, 1983).
HSV encodes a number of DNA replication proteins which are located in the replication 
compartment of infected cells (Quinlan etal., 1984; Kops and Knipe, 1988; Goodrich et 
al., 1990). Some of these proteins interact with specific viral DNA sequences which 
serve as origins of DNA replication. Three origins of replication have been identified, 
two designated Oris have the same sequence and map in the c inverted repeat sequences 
of the S component (Vlazny and Frenkel, 1981; Spaete and Frenkel, 1982; Stow, 1982; 
Stow and McMonagle, 1983; Deb and Doelberg, 1988). The third, O h l is located in the 
middle of the long unique segment (Weller et al., 1985; Gray and Kaemer, 1984). 
Sequence analysis revealed palindromic organisation of Oris and Or/L. O h l exhibits a 
single perfect palindrome of 144bp while Oris exhibits a 45bp palindrome (Weller et al., 
1985; Knopf etal., 1986; Lockshon and Galloway, 1986).
Genes involved in DNA synthesis were identified by transfection of cells with a plasmid 
containing an origin of HSV replication and various fragments of the HSV genome 
(Challberg, 1986). Seven L component genes were identified whose products are 
essential and sufficient for viral DNA synthesis (Wu et al., 1988). These are: UL30 and 
UL42 which encode the subunits of the viral DNA polymerase in which UL30 is the 
catalytic subunit and UL42 acts to increase the processivity of the enzyme (Powell and 
Purifoy, 1977; Coen et a i, 1984; Parris et al., 1988; Gallo et al., 1988; Crute and 
Lehman, 1989), UL29 specifies a single-strand specific-DNA binding protein (ICP8) 
(Purifoy and Powell, 1976; Ruyechan and Weir, 1984; Quinlan et al., 1984; Kops and 
Knipe, 1988; Wu et al., 1988), UL9 specifies a protein which binds to a specific 
sequence within the origins of viral DNA synthesis (Elias et al., 1986; Elias and 
Lehman, 1988; Koff and Tegtmeyer, 1988; Olivo etal., 1989; Elias et al., 1990). The 
products of UL5, UL8 and UL52 form a complex in which each protein is present in 
equimolar ratios and functions as a primase and a helicase (McGeoch et al., 1988b; 
Crute et al., 1989; Calder and Stow, 1990; Dodson and Lehman, 1991; Calder et al..
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1992; Klinedinst and Challberg, 1994).
HSV enzymes involved in nucleic acid metabolism include thymidine kinase (Kit and 
Dubbs, 1963; Dubbs and Kit, 1964; Tenser and Dunstan, 1979), ribonucleotide 
reductase (Bacchetti e ta l ,  1986; Ingemarson and Lankinen, 1987; McGeoch etal., 
1988a), uracil-DNA glyosylase (Caradonna and Cheung, 1981; McGeoch e ta l ,  1988a; 
Worrad and Caradonna, 1988) and dUTPase (Wohlrab and Francke 1980; Caradonna 
and Cheung, 1981; Williams and Parris, 1987). Some of these enzymes are discussed in 
section 1.7 in relation to their role in HSV pathogenicity.
1.5.4. Cleavage and packaging of HSV DNA
Following viral DNA replication, newly synthesised concatameric DNA molecules are 
processed into unit length genomic molecules and packaged into capsids. There is 
evidence that cleavage and packaging are linked processes. Variants with mutations in 
capsid genes UL19, UL38, UL18 and UL26 encoding the protease fail to process 
concatamers to full-length molecules (Weller e ta l, 1987;Pertuiseta/., 1989; Desai et 
a l, 1993; Gao et a l, 1994). Cleavage of concatamers occurs within the terminally 
reiterated ‘a ’ sequences at the junctions between adjacent viral genomes (Vlazny and 
Frenkel, 1981; Mocarski and Roizman, 1982; Deiss et a l, 1986; Deiss and Frenkel, 
1986). The process of DNA cleavage (Mocarski and Roizman, 1982) generates genomes 
with (i) a free L-component terminus consisting of one to several directly repeated ‘a ' 
sequences and ending in a DRl containing 18bp and one 3' nucleotide extension (ii) a 
free S-component terminus consisting of one ‘a ’ sequence with a terminal DRl 
sequence containing only a single base pair and one 3' nucleotide extension. Joining of 
the two partial DRl sequences forms a complete DRl which results in circularisation of 
the DNA. Cleavage within this shared DRl results in linearisation for packaging 
(Mocarski and Roizman, 1982). Two conserved domains designated p a d  and p a d  were 
identified in Ub and Uc, respectively and appear to be essential for the cleavage and 
packaging process (Varmuza and Smiley, 1985; Deiss et a l, 1986). Viral proteins 
responsible for cleavage and packaging have not been identified. Two viral proteins
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(VP 1/2 and an uncharacterised 140-KDa protein) play a role in recognition of the DRl- 
Uc region by forming a complex which binds specifically to the Uc sequence containing 
p a d  (Chou and Roizman, 1989; McNabb and Courtney, 1992). Recently, Baines et al 
(1994) reported that the ULl5 gene encodes two polypeptides which share sequences 
from the second exon and which are required for cleavage of viral DNA from 
concatamers and packaging into capsids.
1.5.5. Virion assembly
Capsids are assembled in the nucleus and viral DNA is packaged into pre-formed 
capsids (Preston et al., 1983). Little is known about how virus particles are formed but 
the available evidence suggests that VP22a (ICP35) is required for encapsidation of viral 
DNA (Preston et al, 1983; Rixon et a l, 1988; Sherman and Bachenheimer, 1988). 
VP22a is an abundant protein in B capsids and was initially identified as the product of 
HSV-1 gene UL26 from the genomic location of the lesion in the mutant fjl201. This 
mutant is defective in processing of the VP22a protein at the non-permissive 
temperature (NPT). When cells infected with rjl201 were shifted from NPT to the 
permissive temperature in the presence of cycloheximidine, both processing of VP22a 
and packaging of viral DNA took place indicating that VP22a is involved in the 
packaging process (Preston et a l, 1983). Nucleotide sequencing studies assigned the 
coding sequence of VP22a to the open reading frame UL26 (McGeoch et a l, 1988a). In 
a subsequent study, Liu and Roizman (1991b) showed that the domain of UL26 contains 
two transcriptional units which coterminate at the 3' end but have different 5' ends. 
VP22a is encoded by the 3' domain of UL26, designated UL26.5.
1.5.6. Envelopment and egress
Assembled capsids leave the nucleus and gain tegument and envelope before exiting 
from cells. These events are poorly understood. It is apparent that capsids leave the 
nucleus by budding through the inner nuclear membrane into the space between the 
inner and outer nuclear membranes (Darlington and Moss, 1968; Nii et a l, 1968;
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Johnson and Spear, 1982). Opinions differ concerning the route by which virions leave 
the perinuclear cistemae. Two pathways have been suggested (Fig. 1.3). In the first, 
virions enveloped at the inner nuclear membrane fuse with the outer nuclear membrane 
to release capsids into the cytoplasm. In the second pathway, the envelope gained at the 
inner nuclear membrane is retained and virions leave the perinuclear cistemae in a 
vacuole formed from the outer nuclear membrane. Both models propose that maturation 
of virions takes place in the Golgi complex and that mature virions leave the cell by 
exocytosis from the Golgi-derived vesicle (Rixon, 1993).
The first evidence that an HSV gene is required for transit of virions to the perinuclear 
space was provided by Baines et al (1991). Deletion of 53% of the UL20 gene, encoding 
an integral membrane protein, resulted in accumulation of enveloped and unenveloped 
capsids in the space between the inner and outer nuclear lamellae. The mechanism by 
which the product of UL20 enables the transport of virions is unclear. Another gene, 
U L ll encoding a myristylated protein might also play role in virus envelopment and 
release (MacLean et al., 1989,1992; Baines and Roizman, 1992; Baines e ta l, 1995).
1.5.7. Shutoff of host macromolecular metabolism
Infection of cells with HSV leads to early shutoff of host gene expression due to the 
activity of the virion host shutoff iyhs) protein encoded by the UL41 gene (McGeoch et 
al, 1988a; Kwong e ta l, 1988; Fenwick and Everett, 1990b; Smibert e ta l, 1992). Host 
DNA synthesis is shutoff (Roizman and Roane, 1964), host protein synthesis declines 
very rapidly (Read and Frenkel, 1983; Sydiskis and Roizman, 1966), host ribosomal 
RNA synthesis is reduced (Wagner and Roizman, 1969) and glycosylation of host 
proteins ceases (Spear et a l, 1970). The effect of the vhs protein is not limited to 
preexisting cellular mRNAs, but also induces destabilisation and degradation of viral IE,
E and L mRNAs (Fenwick and Everett, 1990a; Strom and Frenkel, 1987; Kwong and 
Frenkel, 1987). Thus virus mutants that encode a defective vhs protein are defective in 
virion host shutoff and produce viral mRNAs with longer half-lives than those mRNAs 
produced by the wild-type virus (Strom and Frenkel, 1987; Kwong and Frenkel, 1987;
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Figure 1.3. Proposed pathways for virion egress.
In the first pathway (A), tegumentation takes place in the cytoplasm and the virion envelope is 
derived from the cytoplasmic membrane. In the second pathway (B), tegumentation takes place 
in the nucleus and the virion envelope is derived from the inner nuclear membrane. In both 
cases, maturation of virions takes place in the Golgi complex and mature virions leave the cell 
by exocytosis. (Adapted from Rixon, 1993)
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Oroskar and Read 1987, 1989). The level of vhs activity varies markedly between 
different HSV strains and is particularly weak in HSV-1 strain 17+ (Fenwick and 
Everett, 1990a). Recent studies (Smibert et a l, 1994) have shown that the vhs protein 
forms a complex with VP16(a-TIF) and blocks the ability of VP 16 to enter a 
multiprotein complex on the immediate-early TAATGARATTC element.
Other HSV proteins can also serve to suppress host protein synthesis. Overton et al 
(1994) demonstrated that the product of the ULl3 gene is also involved. Cells infected 
with ULl3-negative mutants are able to synthesise actin at the same level as mock- 
infected cells whereas actin synthesis is considerably reduced in cells infected with wild- 
type virus. The amounts of UL41 protein present in wild-type and ULl 3-negative 
virions are approximately equivalent. The level of UL41 protein expressed in cells 
infected with ULl 3-negative mutants is drastically reduced compared to wild-type 
infected cells, but the kinetics of synthesis are not affected. The role of UL13 in
host shutoff is unlikely to activate the UL41 gene product by phosphorylation
1.5.8. HSV gene expression during productive infection
During productive infection by HSV, genes are expressed sequentially and coordinately 
in a cascade fashion (Honess and Roizman, 1974, 1975). HSV genes can be classified 
broadly as a , P and y (Honess and Roizman, 1974, 1975) or immediate-early (IE), early 
(E) and late (L) (Clements et a l, 1977). This classification is based on the kinetics of 
synthesis of individual viral transcripts and proteins and requirement for either de novo 
protein or DNA synthesis.
IE gene expression is detectable at Ih post-infection with peak synthesis occurring at 3- 
4h post-infection and declining rapidly thereafter, although low levels of synthesis are 
detectable at later times (Honess and Roizman, 1974). There are five IE genes (Table 
1.2) some of whose products are the major regulatory proteins, required to induce 
synthesis of early and late transcripts (Honess and Roizman, 1974, 1975; Deluca et al, 
1985; O’Hare and Hayward, 1985; Sacks et a l, 1985). Transcription of IE genes is 
activated by a late structural protein, VP 16 (Vmw65) (Batterson and Roizman, 1983).
13
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E genes are expressed prior to the onset of HSV DNA replication and require IE gene 
expression. Transcription of E genes and synthesis of proteins begin by 3h post­
infection, peak at about 5-7 and declines thereafter (Honess and Roizman, 1974). These 
genes can be divided into subclasses (El and E2) on the basis of their times of 
expression and abundance. The appearance of E gene products signals the onset of viral 
DNA synthesis and most viral genes involved in viral nucleic acid metabolism appear to 
be in the E group.
L genes are maximally expressed after the onset of viral DNA replication and can be 
divided into 2 subclasses [LI (EL or leaky late) and L2] on the basis of an obligatory 
requirement of DNA replication for expression (Costa et al., 1981). Most L genes are 
structural genes and assembly proteins.
Physical mapping studies have shown that two of the five immediate early genes are 
diploid being located within the repeat sequences flanking the U l and Us regions of the 
genome, while E and L genes are located in U l and Us (Murchie and McGeoch, 1982; 
McGeoch et a i, 1985).
In contrast to the sequence of events that occurs during productive infection, HSV gene 
expression in latently-infected cells is limited mainly to the latency-associated 
transcripts (LATs), a family of transcripts ranging in size from 2.0 to >8Kb (Spivack and 
Fraser, 1987; Zwaagstra etal., 1990) [see sections 1.6.1 and 1.6.3].
1.5.9. Regulation of HSV gene expression
Expression of HSV genes is controlled by both viral and cellular trans-acting factors 
which require cfs-acting sites. A number of regulatory sequence elements are found in 
IE gene promoters. E promoters consist of a near upstream region composed of binding 
sites for cellular transcription factors linked to a TAT A/cap site (McKnight and 
Kingsbury, 1982; Everett, 1984, McKnight and Tjian, 1986). True HSV-1 late promoters 
appear to have a simpler structure with a TATA element being the only consensus 
element identified in the upstream regulatory region (Wagner, 1985). Deletion studies 
have indicated that little sequence information upstream from this element is required
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for efficient expression (Homa etal,  1986,1988).
One of the unique regulatory sequence elements found in IE gene promoters is 
TAATGARAT, R=Purine (Mackem and Roizman, 1982; Whitton and Clements, 1984; 
Gaffney etal ,  1985) which is required for the induction of IE genes by a-TIE (Vmw65). 
Induction by Vmw65 occurs through binding of the cellular transcription factor Oct-1 
(Stem et al,  1989) to the cw-acting site TAATGARAT and interaction of Vmw65 with 
Oct-1 to form a complex (Gerstar and Roeder, 1988; Kristie and Roizman, 1987; O’Hare 
and Goding, 1988; Preston et al,  1988). An additional cellular factor termed complex 
forming factor (CEE) binds directly to Vmw65 in the absence of Oct-1 or DNA (Kristie 
et al ,  1989; Xiao and Capone, 1990; Katan et al,  1990), therefore it is likely that 
Vmw65-CFF interaction is the first step in complex formation which subsequently 
recognises the DNA-bound Oct-1. Recently, Ralph etal  (1994) demonstrated that a 
cellular factor in Vero and NB41 A3 cells expressed after release from growth arrest can 
activate IE gene expression.
Sequence comparison of the TAATGARAT motif of IE promoters showed that some 
have a 5’ extension with an ATGC sequence lATGCTAATGARAT) (APRhys et al,
1989). The extended (represented by RL2) and the standard (represented by RSI) motifs 
were tested by Douville et al (1995) for binding Oct-l/Vmw65 and for transcriptional 
activity. The extended RL2 sequence binds to Oct-l/Vmw65 with higher affinity and 
drives transcription more efficiently than RSI which is poorly active on its own. 
Neighbouring DNA sequence motifs CGGAAR which bind the cellular GABPoc/p factor 
act in synergy with the RSI sequence and compensate for its weak activity.
A second sequence element, RTCGTCNNYNYSG, Where R=purine, Y=pyrimidine, S=
C or G and Y is any base, is a high-affinity binding site for Vmw 175 (Kristie and 
Roizman, 1986; DiDonato et al,  1991) and is thought to be the major negative 
regulatory element for promoters (Roberts etal ,  1988; DiDonato e ta l ,  1991). A third 
element is the binding site for the cellular transcription factor Spl (Jones and Tjian, 
1985; Jones etal ,  1985).
Three of the HSV IE nuclear proteins (VmwllO, Vmwl75 and Vmw63) perform
15
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regulatory functions cooperatively, but the mechanism underlying this is not understood. 
Vmw 175 is the major transcriptional regulatory protein required to activate transcription 
of E and L genes for progression of the lytic cycle and to repress transcription from its 
own and other IE genes (Deluca et al., 1985; Kristie and Roizman, 1986; DiDonato et 
al., 1991). VmwllO is able to transactivate all classes of HSV genes that exhibit a basal 
level of transcription. The mechanism by which VmwllO activates viral gene expression 
is not known. VmwllO and Vmwl75 activate E and L gene expression synergistically 
( Everett , 1984; O’Hare and Hayward, 1985; Quinlan and Knipe, 1985). Yao and 
Schaffer (1994) reported that VmwllO and Vmwl75 interact physically. Vmw63 by 
itself appears to have little effect on the expression of HSV genes. However, it can act as 
a tr<3/î5-repressor or a tra«5-activator in transfection assays in combination with 
VmwllO and Vmwl75 (Everett, 1986; McMahan and Schaffer, 1990; Sekulovich etal., 
1988; Su and Knipe, 1989). A recent study (Purves et al., 1993) demonstrated that 
Vmw68 is also involved in the regulation of HSV gene expression by enhancing the 
level of VmwllO expression.
1.6. HSV latent infection
One of the features of infection with most human herpesviruses is the ability to establish 
and maintain latency with subsequent reactivation. Latency has been defined as the 
persistence of the virus in a host in a non-infectious form. At the cellular level, latency 
has been defined as the presence of the viral genome in the absence of the production of 
infectious progeny (Fraser et al., 1992). Latency is established following a primary 
infection. Skin, cornea and mucous membranes are the portals of entry in which HSV 
multiplies forming mucocutaneous lesions. After replication at the site of infection, 
virions are transported by axons to the cell body of sensory neurons within the dorsal 
root ganglia (Cook and Stevens, 1973). Latency is established in a range of sensory 
ganglia (Hill, 1985) e.g. trigeminal (Bastian etal., 1972; Baringer and Swoveland, 1973; 
Baringer, 1974; Efstathiou et a l, 1986) and cervical ganglia (Balan et a l, 1994) in 
HSV-1 infection and sacral, lumbar and thoracic ganglia (Galloway et a l, 1979) in
16
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HSV-2 infection. However both viruses can establish latent infection in any dorsal root 
ganglia (Stevens and Cook, 1971). Periodically, in response to a variety of stimuli, such 
as stress, fever, menstruation, therapeutic irradiation and UV light, latent virus can be 
reactivated and subsequently pass down the axon of the sensory neuron to replicate at or 
near the initial site of infection (Whitley, 1990). Depending on the host immune 
response, the resulting disease in most cases is cutaneous lesions. Occasionally acute 
fatal encephalitis occurs (Hill, 1985). The frequency of HSV reactivation depends upon 
the virus type and the site of infection (Lafferty et a l, 1987). Genital HSV-2 infections 
recur 8-20 times more frequently than HSV-1 genital infections with more than 80% of 
patients with primary HSV-2 genital infections having a recurrence within 12 months 
compared with 55% with HSV-1 genital infections (Lafferty et a l, 1987; Whitley, 
1990). Conversely, oral HSV-1 infections recur much more frequently than oral HSV-2 
infections (Spruance e ta l, 1977; Lafferty e ta l, 1987)
Latency is a complicated biological phenomenon which involves viral, cellular and host 
factors. It can be divided into three phases: establishment, maintenance and reactivation 
(Roizman and Sears, 1987).
1.6.1. Establishment and maintenance of latent infection
The initial work on establishment of latency came from a hypothesis that neurons 
harbouring latent virus lack host factors for the transcription of viral genes. An alternate 
hypothesis is that in the environment of the sensory neuron, a specific viral gene arrests 
the viral gene cascade which consequently leads to the establishment of latency 
(Roizman and Sears, 1987). The search for these putative viral genes has taken two 
directions. The first involves analysis of ganglia harbouring latent virus for the presence 
of viral gene products [see section 1.6.3]. The second involves analysis of HSV mutants 
for their ability to establish latency. Using deletion mutants, it has been shown that viral 
DNA replication and genes associated with initiation of lytic infection are not required 
for establishment of latency. These include thymidine kinase (Tenser et a l, 1979,1981, 
1989 ; Coen et a l, 1989; Katz et a l, 1990; Kosz-Vnenchak et a l, 1990), VmwllO
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(Clements and Stow, 1989), Vmw68 (Sears etal ,  1985), Vmw65 (Steiner et al,  1990; 
Valyi-Nagy et al., 1991), Vmwl75 (Katz et al, 1990; Dobson et al,  1990), viral DNA 
polymerase (Wilcox and Johnson, 1988) and ribonucleotide reductase (Katz et al,
1990). Similarly, latent infection with wild-type HSV can be established in ganglionic 
neurons in which no prior viral IE gene expression or DNA replication has taken place 
(Speck and Simmons, 1991; Margolis et al, 1992). This result indicated that the latent 
and productive pathways may diverge early in the acute ganglionic infection and raises 
the important question of which viral or cellular factor(s) is responsible for selection of 
the latent as opposed to the lytic pathway?. Data has emerged which suggests that the 
establishment and maintenance of neuronal latency is the result of failure of viral IE 
expression (Stevens et al,  1987; Croen etal,  1987; Margolis e tal ,  1992). Failure of IE 
gene expression could be due to loss of Vmw65 when the virus is carried from the 
peripheral site to the nucleus of the sensory neuron (Roizman and Sears, 1987). This was 
supported by the observation that HSV-1 mutants which lack the rra«5-inducing 
function of Vmw65 establish latent infections capable of reactivation (Steiner et al,  
1990; Valyi-Nagy et al, 1991). A contradictory finding that latency can be established 
in transgenic mice in which Vmw65 has been expressed in all cell types including 
sensory neurons was shown by Sears et al (1991). The block of IE expression may be 
due to the lack of Oct-1 which has been shown to be present at a very low levels in most 
neurons (He et al,  1989). An alternative possibility is the presence of a neuronal specific 
octamer-binding protein which represses HSV-1 IE gene expression by preventing 
trans-SiCivvaiion by the Oct-l/Vmw65 complex. To study the nature of the octamer 
binding, a series of immortalised rat ganglionic neurons were prepared by fusing 
primary sensory neurons of neonatal rat DRG with the C l300 mouse neuroblastoma cell 
line. The resulting cell lines (ND) proliferate indefinitely and possess the characteristics 
of primary sensory neurons which are not found in the parental neuroblastoma (Suburo 
et al ,  1992). Transfection of these cells with a construct in which expression of the CAT 
gene is driven by the HSV IE promoter showed a very low level of IE promoter activity 
compared to that observed in permissive fibroblasts. It was suggested that neuronal cells
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contain an inhibitory octamer binding protein which following infection, binds to the 
TAATGARAT motif of IE promoters to prevent binding of the rranj-activating complex 
of Oct-l/Vmw65. This was tested by cotransfection of lE-CAT with increasing amounts 
of a plasmid containing a cloned TAATGARAT motif. A steady increase in the lE-CAT 
activity in neuronal cells was observed indicating removal of the inhibitor by excess 
TAATGARAT and activation of the IE promoter by the Oct-Wmw65 complex (Kemp 
et al., 1990; Wheatley et al., 1991). The neuronal octamer-binding repressor was 
identified by DNA mobility shift assays and found to be Oct-2 which showed a similar 
mobility to B cell Oct-2 and reacted with a polyclonal antibody to Oct-2 (Lillycrop et 
al., 1991). The Oct-2 mRNA in ND cells was detected using PCR and the cDNA 
product showed that the ND cell Oct-2 protein was identical to the B cell protein in the 
central POU domain which mediates DNA binding (Lillycrop etal., 1991; Latchman et 
al., 1992). Deletion of a forty amino acid region in the N-terminus of Oct-2 abolishes the 
inhibitory effect on the IE promoters (Lillycrop et al., 1994a). Two isoforms, Oct 2.4 
and Oct 2.5, are overexpressed in neuronal cells (Wirth et al., 1991) and are unable to 
form a complex with Vmw65 due to differences between the POU domains of Oct-1 and 
Oct-2 ( Stem et al., 1989; Gerster and Roeder, 1988). Unlike Oct-1, Oct 2.4 and Oct 2.5 
lack a gene activation domain at the C terminus of the molecule (Wirth et al., 1991) and 
therefore binding of Oct-2 to the TAATGARAT motif does not stimulate transcription 
but prevents binding of the activating complex of Oct-l/Vmw65 (Lillycrop et a l, 1991). 
In co-transfection assays using IE3-CAT, both Oct-2.4 and Oct-2.5 were able to inhibit 
the IE promoter while Oct-2.1, the predominant B cell isoform which possesses the C- 
terminal activation domain, activated the IE promoter (Lillycrop and Latchman, 1992; 
Lillycrop et a l, 1994a). The ability of Oct-2.4 and Oct-2.5 to inhibit the viral lytic cycle 
was further tested by Lillycrop et al (1994a) in permissive BHK cells which had been 
engineered to stably express either Oct-2.4 or Oct-2.5. Following infection with HSV- 
1(F), a clear reduction in the transcription level of all five viral IE gene was observed. 
The subsequent stages of the HSV lytic cycle were also affected as indicated by 
reduction in the expression level of E and L genes represented by TK, gB and gC. A
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decline in viral glycoprotein production was paralleled by a decline in viral yield. In 
contrast, a small increase in IE gene expression and viral yield was observed by 
expressing Oct-2.1. Lillycrop etal (1994a) concluded that expression of these isoforms 
is likely to play a role in establishment of latency by making neuronal cells non- 
permissive for the viral lytic cycle. The role of Oct-2 in repressing IE gene expression in 
normal unimmortalised sensory neurons in vivo is not known yet, but Oct-2 mRNA has 
been detected in sensory neurons of rat DRG by in situ hybridisation, PCR and DNA 
mobility shift assays (Lillycrop etal., 1991; Wood etal., 1992).
Expression of a low level of HSV genes, in particular Vmwl75, during latency has been 
demonstrated recently by Kramer and Coen (1995) using a sensitive quantitative RNA 
PCR. Vmw 175 specific RNA was found in variable amounts in about 20% of ganglia 
with 1-7 RNA molecules per viral genome. These amounts were similar at 30 and 60 
days postinfection. TK-specific RNA was found at a maximum level of 3.2x10^ 
molecules per ganglia (500 molecules per viral genome). It was concluded that a low 
level of Vmw 175 expression in the absence of detectable reactivation led to TK 
transcription. This finding confirms the previous detection by immunofluoresence and 
by in situ hybridisation of a low level of Vmwl75 (Green et al., 1981) and VmwllO 
(Croen etal., 1987).
1.6.2. The latent viral genome
Studies on latently infected ganglia of experimental animals demonstrated that the HSV 
genome is maintained in a nonlinear endless form (Rock and Fraser, 1983; Efstathiou et 
al., 1986) due to joining of the termini (Rock and Fraser, 1985). Based on density 
gradient centrifugation experiments, Mellerick and Fraser (1987) provided evidence that 
the latent genome can be separated from host chromosomal DNA and thus persists in a 
non-integrated state. Additional experiments indicated that the latent HSV genome has a 
nucleosomal structure similar to that of cellular chromatin (Deshmane and Fraser, 1989) 
and is not extensively methylated (Dressier etal., 1987). The estimated copy number of
20
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viral DNA in a latently infected neuron in a sensory ganglion ranges from 10 to >100. 
This multiple copy number may arise by several possibilities: i) infection with an 
average m.o.i. of 10-10^ virions/cell, which would not subsequently increase in number, 
ii) a low level of genome replication prior to or during the latent phase (Roizman and 
Sears, 1987). As gene expression during latency is repressed, this replication could not 
be accomplished by viral enzymes which recognise the origins of viral DNA synthesis 
(OWl, Oris) used during the lytic infection. It was predicted that the viral genome 
contains at least one cellular origin for viral DNA synthesis, which is recognised by 
cellular enzymes. Sears and Roizman (1990) reported that the 1.6Kb BamWl-o fragment 
mapping in U l contains a host origin ipriw) of DNA synthesis. This fragment is within 
the ORF encoding the large subunit of ribonucleotide reductase. Grin was predicted by 
Sears and Roizman (1990) to play a role in reactivation.
1.6.3. Transcription during latency
In both HSV-1 and HSV-2, a single region in R l  known as the latency associated 
transcript or LAT has been shown to encode RNA (Stevens et al., 1987; Croen et al., 
1987; Deatly et a l, 1987; Rock et a l, 1987, Mitchell et a l, 1990a,b). This region has 
been sequenced for HSV-1 strains KOS(M), 17+ and F (Wagner et a l, 1988; Perry and 
McGeoch et a l, 1988; Wechsler et al, 1989) and for HSV-2 strain HG52 (McGeoch et 
a l, 1991). The location of the LAT promoter has been confirmed by transient CAT 
assays (Zwaagstra et a l, 1989, 1990) and analysis of mutant viruses with deletions 
encompassing the promoter region (Mitchell et al, 1990c; Dobson et a l, 1989).
Nothem blots of RNA isolated from latently infected ganglia demonstrated the presence 
of uncapped 3' co-terminal poly(A~) RNA species of sizes 1.45, 1.5 and 2.0Kb mapping 
in an antisense direction to part of the RL2 gene (Spivack and Fraser, 1987; Devi-Rao et 
a l, 1991). Subsequently, it has been reported that these transcripts may arise as stable 
introns from a larger (8.3Kb) capped polyadenylated transcript (Fig. 1.4) which extends 
antisense to both the RLl and RL2 genes across the L-S junction (Spivack and Fraser, 
1987; Zwaagstra et a l, 1990; Spivack et a l, 1991; Farrell et a l, 1991). The 2.0Kb
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Figure 1.4. The LAT region of HSV-1
The HSV genome is shown (A). The LATs are transcribed from the repeat regions. The LAT 
region transcripts (B) overlapped by transcripts expressed during the lytic infection. The latency 
active promoter(s), LPl and LP2 with cis elements (C) (Adapted from Goins et al, 1994).
In this figure the numbering system used for LAT promoters has been changed. The 5' end of 
the 2Kb LAT is referred to as +1. This means for example that the DNA sequence recognised 
by LPBF referred to in the text at position -65—72 is numbered -662—669.
o 00
= i<s>
o z
roo‘
%; :
CAAT 
AP2 — ro
LPBF -  
CRE -  
TATA“
-597—  
Spl -
AP2 —
Cn
ro
E2F
IN)
G+C \  
Rich ^
AP2
C/T
II ro<T> t g
■ Ii
ÎO
CO
Introduction
transcript is abundant and can be detected readily in neurons harbouring latent virus 
(Spivack and Fraser, 1987; Stevens et al., 1987). The unspliced 8.3Kb RNA is much less 
abundant and the presumed 6.5Kb spliced species which gives rise to the 2.0- and 1.5- 
Kb LATs is not present in sufficient amounts to be detected (Mitchell et al, 1990b; 
Wagner et a l, 1988; Zwaagstra et a l, 1990). The relationship between these transcripts 
has not been completely elucidated. Recently, Lagunoff and Roizman (1994) 
demonstrated that the domain of the genome covered by the 8.3Kb transcript encodes in 
the same orientation a protein ORF P.
The role that LATs play in the latent state has been examined with LAT" mutants. 
Mutant viruses with deletions in the promoter or the transcribed region of LAT are able 
to establish and maintain latency and reactivate (Javier et a l, 1988b, Ho and Mocarski, 
1989; Block et a l, 1990; Mitchell et a l, 1990c). Several laboratories have reported that 
LAT deletion mutants demonstrate a reduced capacity to reactivate and the kinetics of 
reactivation of these mutants is slower than wild-type (Steiner et a l, 1989; Leib et a l, 
1989b; Hill et a l, 1990; Trousdale et a l, 1991; Devi-Rao et a l, 1994), suggesting that 
LAT expression is non-essential for establishment and maintenance of latency but plays 
a role in reactivation (Javier et al, 1988b, Ho and Mocarski, 1989; Block et a l, 1990; 
Mitchell et a l, 1990c; Perng et a l, 1994). The observation that the 2.0Kb LAT is 
antisense to the 3' domain of the RL2 gene led to speculation that LAT transcripts enable 
the establishment of latency by suppressing the expression of RL2 and hence shutoff of 
the viral lytic cycle. Evidence for this has been shown by Farell et al (1991) in transient 
transfection assays. There is no evidence in animal models to support this finding.
To date, the precise function of LATs is unclear
. Doerig et al (1991), using an antiserum prepared against a bacterially- 
expressed fusion protein containing part of a ORF within the 2.0Kb LAT, reported an 
HSV-1 latency associated protein in primary neurons which had been latently infected in 
vitro. This putative 80KDa latency-associated protein has not been identified in latently 
infected tissues.
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1.6.4. Latency promoter
Two LAT promoters (Fig, 1.4) have been identified in HSV-1. The first is a TATA box- 
containing promoter (referred to as LPl), located approximately 700bp upstream of the 
5' end of the major 2.0Kb LAT (Zwaagstra et a l, 1991; Batchelor and O’Hare, 1990). 
The second is a TATA-less promoter termed LP2, located downstream of LPl and 5' 
proximal to the major 2.0Kb LAT (Goins et al., 1994). In addition to the TATA box, 
LPl contains Spl-binding sites and a number of potential control elements which could 
have a role in the expression of LAT during latency. These include a binding site for a 
nuclear factor called the Latency Promoter Binding Factor (LPBF). The DNA sequence 
recognised by LPBF is located near the TATA box of the promoter, between -72 and -65 
with the sequence CCACGTGG. Removal of this site results in up to a 32-fold loss of 
promoter activity in transient transfections (Zwaagstra et al., 1991) of both neuronal and 
non-neuronal cells. LPBF has not yet been characterised and the significance of its 
binding to the LAT promoter region is unknown. Between the LPBF and the TATA box 
there is a cAMP response element (CRE) which stimulates LAT expression in the 
presence of cAMP in cell culture (Lieb et al., 1991). There are potential binding sites for 
Vmwl75 and Vmw65(VP16) in the LAT promoter region (Zwaagstra et a i, 1989; 
Batchelor and O’Hare, 1990). Vmwl75 has been reported to repress LAT expression in 
transient assays (Batchelor and O’Hare, 1990; Rivera-Gonzalez etal., 1994). A similar 
site for Vmwl75, found at the cap site of RSI is involved in its autoregulation (Roberts 
et al., 1988). However, Vmw65 has little or no effect upon the level of reporter gene 
activity directed by the LAT promoter (Batchelor and O’Hare, 1990).
It is not clear what makes the LAT promoter functional during latency. Lokensgard et al. 
(1994) tried to address this issue by constructing several recombinant viruses, some of 
which contain the upstream HSV-1 LAT(LPl) promoter region combined to the 
Moloney murine leukemia virus (MMLV) long terminal repeat (LTR), driving 
expression of the lac Z reporter gene at the gC locus. The LTR of MMLV was able to 
maintain transcription of p-galactosidase during latency in murine DRGs compared to a 
decrease to undetectable levels in expression from the virus with the LAT promoter
23
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alone. It was concluded that the LTR provides a DNA element designated long-term 
expression (LTE) element which functions to prevent promoter inactivation during 
latency. It is possible that the nucleosomal structure of the viral genome represses LAT 
transcription and the function of LTE may be to keep this region open specifically to 
allow LAT region transcription to continue. An analogous HSV-LTE region has not 
mapped, but is predicted to exist downstream of the LAT cap site.
1.6.5. Reactivation from latency
Reactivation of HSV results in the appearance of infectious virus at the site of initial 
primary infection where lytic phase replication can proceed until the host immune 
response clears it. It has been shown that very few latently infected neurons can be 
reactivated and express viral antigens after in vivo induction by neurectomy or by 
hyperthermia (McLennan and Darby, 1980; Sawtell and Thompson, 1992a,b). The 
molecular basis of reactivation is poorly understood. IE expression has been implicated 
in the switch from latency to the lytic phase. Leib et al (1989a) reported that RL2 
deletion mutants of HSV-l(KOS) were able to establish latency in the mouse eye and 
footpad models but were impaired in reactivation from ganglion explants. In contrast, 
Clements and Stow (1989) demonstrated that a RL2 deletion mutant of HSV-1(17+) 
reactivated efficiently from murine ganglia, although the kinetics of reactivation were 
slower. The authors suggested that this difference might be due to strain variation or to 
the extent of the deletions in the mutants. The possibility that the KOS mutants might 
contain a secondary mutation was not excluded. In an in vitro latency system of HSV-2, 
it has been shown that VmwllO is required to reactivate latent HSV-2 (Harris et a i, 
1989; Zhu e ta l, 1990).
The process of reactivation has been investigated using RNA polymerase chain reaction 
(RNA-PCR) (Minagawa etal., 1994). It was observed that Vmw 110-specific RNA was 
first detected 24h after explantation while LATs remained detectable 120h after 
explantation. In contrast, RNAs encoding Vmwl75, Vmw63, TK and Vmw65 were 
detectable within 48h, only following in vivo immunosuppressive and antimetabolic
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treatment with cyclophosphamide and dexamethasone. It was suggested that reactivation 
of HSV-1 from trigeminal ganglia occurs in two steps: (i) initiation of VmwllO gene 
transcription and (ii) accumulation of other viral transcripts which could be regulated by 
the host immune system.
The role of nerve growth factor (NGF) in maintenance of latency was demonstrated by 
Wilcox and Johnson (1987,1988). The relationship between the levels of NGF and Oct- 
1 and reactivation was demonstrated by Wood et al (1992). In the absence of NGF from 
sensory neuron cultures, the level of Oct-2 mRNA decreased without affecting the level 
of Oct-1 which can bind to the TAATGARAT motif to activate gene expression and in 
turn reactivation (Wood et al., 1992). HSV reactivation can take place by other 
mechanisms which do not involve the Oct-l/Vmw65 complex. Smith et al (1992) 
reported that treatment of sensory neurons with cAMP can reactivate HSV. An increase 
in the intracellular cAMP level stimulates transcription of IE genes via a cAMP response 
element in the IE gene promoter (Wheatley etal., 1992). Moreover, the IE promoters are 
stimulated by another POU family transcription factor, Bm-3a which is expressed by 
specific sensory neurons in vivo. Bm-3a levels increase following treatment of neuronal 
cells with cAMP. The ratio of Bm-3a to Oct-2 in neuronal cells may determine whether 
lysis or latency results from an infection with HSV. A rise in the Bm-3a to Oct-2 ratio 
may stimulate IE promoters and consequently viral reactivation in latently infected cells 
which do not express Vmw65 and can not activate IE promoters via an Oct-l/Vmw65 
complex (Lillycrop etal., 1994b).
1.7. Pathogenicity of HSV
The pathogenicity of human herpesviruses, HSV-1 and HSV-2, is dependent upon the 
ability of the virus to replicate and establish latency in the host. Virulence provides a 
measure of the pathogenicity of a virus. Neurovirulence is the term normally used in 
connection with central nervous system (CNS) disease induced by a virus. 
Neurovirulence of HSV is the consequence of (i) peripheral replication (ii) invasion of 
the CNS (invasiveness) and (iii) growth in the CNS (neurogrowth) (Roizman and Sears,
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1990).
A number of animal models have been used to study the neurovirulence of HSV. These 
include mice (Underwood and Weed, 1974), rabbits (Schlitt et a l, 1986) and guinea pigs 
(Scriba and Tatzber, 1981). The degree of virulence is dependent on host and viral 
factors. The host factors include age (Zawatzky e ta l, 1982; Ben-Hur et a l, 1983), route 
of inoculation (Dix et al., 1983), state of skin and mucous membranes (Sprecher and 
Becker, 1986, 1987), animal strain (Caspary et a l, 1980), interferon (Lopez, 1985), 
humoral immunity (McKendall etal., 1979) and cytotoxic immunity (Nash et a l, 1985). 
Viral factors include the virus type and strain (Halliburton e ta l, 1987). In some strains, 
individual plaque stocks of a HSV strain exhibit different degrees of virulence within the 
same host species (Taha et al, 1988). In addition, serial passage of the virus in vivo 
(Kaemer e ta l, 1983), in vitro (Goodman and Stevens, 1986) and body temperature of 
the host (Thompson and Stevens, 1983a) also affect the outcome of infection.
As the virulence characteristics of each individual HSV strain must be genetically 
determined, many laboratories have been involved in identifying the genes and gene 
products that control pathogenicity. A number of genes can be assigned particular 
biological functions, each of which contributes to pathogenicity. A mutation in a gene 
that reduces the capacity of the virus to grow peripherally, to invade the CNS or to grow 
in the CNS could be designated a virulence gene (Roizman and Sears, 1990). These 
genes will be discussed in the following sections according to progression of the CNS 
disease in acute HSV infection, although some are involved in more than one virulence 
function e.g. UL23, UL39-UL40 and RLl (yi34.5).
1.7.1. HSV genes involved in peripheral replication
Gene function in vivo has been defined in experimental animals following inoculation at 
different sites e.g. foot pad, ear, eye and peritoneum.
1.7.11. US7 and US8
The US7 and US8 genes encode the glycoproteins gl and gE, respectively (McGeoch et
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al., 1985). Balan etal (1994) constructed mutants of HSV-1 strain SC16 lacking either 
gl or gE by inserting a lacZ gene. The virulence of the mutants was evaluated using the 
mouse ear model. At various times post-inoculation, virus titres were determined at the 
inoculation site, the innervating sensory ganglia (cll, cIII, cIV), spinal cord and brain 
stem. Mutants lacking gl or gE failed to replicate efficiently at the inoculation site and 
were barely detectable in sensory ganglia or in the CNS. In epithelial cells in vitro, it 
was found that the mutants were able to adsorb to and enter cells at a normal rate but 
formed minute plaques due to failure of cell-to-cell spread. It was concluded that the gE- 
gl complex plays a part in transmission of the virus from infected to uninfected cells by 
cell contact.
I.7.I.2. ULIO
This gene was identified in the HSV-1(17+) genome by McGeoch et al (1988a) and 
encodes a glycosylated membrane protein with 8  transmembrane domains and 2 
glycosylation sites (MacLean, C etal., 1991; Baines and Roizman, 1993). The product 
of the ULIO gene is present in virions, light particles and plasma membranes of infected 
cells (Baines and Roizman, 1993; MacLean et al., 1993) and has been designated gM 
(Baines and Roizman, 1993). It is not essential for growth in tissue culture (MacLean, C 
et al., 1991, 1993; Baines and Roizman 1991). Its role in vivo was investigated by 
MacLean et al (1993) using a UL 10-deletion mutant of 17+ in the mouse foot pad 
model. Compared to wild-type and revertant viruses, the mutant was found to be 
impaired in growth at the periphery, in spread to the nervous system and in reactivation 
from latency. It was also impaired in growth in the central nervous system and was 35 
fold less virulent than the revertant virus.
17.1.3. UL56
Intraperitoneal (IP) injection is a common route of inoculation of HSV-1 into laboratory 
animals. Little is known about genes involved in IP virulence, but recently the UL56 
gene has been implicated (Rosen-Wolff and Darai, 1991). The HSV-1 strain HFEM
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with a 4.1 Kb deletion between 0.762 and 0.789 m.u. (Koch et al,, 1987) was shown to 
be avinilent in tree shrews (Rosen-Wolff and Darai, 1985) and mice (Becker et a l, 
1986) following IP inoculation. Virulence was restored to HFEM when rescued with 
BamHl-b (0.738-0.809 m.u.) or a Mlul fragment from 0.7615-0.789 m.u. or Hpal-p 
(0.762-0.787 m.u.) from the virulent strain F (Rosen et a l, 1985; Rosen et al., 1986; 
Becker et al., 1986). Comparative analysis of HSV-1 strain F and HFEM revealed the 
absence of a 1.5Kb RNA in cells infected with HFEM. This transcript was found to be 
that of the UL56 gene (Rosen-Wolff and Darai, 1991).
1.7.2. Genes involved in neuroinvasiveness of HSV
The neural spread of HSV from the site of primary infection to the central nervous 
system (CNS) requires viral functions which are discussed below:
1.7.21. UL23
UL23 encodes thymidine kinase (TK) which is a key enzyme in the de novo synthesis of 
precursors for DNA synthesis (Kit and Dubbs, 1965; Klemperer et al., 1967). It has 
been shown that TK-deficient (TK*) mutants of HSV-1 and HSV-2 are less virulent than 
TK+ viruses following either peripheral (mouse ear) or intracerebral inoculation (Field 
and Wildy, 1978). Tenser etal (1979, 1981) reported that TK* mutants of HSV-1 (KOS) 
replicate efficiently in the cornea but are defective in replication in the trigeminal 
ganglion. Consistent with this was the report by Stanberry et al (1985) that the TK 
producing HSV-2 strains 333 and MS replicated to high titre in the vagina and spinal 
cord of guinea pigs while TK* viruses resulted in similar vaginal titres but low spinal 
cord titres. Latent and recurrent infections were observed in animals inoculated with 
either TK+ or TK* viruses. This demonstrated that TK is not essential for establishment 
of latent infections but may be necessary for efficient virus reactivation or virus 
replication following reactivation (Tenser et al., 1989, Coen etal., 1989; Efstathiou et 
al., 1989).
The role of TK in viral pathogenesis is of special clinical interest because TK* mutants
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are resistant to the widely used anti-HSV drug, acyclovir (Field et a l, 1980). Such TK*, 
acyclovir (ACV) resistant mutants can arise during treatment of HSV infection with 
ACV (Kit et a l, 1987). The resistance stems from the requirement for viral TK to 
activate ACV efficiently (Elion e ta l, 1977).
I.7.2.2. UL30
UL30 encodes DNA polymerase, a key enzyme in replication of herpesvirus DNA in 
vivo. HSV strains with a defect in UL30 show reduced virulence as demonstrated from 
impaired replication in the central nervous system. Mutations in this gene also confer 
resistance to one or more antiviral compound. Larder et al (1986) reported that a defect 
in DNA polymerase accounted for the reduction in virulence of the variant RSC-26 of 
HSV-1 strain SC 16 in the mouse ear model. This variant contains a single nucleotide 
change at position 1790 which confers resistance to ACV and phosphonoacetic acid 
(PAA). Recombinants generated from rescuing RSC-26 with a wild-type DNA fragment 
containing the DNA polymerase gene, restored the wild-type phenotypes of sensitivity 
to antiviral drugs, DNA polymerase activity and virulence. The pathogenicity of other 
polymerase mutants has been determined by Field and Coen (1986).
A connection was established between the neuroinvasiveness of a number of HSV 
strains and the DNA sequence between 0.31-0.44 m.u. of the HSV genome (Oakes et al 
1986). HSV-2 strain 186 was found to be non-neuroinvasive following ocular 
inoculation although it has normal TK activity and is virulent following intracerebral 
inoculation. The HSV-l/HSV-2 intertypic recombinant HSV-R (BIE), in which HSV-2 
DNA sequences between 0.31-0.44m.u. were exchanged with HSV-1 (17+) DNA 
sequences, acquired the ability to spread from the cornea to the trigeminal ganglia and 
brain. This region of the genome is located within the sequences previously shown by 
Thompson et al (1986) to be responsible for invasion of the CNS following footpad 
inoculation (m.u. 0.25-0.53). This function was later attributed to the viral DNA 
polymerase gene (Day e ta l, 1988).
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I.7.2.3. UL50
This gene codes for the enzyme deoxyuridine triphosphate nucleotidohydrolase 
(dUTPase) which catalyses the hydrolysis of dUTP to dUMP and pyrophosphate 
(Wohlrab and Francke, 1980; Caradonna et ai, 1981). The gene encoding dUTPase has 
been mapped to UL50 (McGeoch et a i, 1988a). In tissue culture, dUTPase is not 
essential for HSV replication (jFisher and Preston, 1986; Williams, 1988; Barker and 
Roizman, 1990). Infection with wild-type HSV-1 results in down regulation of the 
cellular dUTPase while infection with dUTPase deficient mutants does not (Williams,
1988). In the mouse model, Pyles et al (1992) demonstrated that dUTPase is an 
important virulence and neuroinvasiveness determinant. Two dUTPase negative mutants 
(dUT") of HSV-1 were characterised in vitro and in vivo. The 1218 mutant contains an 
insertion of four codons in the dUTPase reading frame (Fisher and Preston, 1986) and 
the 17B1 mutant has a deletion of 928bp and encodes only the first six amino acids of 
the protein. Like the wild type HSV-1(17+), both mutants replicate efficiently in 
primary mouse embryo cells. The mutants were 10-fold less virulent than 17+ following 
intracerebral inoculation and 1000-fold less virulent following footpad inoculation. The 
replication kinetics of mutants compared to 17+ were assayed following footpad 
inoculation to determine the anatomical location of the invasiveness restriction. It was 
found that both mutants replicated with wild type kinetics in non-neural tissues 
(footpad) and entered and replicated efficiently in the peripheral nervous system (sciatic 
nerve and dorsal root ganglia). Replication was reduced in the spinal cord indicating that 
the mutants were defective in entry into or replication in the central nervous system. 
However, the mutants were capable of establishing latent infection but demonstrated a 
reduced reactivation frequency. The reactivation frequency of the 17B1 mutant was half 
that of the wild-type by seven days post DRG explantation. The mutants were severely 
impaired in in vivo reactivation following hyperthermia induction (heat stress) (Sawtell 
and Thompson, 1992a). 19% and 21% of DRG infected respectively with 1218 and 
17B1 reactivated compared to 82% of the 17+-infected DRG. Restoration of the 
dUTPase gene resulted in wild-type levels of virulence, neuroinvasiveness and
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reactivation frequency from latent infection.
17.2.4. US6
US6  encodes the glycoprotein D which is required for virus penetration into cells (Fuller 
and Spear, 1987; Highlander et a l, 1987) and has also been implicated in 
neuroinvasiveness. Kumel et al (1982) reported that the HSV-1 strain ANG is non- 
neuroinvasive following intraperitoneal, intravaginal or footpad inoculation. The 
generation of the neuroinvasive variant, ANG path following serial passage of the ANG 
strain in mouse brain was reported by Kaemer et al (1983). ANG path was able to 
spread from the site of inoculation to the central nervous system following 
intraperitoneal (Kaemer et ai, 1983) or footpad (Izumi and Stevens, 1990) inoculation. 
The increase in neuroinvasiveness of ANG path was attributed to a single amino acid 
substitution, from alanine to glycine, at position 84 of gD (Izumi and Stevens, 1990).
I.7.2.5. UL27
This gene codes for the glycoprotein B (gB) which is involved in viral fusion and entry 
into cells (Cai et al., 1988). Little is known about the role of gB in the virulence of 
HSV. It was shown that the HSV-1 strain KOS is non-neuroinvasive being blocked at 
the level of the spinal ganglia following footpad inoculation. The neuroinvasiveness of 
KOS was enhanced when its genome was recombined with the Hindlll-a fragment 
mapping between 0.25-0.53 m.u. (Thompson etal., 1986). The UL27 gene is located in 
Hindlll-a and it was shown to contain a single base change that appeared to affect the 
neuroinvasiveness phenotype of KOS. Another region of the genome which was 
responsible for the non-neuroinvasiveness of this strain was localised to the 6.3Kb 
BamHl-aÆcoRl-d fragment (0.15-0.19 m.u.) containing the entire ULIO, U L ll, UL12, 
UL13 and part of the UL9 and UL15 open reading frames. It is not yet known which of 
these ORFs is responsible for the non-neuroinasiveness of KOS (Yuhasz and Stevens,
1993).
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1.7.2 6. UL5
In previous studies, Javier et al (1988a) demonstrated that the HSV-l(17+)/HSV- 
2(HG52) intertypic recombinant (R13-1) was attenuated by 10^ fold in virulence 
following intracerebral inoculation of mice. Bloom and Stevens (1994), found that 
following footpad inoculation, no virus was detected in the brain and a reduced amount 
of R13-1 was found in the sciatic nerve, dorsal root ganglia and spinal cord. 
Examination of the spinal ganglia by immunofluorescence revealed that R13-1 is 
restricted in replication in neurons but not in glial cells. A few neurons of R 13-1- 
infected ganglia expressed viral antigens but most antigens were found in supporting 
cells. It was found that the block in the infectious cycle occurred prior to the initiation of 
late events. R13-1 produced normal levels of early RNA, but production of DNA and 
late RNA was less than that of the wild-type. In R13-1, the UL5 gene of HSV-1 is 
replaced by that of HSV-2. Marker rescue of R13-1 with the HSV-1 UL5 gene restored 
the virulence of R13-1 to that of wild-type. The UL5 product is a component of the 
helicase-primase complex, essential for DNA replication. It interacts with two other 
virally encoded components, UL8 and UL52 to form this complex (Crute et al., 1989). 
In R13-1, the origin-binding complex is composed of UL5 and UL8  products from 
HSV-2 and the UL52 product from HSV-1. It was postulated that replacement of UL5 
with its HSV-2 counterpart results in the formation of an altered helicase-primase 
complex, although a mutation in HSV-2 UL5 was not ruled out.
1.7.3. HSV genes involved in intracerebral virulence (Neurogrowth)
I.7.3.I. UL53
This gene is known to be the locus of a mutation that causes a syncytial plaque 
phenotype (Debroy et al., 1985; Pogue-Geile and Spear, 1987). UL53 encodes a 
glycosylated protein, gK (Hutchinson et al., 1992b) which contains four transmembrane 
regions and two N-glycosylation sites (Debroy et al, 1985; McGeoch et a l, 1988a). The 
product of UL53 was found to be responsible for intracerebral pathogenicity (IC) using
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two intratypic recombinants, R-15 and R-19 (Moyal e ta l, 1992). The molecular basis 
of pathogenicity of R-15 and R-19 was analysed by Ben-Hur et al (1987). Both R15 and 
R19 were generated by cotransfection of HFEM DNA with BamHl-b (0.738-0.809 m.u.) 
from strain F, to replace the deletion in the HFEM genome (0.762-0.789 m.u.). On 
intracerebral inoculation of mice, R-19 was as virulent as the parental HFEM while R- 
15 was avinilent (Rosen e ta l, 1985). The recombinant R-15 regained virulence when 
rescued with the BamHI fragment / (0.70-0.738 m.u.) from R-19. The virulence function 
was localised to a 2.0Kb Nrul-BamYH fragment which contains the UL53 gene. The 
virulence phenotype of the recombinants was linked with the morphology of the 
plaques. R-19 produces large syncytial plaques in monkey kidney BSC-1 cells while R- 
15 produces tiny syncytial plaques. Nucleotide sequence analysis was determined for 
the UL53 gene in R-15 and R-19 and three mutations were found in the amino acid 
sequence of UL53 of R-15 which were considered responsible for its avirulence 
phenotype and small plaque morphology (Moyal e ta l, 1992).
I.7.3.2. UL39-UL40
These genes code for the ribonucleotide reductase (RR) which is another key enzyme in 
the de novo synthesis of precursors for DNA synthesis. RR reduces the four 
ribonucleotide diphosphates to 2'-deoxyribonucleotide diphosphates (Thelander and 
Reichard, 1979). The enzyme consists of two non identical subunits (Cohen et a l, 
1985); the large subunit termed RRl (Mr 140000; also known as ICP6  for HSV-1 and 
ICPIO for HSV-2) and the small subunit termed RR2 (Mr, 38000) which are encoded by 
the UL39 and UL40 genes, respectively (McGeoch e ta l, 1988a). Despite the essential 
role of RR in DNA synthesis, in certain tissue culture systems RR is not essential for 
growth of HSV in dividing cells (Goldstein and Weller, 1988a). Studies with a deletion 
mutant (ICP6 A) lacking 90% of the coding region of UL39 demonstrated that RRl is 
essential for growth in dividing cells at high temperature (39.5°C) and in non-dividing 
cells under serum starved conditions. It was concluded that actively dividing cells 
contain a factor(s) which can complement the function of RRl and that this factor(s) is
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limited or absent in both growth restricted cells and cells at 39.5°C (Goldestein and 
Weller, 1988a,b). The enzyme appear to be essential for productive acute and 
reactivable latent infections in mice. In the eye model, Jacobson et al (1989) have shown 
that the RR deletion mutant ICP6 A is severely impaired in growth in the eye and 
trigeminal ganglia and failed to establish reactivable latent infections. The mutant also 
grew poorly in human primary comeal fibroblasts, suggesting that RR may be required 
for virulence in human infections (Brandt et a i, 1991). This finding was supported by 
Yamada et al (1991) when testing the pathogenicity of RR-null mutants which failed to 
grow in the cornea and in the nervous tissue of 4-week old mice. Mutants were detected 
in brain tissues following superinfection with a TK-deficient mutant of HSV-1. In 
hairless guinea pigs, the ICP6 A mutant produces cutaneous lesions as severe as those of 
the wild-type HSV-1 (Turk et al., 1989). Cameron et al (1988) found that temperature 
sensitive mutants, rjl207 and ts 1 2 2 2  with lesions in either subunit were about 1 0 ^ fold 
less virulent in mice than the parental HSV(17+) following intracerebral inoculation.
1.7.3 3. RLl (yi 34.5 )
Several laboratories have associated loss of capacity of HSV-1 or HSV-2 strains to cause 
death following intracerebral inoculation of mice, with genetic defects located at or near 
the termini of the long component of the genome. The existence of a virulence locus in 
the long repeat region of HSV was first demonstrated by Thompson and Stevens 
(1983b) using the 17+/HG52 intertypic recombinant, RE6 . Following intracerebral 
inoculation of mice, RE6  was avirulent with a LD50 of 3.2x10^ pfu/mouse compared to 
10 pfu/mouse for strains 17+ and HG52. Neurovirulence was restored to RE6  by HSV-1 
DNA sequences between 0.71 and 0.83 map units (Thompson et al., 1983). 
Subsequently further mapping localised this to a SstVXholl (0.82 and 0.832 m.u.) of the 
Hind in-c subfragment (Thompson et a l, 1989). The same region was also implicated 
in virulence of HSV by Javier et al (1987) using another intertypic recombinant, RS6 .
In our laboratory, a genomic region associated with HSV virulence has been determined 
using a deletion variant JH2604 of HSV-2 strain HG52 (Taha et a l, 1989a,b). This
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variant has a deletion of 1488bp within each copy of BamHI-v (0-0.02 m.u. and 0.81-
0.83 m.u.) of R l  including one copy of the 17bp direct repeat element of the ‘a ’ 
sequence and terminating 522bp upstream of the 5' end of the RL2 gene. JH2604 was 
shown to be avirulent in Balb/c mice with a LD50  >10^p.f.u./mouse compared to 
<10^p.f.u./mouse for the wild-type HG52. When the deleted sequence was introduced 
into the parental virus genome, avirulent recombinants with an LD50 > 1 0^ p.f.u./mouse 
were produced. Construction of revertants confirmed the localisation of a virulence 
locus. The avirulent phenotype of JH2604 was due to inability to replicate within 
neuronal cells of the brain as demonstrated by immunohistochemical staining using 
polyclonal anti-HSV serum. HSV antigens were widely distributed in neuronal and 
supporting cells inoculated with wild-type HG52. In JH2604 infected brains, virus 
antigens were located only at the site of inoculation (Taha et a l, 1990). The failure of 
JH2604 to multiply and spread in the CNS could have been due to poor packaging of the 
virus as a result of absence of the normal ‘a ’ sequence function. To exclude this 
possibility, another variant, 2616 which retained the DRl element of the ‘a ’ sequence 
but had a deletion of 786bp extending from 782bp upstream of the 5' end of RL2 to 
463bp downstream from the ‘a ’ sequence was isolated. 2616 was also avirulent 
following intracerebral inoculation of mice. This result demonstrated that the deletion of 
the DRl element of the ‘a ’ sequence did not contribute to avirulence (Harland and 
Brown, 1991). A sequence in an equivalent genomic location in HSV-1 strain 17+ was 
shown to play a role in neurovirulence (MacLean, A et a l, 1991).
A diploid gene designated yi 34.5 (RLl) has been localised to R l  of the HSV-1 
genome, between RL2 and the ‘a ’ sequence. The promoter and transcriptional initiation 
site of RLl are located in the terminus of the ‘a ’ sequence (Chou and Roizman, 1986). 
In HSV-1 strain F, RLl was predicted to encode the protein ICP34.5, a 43.5K 
polypeptide which contains the triplet Pro-Ala-Thr (PAT) repeated 10 times [(PAT) 1 0 ] 
(Chou and Roizman, 1986). In a subsequent study, Chou and Roizman (1990) revised 
the sequence of Yi 34.5, by making 25 alterations to the original sequence resulting in 
the gene containing only 263 codons instead of the previously published 358 codons
35
Introduction
(Ackermann et al., 1986). The revised sequence of HSV-1 strain F was almost identical 
to the published HSV-1 strain 17+ sequence (Perry and McGeoch, 1988), with the only 
major difference being a 2bp insert in the strain 17+ sequence. The two extra 
nucleotides rendered 60% of the 17+ sequence, including the PAT repeat, out of frame 
(Dolan et al., 1992). Revision of the 17+ sequence identified an equivalent ORF, 
designated RLl, to that in strain F (Dolan et al., 1992). RLl in 17+ encodes a 
polypeptide of 248 amino acids which contains 5 copies (Fig. 1.5) of the PAT sequence 
(McKay et al., 1993). In HSV-1 strain F the protein migrates at 39K and in 17+ at 37K 
(McKay et al., 1993). The number of copies of the PAT sequence was found to be 
variable among other HSV-1 strains (Chou and Roizman, 1990) and is absent in RLl of 
HSV-2 strain HG52 (McGeoch etal., 1991).
The ICP34.5 protein was detected in lysates of Hep-2 cells infected with HSV-1(F) 
using an antiserum raised against a peptide consisting of 10 copies of the PAT repeat 
(Ackermann et a l, 1986). A similar antiserum recognised ICP34.5 from HSV-1 strain F 
infected BHK cell extracts but was approximately 30-fold less efficient at detecting the 
strain 17+ protein. This difference in detection level was attributed to either a lower 
level of ICP34.5 expression in HSV-1 ( 17+)-infected cells or to a lower antibody 
affinity, as ICP34.5 of HSV-1(17+) contains only five copies of the PAT sequence 
(McKay e ta l, 1993). To facilitate detection of ICP34.5 in strain 17+-infected cells, the 
RLl gene was expressed in a bacterial expression system and the protein used to raise a 
polyclonal anti-ICP34.5 serum (McKie e ta l,  1994). Using this antiserum, ICP34.5 
HSV-1(17+) was detected at levels comparable to that of HSV-1(F) indicating that the 
previous differences were due to weak antibody affinity (McKay et a l, 1993). 
Ackermann et al (1986) and McKay et al (1993) using cell fractionation studies reported 
the accumulation of ICP34.5 largely in the cytoplasm of infected Hep-2 and 
BHK21/C13 cells, respectively. Using the polyclonal serum in fluorescence studies, the 
protein was localised to dense punctuate patches with minimal perinuclear staining in 
the cytoplasm of BHK21/C13 cells infected with HSV-1(17+) (McKie et a l, 1994). 
Insertion of a translational stop codon at the beginning of the RLl coding sequence
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abolished the virulence phenotype of HSV-1 strains F and 17+. The mutant viruses grew 
well in culture but failed to grow and spread in the CNS of mice after intracerebral 
inoculation. Reinsertion of the wild-type genes into these mutants restored the virulence 
phenotype (Chou et al., 1990; McKie et a l, 1994). Recently, Bolovan et al (1994) 
suggested a generalised function for ICP34.5. The requirement of ICP34.5 for 
productive infection of the cornea was demonstrated using the mutant 17 term A of HSV- 
1(17+). This mutant contains an insertion of 20bp in both copies of RLl at the B5ÆII 
site which results in termination of ICP34.5 after the N-terminal 30 amino acids. In the 
eyes of four week-old Swiss Webster mice, the mutant did not replicate efficiently and 
could not be recovered from the eyes and the trigeminal ganglia 3 days post-inoculation, 
although 17+ was recovered until day 7 post-inoculation. Similar findings with the RLl 
deletion mutant, 1716 and a stop codon insertion mutant, 1771 were demonstrated by 
Spivack et al (1995) in a mouse eye model. In contrast, the mutant 17 term A was as 
efficient as 17+ in replication in the foot pad (Bolovan et a l, 1994). The role of ICP34.5 
in neuroinvasiveness was also demonstrated by Bolovan e ta l (1994). The mutant 
17 term A was avirulent in Swiss Webster mice following footpad or ocular inoculation 
and the mice did not display any signs of central nervous system disorder. The reduction 
in the neuroinvasiveness of the mutant was due to severe restriction in replication in the 
dorsal root and trigeminal ganglia. A similar finding was reported for both 1716 and 
1771 following footpad inoculation of mice (Robertson et a l, 1992; Spivack et a l, 
1995).
Nucleotide sequence analysis of the corrresponding region of the HSV-2 strain HG52 
genome identified an equivalent RLl ORF. The HSV-2 HG52 RLl coding sequence 
starts at an ATG which aligns with the initiating ATG of HSV-1 strain F (Chou and 
Roizman., 1990) and strain 17+ (McGeoch et a l, 1991). In HG52, the coding sequence 
is interrupted by a set of repeated sequences consisting of six complete copies and one 
partial copy of a 19bp element which contains a TAG stop codon blocking all forward 
reading frames (Fig. 1.5). McGeoch et al (1991) considered that this repeat family 
which is flanked by excellent candidate splice donor and acceptor sites must be an
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intron, removal of which would bring the coding sequence back into frame. The spliced 
type 2 gene is predicted to encode a protein of 261 amino acids with 83% of the carboxy 
terminus being homologous (Fig. 1.5) to that of HSV-1 (McGeoch et a l, 1991) and to 
approximately 55% of the mouse protein MyD116 (McGeoch and Barnett, 1991). A 
corresponding domain is found in the LMW23-NL gene of the African Swine fever 
virus (Sussman et a l, 1992) and in the hamster GADD34 gene (Chou and Roizman,
1994) induced by growth arrest signals and DNA damaging agents (Fornace et a l,
1989).
1.8. Aims of the project.
The work presented in this thesis had the following objectives:
1. To confirm that the predicted ORF of RLl in HSV-2 strain HG52 was correct by 
constructing a RLl null mutant virus.
2. To confirm the presence of the intron in the predicted ORF of RLl and investigate its 
role in gene expression by constructing an intronless mutant virus.
3. To determine whether the 189bp conserved region played a role in virulence of HG52 
by making truncated versions of RLl.
4. To characterise the phenotype of mutant viruses in vivo and in vitro by comparison 
with the parental wild-type virus HG52.
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CHAPTER 2: MATERIALS AND METHODS
2.1. MATERIALS.
2.1.1. Cells
Baby hamster kidney 21 clone 13 (BHK21/C13) cells (MacPherson and Stoker, 1962) and 
3T6 mouse embryo fibroblasts (Todaro and Green, 1963) were used throughout this study.
2.1.2. Viruses
The wild-type parental virus HSV-2 strain HG52 plaque 17 (Timbury, 1971; Taha et a l ., 
1988) and the avirulent RLl deletion mutant 2604 (Harland and Brown, 1985) were used. 
Viruses were propagated and titrated in BHK21/C13 cells.
2.1.3. Cell culture media
BHK21/C13 cells were grown in Eagle's medium (Gibco) supplemented with 10% (v/v) 
newborn calf serum (Gibco), 10% (v/v) tryptose phosphate broth, 200mM L-glutamine 
(Gibco), 10,000 |ig/ml penicillin (Gibco) and 10,000 |ig/ml streptomycin (Busby etal, 
1964). This medium will be referred to subsequently as ETC 10.
Variations on the basic growth medium were:
PIC Phosphate-free Eagle's medium containing 1% newborn calf serum
EMC 10% Eagle's medium containing 1.5% carboxymethyl cellulose and 10%
newborn calf serum.
3T6 mouse embryo fibroblasts were propagated in Dulbecco’s modified Eagle’s medium 
(Gibco) supplemented with 10% foetal calf serum (Gibco), 200mM glutamine (Gibco), 
10,000 |ig/ml penicillin (Gibco) and 10,000 p.g/ml. streptomycin (Brown et a l 1994a).
2.1.4. Experimental animals
Three week old female Balb/c mice (Bantin and Kingman; Harlan U.K. Ltd.) were used in 
this study.
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2.1.5. Bacterial and phage strains
Escherichia coli strain NM522 [supE, thi, (lac-proAB), hsd5(r-, m-), (F' proAB, lac 192 
M15)] (Gough and Murray, 1983) and E. coli strain BW313 (recAl, spoTl, ung’, dut", 
thi-, Hfr KL16(P045) (Kunkel, 1985) were used for transformation and growth of 
recombinant plasmids and phagemids. The bacteriophages M13K07 and R408 ( >10^  ^
p.f.u./ml ), were used for preparation of uracil-rich single-stranded DNA templates for 
site-directed mutagenesis. Both phages and E. coli strain NM522 were obtained from 
Promega while E. coli strain BW313 was kindly provided by Dr. R. Thompson.
2.1.6. Bacterial growth media
The media used for bacterial growth were:
L-broth lOg/1 NaCl, lOg/1 bactotryptone (Difco), 5g/l yeast extract (Difco).
L-broth agar L-broth containing 1% (w/v) bactoagar (Difco).
2xYT 5g/l NaCl, 16g/l bactotryptone (Difco), 5g/l yeast extract (Difco).
Top agar 0.6% (w/v) bactoagar (Difco) in water.
2.1.7. Oligonucleotides
Synthetic oligonucleotides were synthesised in the department by Dr J.McLauchlan, using 
a model 8600 Biosearch multiple column DNA synthesiser.
2.1.8. Plasmids
The starting plasmid used for construction of RLl containing recombinant phagemids was 
pATl53 BamHI g . This plasmid contains the wild-type HG52 BamHI g fragment and was 
kindly provided by Dr. A. Davison. Subfragments of BamHI g containing the RLl ORF 
were cloned into the phagemid pGEM3zf(-) (Promega).
2.1.9. Enzymes
Restriction enzymes were obtained from New England Biolabs. Exceptions were:
Avian Myeloblastosis Virus reverse transcriptase Promega
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Calf intestinal alkaline phosphatase (CIP) Boehringer Mannheim Corporation
Lysozyme Sigma Chemical Co.
Moloney Murine Leukemia virus reverse transcriptase BRL-GIBCO 
Retrotherm Cambio
Ribonuclease A Sigma Chemical Co.
T4 DNA ligase Boehringer Mannheim Corporation
T4 polynucleotide kinase Boehringer Mannheim Corporation
T7 DNA polymerase Pharmacia
2.1.10. Radioisotopes
All radioisotopes were supplied by Amersham International pic.. They had the following 
specific activities:
[^2p]-Orthophosphate 3000Ci/mmol
5' [a  -  32p] dNTPs ~3000Ci/mmol
[ a -  35s] dATP 400Ci/mmol
2.1.11. Chemicals
The chemicals used were of analytical grade and most were supplied by either BDH 
chemicals UK or Sigma Chemical Co.. Exceptions were:
Acetic acid glacial May and Baker Ltd., Dagenham, England
Ampicillin sodium B.P. (Penbritin) Beecham Research
APS and TEMED Bio-Rad Laboratories
Boric acid and glycerol PROLABO
Caesium Chloride and acrylamide Koch Light Ltd. (Suffolk, England)
2'-Deoxynucleotide-5'-triphosphate (dNTPs) Pharmacia
Gene 32 protein (3.7mg/ml) Pharmacia
Guanidine thiocyanate Fluk Biochemika
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Isopropyl -p-D-thiogalactoside 
NuSieve agarose
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Pharmacia
Bethesda Research Laboratories (BRL) 
FMC BioProducts
2.1.12. Commonly used buffers and solutions
Alkaline lysis solution I
Alkaline lysis solution II 
Alkaline lysis solution III 
Chloroform lisoamylalcohol 
DEPC-treated water 
Formamide dye mix
Gel soak I 
Gel soak II
Hybridization buffer 
Ligation buffer (lOx) 
lOxMOPS buffer 
Phenol chloroform (1:1) 
PBS-A
PBS complete
PBS /calf serum
Random primer buffer (5x)
lOmM EOT A, 50mM glucose, 25mM Tris-HCl pH 8.0 
and 5mg/ml lysozyme added prior to use.
200mM NaOH and 1% (w/v) SDS.
5M potassium acetate pH4.8.
This is a 24:1 mixture of chloroform and isoamylalcohol 
0.5ml of DEPC in 500ml d.HiO.
95% formamide, 20mM EOT A, 0.05% bromophenol 
blue, 0.05% xylene cyanol.
3M NaCl, IM NaOH.
600mM NaCl, IM Tris-HCl, adjusted to pH8.0 with 
HCl.
7% SDS, 0.5M NaP0 4  (NaH2P04; Na2 HP0 4 ), pH7.4. 
200mM DTT, lOOmM MgCl2 , 0.5M Tris-HCl, pH 7.8. 
200mM MOPS, 50mM sodium acetate, lOmM EDTA. 
This is a 1:1 mixture of phenol and chloroform.
170mM NaCl, 3.4mM KCl, lOmM Na2HP04,
1 .8 mM KH2 PO4 , pH7.2.
PBS A plus 6 .8 mM CaCl2 , 4.9mM MgCl2 .
PBS complete containing 5% newborn calf serum.
Three solutions A, B, C at a ratio of 10:25:15 
respectively:
solution A: 0.25M 2-mercaptoethanol, 0.5M dGTP 
or dCTP, 0.5M dATP, 0.5M dTTP, 1.25M Tris-HCl, 
pH7.6, 0.125M MgC12.
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RNA-loading buffer 
Saturated phenol
SSC (20x)
T4 DNA polymerase 
buffer (lOx)
TBE (lOx)
TE
Tris-saline
Trypsin
Trypsin-Versene
Versene
X-gal
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solution B: 2M HEPES, pH6 .6 .
solution C: Hexadeoxyribonucleotides resuspended in
TE at 90 OD units/ml.
lOOmM EOT A, 10% (w/v) Ficoll 400,0.25% (w/v) 
bromophenol blue, 5x TBE.
30% glycerol, 5% bromophenol blue 
Phenol saturated by mixing 1:1 with phenol saturation 
buffer, (lOmM Tris-HCl, pH7.5, lOmM EDTA, lOOmM 
NaCl).
BOOmM trisodium citrate, 260mM NaCl.
IM Tris-HCl pH7.9, IM MgCl2 , IM DTT.
2mM EDTA, 89mM boric acid, 89mM Tris-HCl pH8.0. 
ImM EDTA, lOmM Tris-HCl pH8.0.
140mM NaCl, 30mM KCl, 280mM Na2HP04,
1 mg/ml glucose, 0.0015% (w/v) phenol red, 25mM 
Tris-HCl (pH7.4), 100 units/ml penicillin, 0.1 mg/ml 
streptomycin.
0.25% (w/v) Difco trypsin dissolved in Tris-saline.
1 volume trypsin + 4 volumes versene.
0.6mM EDTA dissolved in PBS containing 0.002% 
(w/v) phenol red.
25mg/ml in dimethylformamide.
2.1.13. Miscellaneous
Hybond N hybridization 
transfer membranes 
Giemsa stain 
Polaroid- 667 film
Amersham
BDH
Polaroid (U.K.)
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Repelcote BDH Chemicals
XS-1 film Kodak
2.2. METHODS
2.2.1. Growth of cells
BHK21/C13 cells were grown in 80oz roller bottles containing 100ml ETC 10 medium at 
37^C for 3 days in an atmosphere of 95% air and 5% CO2  (MacPherson and Stoker,
1962). Confluent cells were harvested by washing the monolayers twice with 25ml of 
trypsin-versene, and resuspending the detached cells in 20ml of ETC 10. Cells were stored 
for a short-term (one week) at 4°C in the refrigerator . When required, they were passed 
and for some experiments were plated on 60mm or 30mm petri dishes or Linbro wells at a 
density of 4x10^, 2x10^ and 5x10^ cells per plate, respectively.
3T6 mouse embryo fibroblasts were grown and harvested under the same conditions using 
Dulbecco’s Modified Eagle’s medium. The yield of cells was determined as described by 
Freshney (1994) using the improved Neubauer counting chamber (Weber, England).
2.2.2. Long-term storage of cells
To provide a large supply of cells for experimental purposes, personal user stocks of cells 
were prepared and stored in a liquid nitrogen freezer. For this purpose, cells were grown 
in a 600ml culture flask under the conditions described in Section 2.2.1. Confluent cells 
were harvested, resuspended in 5ml medium containing 10% DMSO and aliquoted at 
1x10^ cells/ml into glass black capped vials. The vials were wrapped with cotton wool 
and placed in a polystyrene foam box lined with several layers of napkins to provide 
sufficient insulation during freezing at -70°C at a rate of l°C/min. Following overnight 
freezing at -70°C, vials of cells were transferred rapidly to a liquid nitrogen freezer
(Freshney, 1994). When required, cells were recovered by rapid thawing in a 37 °C water 
bath. Cells were transferred to a 50ml culture flask and warm medium was added. 
Following 8-24h incubation at 37 °C, medium was removed from the flask and replaced 
with a fresh DMSO-free medium. Incubation at 37°C was continued for a further 2-3
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days. Confluent monolayer of cells was trypsinized and cells were grown at 37°C in a 
600ml culture flask. The yield from this flask was split between other flasks and a large 
supply of cells was grown.
2.2.3. Growth and harvest of HS V
Virus stocks were grown as described by Brown et al (1973). Confluent roller bottles 
were infected with 0.003 p.f.u./cell of HSV in 20ml of ETC 10, assuming lxlO& cells per 
roller bottle. These were incubated at 31°C for 4 -5 days, until c.p.e. was complete, when 
the cells were shaken into the medium. The cells were pelleted in 250ml plastic Falcon 
tubes by spinning at 2K for 10 minutes at 4°C in a Fison's Coolspin. The supernatant and 
cell pellet were separated and two individual virus stocks prepared:
Supernatant stock: The supernatant was poured into 250ml centrifuge bottles and spun at 
12K for 2h (4°C) in a Sorvall OS A rotor. The supernatant was discarded, and the virus 
pellet resuspended in 1ml ETC 10 or PBS/calf serum per roller bottle. The pellet was 
sonicated until homogeneous, before aliquoting into 2ml amounts and storing at -70°C. 
Cell-associated stock: The cell pellet was resuspended in 0.5ml medium/roller bottle and 
thoroughly sonicated before spinning at 2K for 10 minutes at 4°C in a Fison's Coolspin 
centrifuge. The supernatant was kept on ice while the process was repeated. The two 
supernatants were combined to give the cell-associated virus stock. This was aliquoted 
and stored as above.
In many instances the cell-associated and the supernatant stocks were mixed before 
aliquoting and storing at -70°C-
2.2.4. Sterility checks on virus stocks
Brain heart infusion agar (BHI) plates and BHI plates containing 10% horse blood (BHI 
blood agar) were obtained from the Cytology department.
To check for fungal contamination of virus stocks, a small aliquot was streaked in 
duplicate onto BHI plates, which were sealed with parafilm and incubated at RT. Bacterial 
contamination was detected by plating onto BHI blood agar and incubating at 37°C. If no
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colonies were visible after 7  days incubation, the stocks were considered sterile.
2.2.5. Titration of virus stocks
Virus stocks were serially diluted 10-fold in PBS/calf serum. 100|il aliquots were added to 
75% confluent monolayers of BHK21/C13 cells on 60mm petri dishes from which the 
medium had been removed. The plates were incubated at 37°C for 45-60 min to allow 
absorption of the virus to the cells, before overlaying with 6 ml EMC 10%. Plates were 
incubated at 37°C or 38.5°C for 2 days, or at 31°C for 3 days. Monolayers were fixed and 
stained with Giemsa at RT for Ih. After washing, plaques were counted using a dissecting 
microscope and virus titres calculated as p.f.u./ml.
2.2.6 Temperature sensitivity
Confluent BHK/C13 cells were infected at a multiplicity of 5 p.f.u./cell. Following 
separate 24h incubation at 31°C, 37°C, or 38.5°C, the monolayers were harvested, 
sonicated and the progeny virus titrated on BHK/C13 cells at 37°C.
2.2.7. Preparation of HSV DNA
The DNA of HSV stocks was prepared according to the method of Wilkie (1973) and 
Brown et al (1984). To prepare a large scale HSV DNA stock, 10 roller bottles containing 
almost confluent monolayers of BHK21/C13 cells were infected at 31 °C at a m.o.i. of 
0.003 p.f.u./cell. The infection was allowed to proceed until c.p.e. was extensive (4-5 
days). The cells were shaken into the medium and spun at 2K for 10 minutes in a Fison's 
Coolspin. The supernatant was kept on ice while the nuclei were extracted from the cell 
pellet by treatment with 0.5% (w/v) NP40 in RSB (lOmM KCl, 1.5mM MgCl2 , lOmM 
Tris-HCl, pH 7.5) followed by centrifugation (2K for 10 minutes) to pellet the cell debris 
and nuclei. This was repeated before pooling the supernatants and spinning to pellet the 
virus at 12K for 2h in a Sorvall GSA rotor.
The virus pellet, containing cell released and cytoplasmic virus was resuspended in NTE 
buffer (lOmM Tris-HCl, pH7.5, lOmM NaCl, ImM EDTA) before adding EDTA and
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SDS to a final concentration of lOmM and 2% (w/v) respectively to lyse the virus. Viral 
DNA was extracted 3-4 times with saturated phenol and once with chloroform: 
isoamylalcohol, prior to precipitating with 2 volumes of ethanol at RT for 5 minutes. 
DNA was pelleted at 2K for 10 minutes, washed with 70% ethanol, dried at 37°C and 
resuspended in a minimal volume of H2 O containing RNase A (50|ig/ml).
2.2.8. In vivo labelling of viral DNA
This is a modification of the method described by Lonsdale (1979). Confluent monolayers 
of BHK21/C13 cells in Linbro wells were infected with either lOOjil of a plate stock or 
2x10^ p.f.u. of a virus stock. After absorption for 45 minutes at 37°C, the virus was 
removed and the cells washed with and maintained in PIC for 2h at 31°C. One pCi of 
orthophosphate (32p) in 50pl PIC was added per well and incubation continued at 31°C 
for 2-5 days. At the end of the incubation period, 0.5ml of 5% (w/v) SDS was added to 
each well. Trays were incubated at 37 °C for 5-10 minutes before scraping the cells off the 
wells and adding them to 1ml of phenol. The samples were inverted and incubated at RT 
for 10 minutes, with a further inversion after 5 minutes. They were centrifuged at 2K for 
10 minutes at RT in a Fison's Coolspin before removing the top layer into 2 volumes of 
ethanol. After gently inverting the tubes, they were spun as before. The ethanol was 
poured off and the DNA dried for 10 minutes at 37 °C with the tubes in an inverted 
position. Two hundred pi of a RNAse A (50pg/ml) solution were added to each sample 
and the DNA left to dissolve for 2h at 37°C. The DNA was then ready for digestion with 
the appropriate enzyme(s).
2.2.9. Transfection of DNA into cells using the calcium phosphate technique
This method is a modification of that described by Stow and Wilkie (1976). Five hundred 
pi HEBS, pH7.05, (130mM NaCl, 4.9mM KCl, 1.6mM Na2 HP0 4 , 5.5mM D-glucose,
21mM HEPES) containing lOpg/ml calf thymus DNA [section 2.2.11], 0.2-2pg intact 
virus DNA, 1-lOpg plasmid DNA and 130mM CaCl2 , were added to semi-confluent
monolayers of BHK21/C13 cells on 60mm petri dishes, from which the medium had been
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removed. Following incubation at 37°C for 45-60 minutes, cells were overlaid with 6ml 
ETCIO.
Four to eight hours later the media was removed from the plates which were washed once 
with ETCIO. 1.5ml 25% (v/v) DMSO in HEBS was added and the plates incubated at RT 
for 4 minutes. The DMSO was removed and the plates washed twice and overlaid with, 
6ml ETCIO. Incubation was continued at 37°C until c.p.e. was complete.
2.2.10. Isolation of single plaques from a transfection
Once c.p.e. from a transfection was complete, the cells were scraped into the growth 
media, transferred into a black-cap vial and sonicated until homogeneous. Serial 10-fold 
dilutions of each transfection were made in PBS/calf serum and the 10"  ^to 10'^ dilutions 
from each plated onto 70% confluent BHK21/C13 cells. After absorption at 37°C for Ih, 
the plates were overlaid with 6ml EMC 10% and incubation continued at 37 °C for a 
further 48h. The plates were washed twice and overlaid with l-2ml of PBS/calf serum. To 
prepare plate stocks, single plaques were isolated and grown in Linbro wells containing 
BHK21/C13 cells. Plates were incubated for 3-4 days at 37°C then stored at -70°C.
2.2.11. Preparation of calf thymus DNA
One gram of double-stranded calf thymus DNA (Sigma) was dissolved in 300ml of dH20 
containing 2% SDS at RT for 1-2 days. DNA was extracted twice with an equal volume of 
chloroformlisoamylalcohol (24:1), mixed for 10-15min and spun at 2000 rpm for lOmin. 
The top aqueous layer containing the DNA was removed and 2 volumes of ethanol were 
added. The DNA precipitate was spooled out using a glass rod and lyophilised in the 
freeze drier. The dried DNA was dissolved in 300ml dH20 (without SDS), digested with 
50pg/ml RNase A for 30min at 37 °C.
The extraction, precipitation and drying of DNA was repeated again as above. Finally, the 
DNA was redissolved gradually in 25ml of dH20 and quantitated spectrophotometrically 
using the formula IOD26O = 40|ig/ml. The concentration was adjusted by the addition of 
dH20 to lOmg/ml. This was then aliquoted and stored at -20°C.
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2.2.12. Ligation
Several strategies of ligation (Sambrook et a l , 1989) were adopted to ligate fragments of 
HSV DNA to plasmid/phagemid vectors. Both vector and insert, were cut with the 
appropriate restriction enzymes. If the vector was cut with a blunt-cutting enzyme its 
digestion was usually carried out in the presence of 1 unit calf intestinal phosphatase 
(Boehringer Mannheim) to prevent recircularization during ligation. The vector was 
purified as described in section 2.2.18 and the fragment as described in section 2 .2 .2 0 . 
Three types of fragment ends could be generated:
a ) Blunt or compatible ends: In this case various quantities of fragment were ligated to 
lOOng of vector DNA at 14°C overnight. Ligation was carried out in Ix ligation buffer 
[see section 2.1.12] in the presence of 2 units of T4 DNA ligase (Boehringer Mannheim), 
b ) 5' overhangs: In the absence of a compatible site in the vector: if the fragment to be 
cloned had 5' overhangs these had to be filled in before cloning into the vector which had 
been cut with a blunt-cutting enzyme e.g. Sma I. Prior to running on a gel, 0.1 volume of 
2.5mM dNTPs and lunit of Klenow fragment of DNA polymerase I which carries the 
5—>3" exonuclease activity was added to the digestion mixture. Following incubation at 
37°C for 30 minutes, the digest was run on a gel. The appropriate fragment was purified 
as described in section 2 .2 .2 0  and ligated to the vector as described in (a) above, 
c ) 3' overhangs: In the absence of a compatible site in the vector: if the fragment to be 
cloned into the vector had 3' overhangs, these had to be exonucleased. The digestion 
mixture was purified as described in section 2.2.18. and redissolved in an appropriate 
volume of dH20. To this was added 1 unit T4 DNA polymerase which has a strong
3' >5 "exonuclease activity and 0.1 volume of T4 polymerase buffer. Following
incubation at 37°C for Ihr, purification and ligation of the fragment was carried out as in 
(i) above.
2.2.13. Glycerol / DMSO stocks of bacteria
Glycerol stocks of bacteria were prepared by centrifugation of an overnight culture (10ml) 
at 2000 rpm for 10 min. The pellets were resuspended in 5ml L-broth, mixed with 5ml of
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99.5% glycerol and stored at -20°C. DMSO stocks were prepared using the same 
procedure except that the pellets were resuspended in L-broth containing 10% (v/v) 
DMSO and stored at -70°C.
2.2.14. Preparation of competent bacteria and transformation
Ten ml of 2xYT broth was inoculated with 15pl of a glycerol stock of bacteria and 
incubated with shaking at 37°C overnight to produce a saturated culture. One ml of this 
culture was used to inoculate 100ml of 2xYT broth which was shaken at 37°C for 2.5-3h 
to get the bacterial cells in mid-log phase. The bacterial cells were pelleted by spinning at 
2K for 10 minutes in a Fison's Coolspin and resuspended in 1/10th volume of 
transformation and storage buffer (lOmM MgCl2 , lOmM MgS04, 10%(w/v) PEG 3,500, 
5% (v/v) dimethyl sulphoxide). After 10 minutes on ice, the bacteria were considered 
competent for transformation.
Typically, Ipl and lOpl of a ligation mix or plasmid preparation were incubated for 30 
minutes on ice with 100|il of competent E.coli. One ml of L-broth was added to the 
transformation mix and incubation was continued for a further hour at 37°C. For selection 
of transformants, lOOpl of the transformed bacteria were plated onto L-broth agar plates 
containing, if appropriate lOpg/ml ampicillin ± 25pg/ml X-gal. Plates were allowed to dry 
at room temperature, before incubating in an inverted position at 37°C overnight (Chung 
and Miller, 1988).
2.2.15. Small scale plasmid preparation
Single, transformed, bacterial colonies were picked and resuspended in 5ml of L-broth 
containing 100|ig/ml ampicillin. Following growth at 37°C for 8-16h, 1.5ml aliquots of 
each culture were spun at low speed (6500g) in a microfuge, the supernatant discarded and 
the cells resuspended in lOOpl of alkaline lysis solution I [see section 2.1.12]. Following 5 
minutes incubation at RT, 200|il of alkaline lysis solution II [section 2.1.12] was added, 
and the cultures mixed vigorously. After a further 5 minutes incubation at RT, 150pl of 
alkaline lysis solution III [section 2.1.12] was added, mixed by vortexing and incubated at
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RT for 5 minutes. A white precipitate consisting of the cell debris was pelleted at high 
speed (13000g) in a microfuge. Plasmid DNA was extracted from the supernatant using an 
equal volume of phenolichloroform followed by ethanol precipitation at RT for 1 minute. 
The DNA was pelleted by spinning at 13,000g for 5 minutes in a microfuge, washed in 
70% ethanol, dried in a Speedivac and resuspended in lOOjil H2 O containing 50|ig/ml 
RNase A (Sambrook, 1989).
2.2.16. Large scale plasmid preparation
The method used was essentially as described by Bimboim and Doly (1979), and 
modified by Maniatis et al (1982). A single transformed bacterial colony from a L-broth 
agar plate was inoculated into 5ml of L-broth containing the appropriate antibiotic and 
shaken at 37°C for 8-16h. The culture was transferred into 500ml L-broth containing the 
appropriate antibiotic in a 2 litre dimpled flask and shaken at 37°C overnight.
The bacteria were pelleted by centrifugation at 8 K for 10 minutes in a Sorvall GSA rotor, 
the pellet resuspended in 7ml alkaline lysis solution I [see section 2.1.12] and incubated at 
RT for 10 minutes. Freshly made alkaline lysis solution II (14ml) was added and 
incubation continued for a further 10 minutes on ice. Ice-cold alkaline lysis solution III 
(10.5ml) was added, incubation continued on ice for 10 minutes and the bacterial debris 
pelleted by centrifugation at 12K for 10 minutes in a Sorvall SS34 rotor. DNA was 
extracted twice with an equal volume of phenoLchloroform and once with an equal 
volume of chloroform. The DNA was precipitated by the addition of 2 volumes of 
ethanol, centrifuged at 12K for 30 minutes in a Sorvall SS34 rotor at RT, washed in 70% 
ethanol, pelleted as before, dried in the incubator and dissolved in water containing 
50|ig/ml RNase A.
In some instances, to remove residual host DNA and RNA, the DNA was further purified 
by isopycnic banding on caesium chloride gradients. In this case, the DNA was only 
extracted once with phenoLchloroform. Caesium chloride was added until the buoyant 
density was 1.55g/ml and ethidium bromide was added to a final concentration of 0.5 
mg/ml. The mixture was pipetted into Oakridge tubes, which were capped, sealed and
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centrifuged at 45,000 r.p.m. overnight in a Sorvall Ti50 rotor. The DNA was visualised on 
a long wave U.V. light box and the lower band which contained the supercoiled plasmid 
DNA was removed using a needle and syringe. After extracting at least 3 times with 
isoamyl alcohol, the DNA was ethanol precipitated as described above. The DNA 
concentration was quantitated by running a small quantity on an agarose gel alongside 
standards of known concentrations (Sambrook e ta l ., 1989).
2.2.17. Restriction enzyme digestion of DNA
The manufacturer's recommended buffers and conditions were generally used for each 
individual restriction enzyme. To achieve complete digestion, Ifig samples of HSV or 
plasmid DNA were digested with 2-5 units of restriction enzyme for 4h at the appropriate 
temperature. If the digested DNA was to be run on an agarose gel, 1/5- 1/6 volume of RE 
stop was added prior to loading, otherwise the digested DNA was recovered as described 
in section 2.2.18.
2.2.18. Phenol-chloroform extraction of DNA from restriction enzyme digestion 
mixtures
If the digestion mixture was not at least 100|il, it was increased to this volume using 
dH2 0 . An equal volume of phenoLchloroform was added, the mixture mixed vigorously,
and spun at 13000g for 2 minutes in a microfuge. The top aqueous layer was removed into 
a separate eppendorf tube and the bottom layer was back extracted with an equal volume 
of dH2 0 . An equal volume of chloroform was added to the aqueous layer and the solution
mixed and spun at 13000g for 2 minutes in a microfuge. The top layer was removed and 
the sample was back extracted as before.
To precipitate the DNA, 2 volumes of ethanol and 0.1 volumes of 3M sodium acetate 
were added. Following 10 minutes incubation on dry ice, the DNA was pelleted at 13000g 
for 5 minutes, washed with 70% ethanol and dried in a Speedivac, before resuspending in 
an appropriate volume of dH2 0 .
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2.2.19. Agarose gel electrophoresis
Restriction endonuclease digested viral or plasmid DNA was analysed on 0.4-1.5% (w/v) 
agarose gels in IxTBE buffer. When cool to about 45°C, the boiled agarose solutions 
were poured onto glass plates (16.5x26.5cm) whose edges had been sealed with tape and 
onto which 12-26 tooth combs had been placed. For non-radioactive samples, ethidium 
bromide was added to the agarose solution to a final concentration of 0.5|ig/ml before 
pouring. The gels were allowed to set at RT for Ih and then transferred to horizontal tanks 
containing IxTBE buffer. DNA samples were mixed with one-fifth volume of RE stop, 
loaded into the gel tracks and electrophoresed at 40-120V for 4-16h (Sambrook et al 
,1989).
For quantitation of fragment and vector DNA prior to transfection or ligation, gels 
containing ethidium bromide were poured into mini-gel kits (Bio-Rad). Samples 
(generally 5-7|il) were run at 50V for l-2h, visualized using a short wave (260) U.V. lamp 
and photographed on Polaroid film. A 1Kb DNA marker (BRL) of known concentration 
was run alongside the DNA samples to enable confirmation of the vector/fragment size 
and quantitation of each sample.
2.2.20. Recovery and purification of DNA from agarose gels
Generally the DNA to be recovered had been digested with restriction enzymes [section 
2.2.17] before running on an agarose gel. In order to cause the minimum possible damage 
to the DNA, it was visualised using a long wave (300-360nm) U.V. lamp. A gel slice 
containing the desired DNA fragment was cut out with a sharp scalpel and the DNA 
recovered and purified using the Prep-A-Gene DNA Purification Kit (BIO-RAD) as 
directed. For this purpose, the gel slice was cut into small pieces and dissolved at 55°C in 
the presence of Prep-A-gene binding buffer. The required amount of Prep-A-gene matrix 
was added, the mixture vortexed briefly, incubated at RT for 10 min and spun at 2000rpm 
for 2 min. The pellet containing the bound DNA was washed twice with the binding 
buffer and three times with the wash buffer. After the last wash, the bound DNA was 
eluted at 37 °C using the elution buffer. The yield was estimated as described in section
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2 .2 . 19.
In many instances, if the DNA fragment was small, it was recovered from the gel using 
the Spin-X™ centrifuge filter unit (Costar). The agarose retained on the filter was washed 
with 0.6M sodium acetate. The DNA was phenoLchloroform extraced, precipitated with 
ethanol plus 3M sodium acetate, washed with 70% ethanol, dried and dissolved with 
dH20.
2.2.21. In vitro labelling of DNA
Gel purified fragments of plasmid DNA were P labelled using the method of nick- 
translation (Rigby et al, 1977). DNA (lO-lOOng) was boiled for 10 minutes and 
radiolabelled in a reaction mix containing: 1 pi of 1% BSA, 20mpCi dCTP, 5pl of 5x 
random primer buffer and 2 units Klenow polymerase in a final volume of 25 pi. The 
mixture was incubated at 37 °C for at least 30 minutes and boiled prior to use for Southern 
blotting.
2.2.22. Southern blotting
Southern blotting was carried out as described by Sambrook et al (1989). Purified virus, 
infected cell DNA or plasmid DNA was digested with the appropriate restriction 
enzyme(s) before running on an agarose gel. The gel was visualised under short-wave 
U.V. light to confirm DNA digestion before placing in 500ml Gel Soak I [see section
2.1.12] for Ih, rinsing with deionised water and transferring to Gel Soak II [section
2.1.12] for Ih. After rinsing as before, it was transferred to 500ml 20xSSC for a further 
Ih. The gel was now ready for blotting onto either one or two sheets simultaneously of 
Hybond™ N hybridization transfer membrane. For each transfer, one sheet of membrane 
and five sheets of Whatmann 3MM chromatography paper, all cut to the exact size of the 
gel were required.
A bundle of Hi-Dry' towels was placed on the bench followed by three sheets of dry then 
two sheets of 20xSSC soaked 3MM paper. The membrane was placed on top of the filter 
papers followed by the gel, thus ensuring that there were no air bubbles between the gel
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and the membrane. A glass plate and heavy weight were placed on top and the blot left for 
at least 4h during which time the DNA was drawn out of the gel onto the adjacent side of 
the nitrocellulose. To transfer DNA to two membranes this procedure was repeated on top 
of the gel.
The DNA was cross-linked to the membrane using a U.V. Stratalinker (Stratagene, USA) 
and hybridized to the labelled probe [section 2 .2 .2 1 ] in a sealed bag containing 2 0 ml 
hybridization buffer [see section 1.1.12]. Hybridization was generally carried out 
overnight at 65°C. The membrane was washed for 3x30 min with 1 litre 2xSSC, 
0.1%(w/v)SDS before drying and setting up for autoradiography against Kodak XS-1 
film.
2.2.23. Purification of a synthetic oligonucleotide
Eighty ml of 6 % acrylamide, IxTBE, 9M urea sequencing gel mix was polymerized with 
160pl of 25% (w/v) APS and 60pl TEMED. This was poured between two 20x22cm glass 
plates separated by 1.5mm spacers and a 10 tooth comb was inserted at the top.
The synthetic oligonucleotides were deprotected at 65°C for 5-6h, frozen on dry ice and 
dried in the speedivac overnight. Each oligonucleotide was resuspended in 50pl H2 O.
Glycerol (5pl) was added to 30pl of oligonucleotide solution and loaded immediately onto 
the gel. Form amide dye mix (2pl) was loaded in a separate well to act as a molecular 
weight marker and the gel was run at 10mA for 3-4h in IxTBE. Electrophoresis was 
stopped when the dye had migrated approximately two thirds of the length of the gel. The 
gel was removed, wrapped in cling-film and viewed against a white chromatographic 
plate using a hand-held long-wave U.V lamp (Sambrook et al, 1989). If the synthesis had 
been successful, then a predominant band, with possibly a few lower molecular weight 
bands, was observed. The top band was cut out with a scalpel, mashed with a glass rod, 
and incubated overnight at 42°C in 1ml elution buffer (0.5M ammonium acetate, 0.25mM 
EDTA, 20% (w/v) SDS). This was filtered through a SPIN-X™centrifuge filter unit to 
remove the acrylamide, phenol: chloroform extracted, ethanol precipitated, washed in 
70% ethanol, dried and dissolved in dH2 0 . The concentration of the oligonucleotide was
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determined spectrophotometrically using the formula: lOD = 20p,g/ml.
2.2.24. Linker-insertion mutagenesis
Insertional mutagenesis was performed according to the method of Sambrook et al 
(1989). For this purpose, an oligonucleotide containing the desired mutation was 
synthesized [section 2.1.7], purified [section 2.2.23],phosphorylated [section 2.2.25(a)] 
and used to prepare the double stranded linker. This linker was prepared by heating the 
phosphorylated oligonucleotide to 70°C and allowing it to cool slowly to RT. The 
annealed DNA was ligated to blunt ended termini of a plasmid vector as described in 
section 2 .2 .1 2  (a).
2.2.25. Single-stranded site directed mutagenesis
This technique was carried out as described by Carter (1991), based on the method of 
Kunkel et al (1987). It includes the following: 
a ) Phosphorylation of the mutagenic oligonucleotide
The oligonucleotide (60 pmole) was purified [section 2.2.23] and phosphorylated by 10 
units of T4 polynucleotide kinase in a mixture containing 500mM ATP, lOOmM DTT and 
lOx Kinase buffer (500mM Tris.HCl pH 8 , lOOmM MgCl2 ) at 37°C for Ih. The reaction 
was terminated by heating at 65°C for 15 min.
b ) Preparation of uradl-rich single-stranded DNA template
Recombinant pGEM3zf(-) phagemid DNAs were transformed into competent cells of 
E.coli strain BW313 (ung~, dut"). A bacterial colony was grown overnight at 37°C in 5ml 
2xYT medium containing lOOmg/ml ampicillin. This culture was used to inoculate 250 ml 
2xYT medium containing 0.25 mg/ml uridine and lOOpg/ml ampicillin. Growth was 
allowed to proceed at 37°C with vigorous shaking to an OD600 of 0.3-0.35. The culture 
was then infected with 1ml of the helper phage M13K07 or R408 (>10^^ p.f.u./ml). 
Following incubation at 37°C for 30 min, kanamycin (75|ig/ml; depending on the helper 
phage) was added to the culture and incubation continued overnight. The bacterial cells
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were pelleted by centrifugation at 12000 rpm (Sorval GSA rotor) for 15 min at 4°C. The 
supernatant was poured into a fresh centrifuge tube and spun for 15min. The phage in the 
supernatant was precipitated by adding 0.25volume of a solution containing 20% 
PEG6000 and 3.5M ammonium acetate. At the end of 30min incubation on ice, the 
mixture was centrifuged for 30min at 12000 rpm at 4°C. The pellet was drained well, 
resuspended in 500|il of TE and transferred into a sterile microfuge tube. An equal 
volume of phenoLchloroform (1:1) was added, the tube was vortexed for one full minute 
and centrifuged at 13000g for 5min. The upper aqueous phase containing the single­
stranded phagemid DNA (ssDNA) was transferred to a fresh tube leaving the large 
interphase behind. This extraction was repeated approximately 5-6 times until there was 
no visible material at the interface. The ssDNA was then extracted with an equal volume 
of chloroform, precipitated with 0.1 volume of 3M sodium acetate and 2 volumes of 
ethanol on dry ice for 30min and pelleted at 13000g for 15min. The pellet was washed 
with 95% ethanol, dried in a vacuum desiccator and dissolved in 20|il dH20. The yield 
was estimated by measuring the OD at 260 nm ( 1 OD260 = 40|ig/ml ). The quality of the 
ssDNA was evaluated by agarose gel electrophoresis. A major band of ssDNA was 
usually observed on a 1% agarose gel if the DNA was of good quality. In some cases, 
major helper phage DNA and a small amount of large chromosomal DNA was observed.
c ) Annealing of the phosphorylated mutagenic oligonucleotide to the template
The ssDNA template was added to a 20, 30, 50-fold molar excess of the phosphorylated 
mutagenic oligonucleotide in the presence of 5xSEQ buffer (200mM Tris-HCl pH7.5, 
80mM MgC12). The sample tubes were incubated in a water bath at 65°C for lOmin, then 
allowed to cool slowly to RT over a period of about 30min. The tubes were spun for a few 
seconds to recover condensation from the lids and placed on ice for 5min.
d ) Synthesis of the complementary mutagenic DNA strand and transformation of 
the reaction products
The primer extension reaction was carried out by adding 10|il of the annealing reaction
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mix to: 2|il 5xSEQ buffer, Ifil 5mM ATP, l|xl lOOmM DTT, l|il dNTPs, l|ig/|il 
acetylated bovine serum albumin (Sigma), Ifig/ixl gene 32 protein, 3U T4 DNA ligase, 5U 
T4 polynucleotide kinase, lU T7 DNA polymerase. Following incubation at 37°C for Ih, 
half of the reaction mix was transformed in to Kcoli NM522 ( dut"*”, ung"  ^) and plated on 
to L-broth agar containing lOOpg/ml ampicillin. Individual colonies were picked and the 
mutants were identified by restriction enzyme [section 2.2.17] and by DNA sequence 
analysis [section 2.2.29] of the plasmid DNA.
e ) Controls 
i ) Negative control
The reaction mixture containing all ingredients except the primer was used to test for non­
specific endogenous priming in mutagenesis experiments. This priming which is caused 
by contaminating nucleic acids in the template preparation may result in lowering the 
mutation efficiency.
ii ) Positive control.
U-phagemid DNA (BIO-RAD) in conjunction with the reverting primer (BIO-RAD) were 
used in the mutagenesis experiments to test for the efficiency of the reagents, enzymes and 
competent cells. U-phagemid DNA is pTZlSU (2860 base) containing an amber mutation 
at codon 16 of the lacZ fragment. The UGG codon (tryptophan) was converted to the 
chain terminating codon UAG. Since the phagemid contains an amber mutation in the 
lacZ fragment, it is therefore unable to complement lacZ”  host strains and yields white 
colonies on plates containing ampicillin and X-gal. The reverting primer is a 
phosphorylated 16-base oligonucleotide (5 pGGl 1 1 1CCCAGTCACG3 ) which converts 
the amber mutation UAG back to the wild type UGG codon for tryptophan. Thus blue 
colonies are produced on plates containing X-gal. The underlined base is the one which is 
converted in the amber phagemid by this primer,
f). Preparation of helper phage stocks
The procedures for growth of the 2 helper phages are slightly different due to their 
differences in genotype. M13K07 has a Kanamycin resistance marker that is
58
Materials and methods
spontaneously deleted with high frequency in the absence of antibiotic selection. 
Therefore, a single kanamycin resistant colony is used to propagate this virus while R408 
can be propagated from a single plaque.
i) Growth of phage M13K07
Phage stock (Promega) was serially diluted in L-broth. A total of five 100 fold serial 
dilutions were prepared in separate sterile vials. lOOfxl of each dilution was added to 200pl 
of log phase E.coli NM522 cells (prepared by adding 1ml of overnight cells to 10ml 
2xYT and shaken for 60 min). Following 5 min incubation at RT, 50|il of the cell and 
phage mixture was plated on L-broth agar containing 70|ig/ml Kanamycin. Plates were 
incubated overnight at 37°C. A single colony was picked, transferred to 50ml of 2xYT 
broth and shaken at 37°C for 8-12h with vigorous agitation. Bacterial cells were pelleted 
by centrifugation at 3K for 15min in sterile tubes. The supernatant was poured into a fresh 
tube and spun again for 15min. To kill any remaining bacterial cells, the supernatant was 
heated at 55°C for 30min before storage at 4°C.
ii) Growth of phage R408
The phage stock (Promega) was serially diluted 100 fold and used to infect NM522 cells 
as described above for M13K07. Following 5min incubation at RT, 4ml of top agar was 
added to each cell/phage mixture and poured on L-broth agar lacking Kanamycin. Plates 
were incubated overnight at 37°C. A single plaque was picked and used to inoculate 50ml 
of 2xYT broth. Isolation and storage of the phage was continued as described above (i).
g) Titrating phage M13K07 and R408 stocks
The prepared phage stocks [section 2.2.25(f)] were serially diluted 100 fold in L-broth. 
200pl of log phase NM522 bacteria were infected with lOOpl of each dilution and 
incubated at RT for 5min. Molten top agar (5ml) was added to each cell/phage mixture, 
poured on L-broth agar and incubated overnight at 37°C. The plaques were counted and 
the number of plaque forming units/ml (pfu/ml) was calculated.
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2.2.26. Construction of M13 recombinant plasmids
M13mpl8 and mpl9 double-stranded DNA was commercially obtained from Pharmacia. 
Typically 10p,g DNA was digested with the appropriate restriction enzyme e.g. Smal.
Following extraction as described previously [section 2.2.18] the DNA was resuspended 
in 10|il H2 O. One pg aliquots of M13 and a wide range of fragment amounts (O.l-lOpg)
were generally used in each ligation mix. Standard cloning methods were employed 
(Sambrook eta l, 1989).
2.2.27. Transformation of E.coli cells with M13
Competent cells of E.coli strain NM522 were prepared as described in section 2.2.14. 
Typically Ipl and lOpl of ligation mix were added separately to 200|il of competent cells 
and incubated on ice for 30 minutes. Five ml melted top agar at 42°C, containing 30pl of 
25mg/ml IPTG in water and 30pl of 25mg/ml X-gal. was added and the mixture poured 
on to 90mm L-broth agar plates and incubated at 37^C overnight.
2.2.28. Preparation of M13 single stranded DNA
Single, colourless, transformed M13 colonies were used to inoculate 1.5ml 2xYT broth 
containing 1/100 dilution of an overnight saturated bacterial culture. Following 4.5-6h 
incubation with shaking at 37°C, the culture was spun at 13,000g in a microfuge to pellet 
the bacteria. The supernatant, which contained the M13 bacteriophage, was retained and 
respun to ensure no bacterial contamination. M13 was precipitated by the addition of 
200pl of a solution containing 20% (w/v) PEG6000 and 3.5M ammonium acetate. 
Following incubation on ice for 10 minutes, bacteriophage were pelleted by centrifugation 
at 13,000g in a microfuge. The supernatant was discarded and the pellet respun before 
removing any excess liquid with an eppendorf tip. After resuspending the pellet in 200|il 
TE, the DNA was extracted once with an equal volume of phenol-chloroform, before 
precipitating with 2 volumes of ethanol and 0.1 volumes of 3M sodium acetate on dry-ice 
for 30 minutes. The DNA was pelleted by centrifugation at 13,000g for 5 minutes in a 
microfuge, washed with 70% ethanol, dried and resuspended in 15pl H2 O containing
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50|ig/ml RNase A (Sambrook eta l, 1989).
2.2.29. Sequence analysis of recombinant M13 clones
Sequence analysis was carried out using the Sequenase Version 2.0 kit (Amersham) in 
accordance with the manufacturer’s instructions. Recombinant bacteriophage single­
stranded DNA (5|il) was annealed to 3ng of 17-mer universal sequencing primer which
hybridizes upstream of the multicloning site in a 5x annealing buffer (200mM Tris.HCl, 
pH7.5, lOOmM MgCl2  and 250mM NaCl) in a total volume of lOpl. Annealing was
carried out by first heating to 55°C for 5 minutes in a 1.5ml eppendorf tube, then allowing 
to cool to room temperature over a period of 30 minutes. The templates were briefly 
chilled on ice, before being labelled and extended using a buffer which contained 1.5|iM 
dCTP, dGTP, l.S^M dTTP, 5nCi 35s dATP, 6 mM DTT and 3 units of Sequenase
T7 DNA polymerase in a total volume of 16p,l. Labelling was carried out at RT for 2-5 
minutes. Each template was extended and terminated by addition of 3.5|il of labelled 
template to 2.5pi of each of the 4 ddNTP termination mixes in microtitre wells, which had 
been pre-warmed to 37°C. Each ddNTP termination mix contained one ddNTP at a 
concentration of 8 pM and dNTPs at a concentration of 80 pM. The plate contents were 
mixed by centrifugation in a Beckman benchtop centrifuge and the reactions carried out 
at 37°C for 10-30 minutes. Four pi formamide dye mix was added to each sample. The 
samples were boiled for 2  minutes before loading onto a gel for electrophoresis.
2.2.30. Electrophoresis and autoradiography of sequencing gels
Electrophesis was carried out at 70W through vertical gels 42x34x0.04 cm in size. Gels 
consisted of 6 % acrylamide (cross-linked with 5%(w/v) N,N'-methylbisacrylamide) and 
9M urea in IxTBE. Polymerization was achieved by addition of 0.05%(w/v) APS and
0.1%(v/v) TEMED. Spacers and gel combs were supplied by Gibco-BRL. Both plates 
were treated with repelcote enabling the gel to be transferred to Whatmann 3MM 
chromatography paper following electrophoresis before using under vacuum. Dried gels 
were then exposed to XS-1 film (35x43 cm) and developed using a X-Omat processor.
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2.2. 31. Computing
DNA sequence analysis of various RLl fragments of HSV-2 HG52 was carried out on the 
Digital Micro VAX 11 and Digital AXP 21001/A500mp computers in this Institute, using 
the University of Wisconsin Genetics Computer Group software package.
2.2.32. Isolation of total RNA
The single-step method of RNA isolation by acid guanidinium thiocyanate (Chomczynski 
et a l, 1987) was used to isolate the total RNA from BHK21/C13 cells infected with 
HG52. Cells were grown in 140mm-tissue culture dishes at a density of 5x10^ cells/dish 
and were infected with the virus at a multiplicity of infection of 10 pfu/cell. Uninfected 
cells (mock) were used as a negative control. Following incubation at 37°C, the ETCIO 
medium was poured off, the cells were then washed with 1 0ml of ice-cold phosphate- 
buffered saline (PBS-A). The cells were scraped off, transferred to a sterile 15-ml 
polypropylene tube and spun at 2000 r.p.m for 5min at 4°C in a Fison’s Coolspin. Cells 
were lysed in 2ml of guanidine thiocyanate (4M guanidine thiocyanate, 25mM sodium 
citrate (pH7.0), 0.5% Sarkosyl (Sigma), O.IM mercaptoethanol). The lysate was drawn in 
to a hypodermic syringe fitted with a 2 1 -guage needle and then expelled into a 
polypropylene tube. This step was repeated 3-4 times to shear the cellular DNA. The 
proteins were removed by extracting once with phenoLchloroform. The aqueous and 
organic phases were separated by centrifugation at 8 K for lOmin at 4°C in a Sorvall SS34. 
The aqueous phase was transferred to a fresh tube and an equal volume of ice-cold 
isopropanol was added. Total RNA was precipitated overnight at -20°C and then 
recovered by centrifugation at 8 K for lOmin in a Sorvall SS34. The pellet was washed 
with 70% ethanol and dissolved in 200|il of Tris-HCL (pH7.8), ImM EDTA (pH8.0). 
MgCl2  and dithiothreitol were added to a final concentration of lOmM and O.lmM, 
respectively. The placental RNAase inhibitor (RNAsin; Promega) and RQl RNase-free 
DNase (Promega) were added, each to a final concentration of lOOOU/ml. The mixture 
was incubated for 60min at 37°C, then EDTA and SDS were added to final concentrations 
of lOmM and 0.2%, respectively. The solution was extracted once with an equal volume
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of phenol ichloroform and the aqueous phase was transferred to a fresh tube. To precipitate 
the RNA, 2.5 volumes of ice-cold ethanol and 0.1 volume of 3M sodium acetate were 
added. Following overnight incubation at -20°C, RNA was collected by centrifugation at 
8K for 5min at 4°C. The RNA pellet was washed in 70% ethanol and resuspended in 
lOOfil DEPC-treated dH20. The concentration of RNA was determined by measuring the 
OD260 of an aliquot of the final preparation. A solution of RNA whose OD26O = 1 
contains approximately 40|ig of RNA per milliliter. For storage of RNA, 2.5 volumes of 
ethanol were added to the RNA solution and stored at -70°C. When needed, it was 
recovered by adding 0.1 volume of 3M sodium acetate (pH5.2) before spinning at 13,000 
r.p.m for 5min at 4°C in a microfuge.
2.2.33. Electrophoresis of RNA through gels containing formaldehyde
The quality of the isolated RNA was checked by denaturing agarose gel electrophoresis 
(Sambrook et al., 1989). The gel tank was treated with 3% H2 O2  overnight and filled with 
IxMOPS buffer. The gel was prepared by dissolving one gram of agarose in the 
appropriate amount of sterile d.H20 and cooled to 65°C. lOxMOPS buffer [section
2.1.12] and formaldehyde (Sigma) were added to give final concentrations of Ix and 
2.2M, respectively. The gel was cast in a chemical hood and allowed to set for at least 
30min at RT. RNA samples (20|ig) were prepared by mixing with 5|il deionized 
formamide (Sigma), Ifil lOxMOPS buffer and 1.6|il formaldehyde. Samples were 
incubated at 65°C for 5min, chilled on ice and then 2|il of RNA-loading buffer [section
2.1.12] + l|il of ethidium bromide (Img/ml) were added. The gel was loaded with the 
samples and run in IxMOPS buffer. When visualized under the UV, the 18S and 28S 
rRNAs were seen and the mRNA appeared as a smear.
2.2.34. Purification of cytoplasmic mRNA directly from tissue culture cells
The Dynabeads mRNA purification kit (Dynal) was used to isolate the polyadenylated 
mRNA [poly (A)"*'RNA] from cells infected with HG52. BHK21/C13 cells were grown in 
100mm tissue culture dishes at a density of 3x10^ cells/dish, then infected and collected
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as described for total RNA isolation [section 2.2.32]. As directed by the manufacturer, the 
cell pellet was resuspended in 100|l i 1 of Ixlysis buffer (lOmM Tris-HCl (pH7.5), 0.14M 
NaCl, 5mM KCl, 1% Triton X-100). Following incubation on ice for Imin, the nuclei 
were pelleted by centrifugation at 6500 r.p.m.for 30sec at 4°C in a microfuge. The 
cytoplasmic supernatant was transferred to a sterile eppendorf tube containing an 
appropriate amount of washed dynabeads oligo (dT)25 in lOOfil 2xbinding buffer (20mM 
Tris-HCl (pH7.5), l.OM LiCl, 2mM EDTA, 1%SDS). The Dynabeads bind approximately 
2pg poly (A)+ RNA per mg of beads. The mRNA was allowed to bind for 5min at RT, 
then the eppendorf tube was placed in the Dynal magnetic particle concentrator (Dynal- 
MPC) for at least 30sec. The supernatant was removed by aspiration with a pipette while 
the tube remains in the Dynal-MPC and then the Dynabeads were washed 3 times with 
200[il washing buffer. To elute the mRNA, 10|il of Ix elution buffer (2mM EDTA 
pH7.5), was added and beads were incubated at 65°C for 2min.
2.2.35. RNA-PCR
a) Selection of primers for RNA-PCR
Appropriate RNA-PCR sense and antisense oligonucleotide primers were designed 
according to:
a) Computer program (Oligo; MedProbe A. A).
This program was used to scan the nucleic acid sequence of the RLl gene and to select the 
possible pairs of primers suitable to direct efficient cDNA synthesis and amplification.
b) Primers of Wallace temperature > 80°C [4°Cx(G+C)+2°Cx(A+T)] were designed as 
recommended by Dutton et al (1993) for amplifying regions of very high G+C content.
b) cDNA synthesis
First strand cDNA was synthesized as described by Saiki et al (1988) using one of the 
following enzymes: (i) Avian Myeloblastosis virus reverse transcriptase (AMV-RT), (ii) 
Moloney Murine Leukaemia virus reverse transcriptase (MuLV-RT), (iii) Retrotherm 
reverse transcriptase. The reagent mixture consisted of l-2|ig total RNA [section 2.2.32]
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or (0.6-3p,g) mRNA [section 2.2.34], 20pmole of antisense oligonucleotide primer or 
random primer (Promega), 200pM dNTPs (Pharmacia), IX RT buffer (purchased with the 
enzyme) in a final volume of 20|il. The mixture was heated at 70°C for 5min and then 
cooled immediately on ice for 5min. RNasin ( 20U; Promega) was added first and then 
20U of either AMV- or MulV-RT. Depending on the enzyme, the reaction was carried 
out at either 37°C (MuLV-RT) or 42 °C (AMV-RT) for 60min and then stopped by heating 
at 65°C for lOmin. When Retrotherm RT (2U) was used, the reaction was carried out for 
lOmin at >60°C depending on the primer-annealing temperature which was calculated as 
recommended by the manufacturer.
c) cDNA-PCR
Aliquots (5|il, 20(il) of cDNA from step (b) was subjected to PCR amplification under 
various cycling conditions. PCR was carried out as described by Saiki et al (1988) in a 
final volume of 50|il overlaid with 50|il mineral oil (Sigma). The PCR reaction consisted 
of IxPCR buffer (purchased with the enzyme), 2.5mM MgCl2  or ImM MgSO^ 
(depending on the enzyme), 200fiM dNTPs, SOpmole each of the sense and antisense 
oligonucleotide primers, 2U of either Taq DNA polymerase (Promega) or Vent DNA 
polymerase (Biolab). In some experiments, a dénaturant such as 5% or 10% DMSO was 
added to the reaction mixture. Appropriate positive and negative PCR controls were 
included in all experiments. Thirty to thirty five cycles of amplification were performed 
with a OmniGene (Hybaid) thermal cycler followed by a cycle of final extension. The 
amplification conditions used depend on the size of the primers (Wallace Temperature) 
and the type of the PCR DNA polymerase. The following are examples of amplification 
protocols:
i) Vent DNA polymerase: 1 cycle (98°C, 5min); 35 cycles [(98°C, 70sec), (55°C, 2min), 
(75°C, 3min)]; 1 cycle.(75°C, lOmin)
ii) High G+C PCR Protocol: (98°C for Imin plus 70°C for 5min) for 30 cycles (Dutton 
etal,. 1993).
iii) Taq DNA Polymerase: 1 cycle (95°C, 5min), 30 cycles [(95°C, 70sec), (55°C, 90
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sec), 72°C, 2min)]; 1 cycle [(95°C, 70sec), (55°C, 90sec), (72°C, lOmin)].
Following amplification, samples were prepared for electrophoresis by chloroform 
extraction of the mineral oil. To visualize the amplified PCR product, one-tenth of the 
product was mixed with RE stop [section 2.2.19] and run on 3% NuSieve agarose (EMC 
BioProducts) gel. A 123 DNA marker (BRL-GIBCO) was run alongside the PCR samples 
to confirm the size of the desired amplified fragment.
2.2.36. Animal studies 
a ) Neuro virulence
Three week old female BALB/c mice were inoculated intracerebrally with individual virus 
stocks. Mice were anaesthetized with halothane and 25|il of the appropriate virus dilution 
in PBS/calf was inoculated into the central region of the left cerebral hemisphere. Four or 
five mice were inoculated with each virus dilution. Depending on the known, or 
postulated neurovirulence phenotype of the viruses being tested, doses were in the range 
10^ to 10  ^ p.f.u./mouse. Stocks were always re titra ted immediately post-injection to 
ensure that the correct dose had been administered. The mice were monitored for 21 days 
and scored for death between days 1 and 21. The neurovirulence of viruses was 
determined by calculating the LD50 values according to the formula of Reed and Muench 
(1938).
b ) Virus growth properties in vivo
The ability of mutant and wild-type virus to replicate in mouse brains following 
intracerebral inoculation was assessed using a mouse model as described by Taha et al. 
(1989a). Twenty-five |il aliquots of wild-type virus (1 0^ p.f.u./mouse) and mutant virus 
(10^ p.f.u./mouse) were injected into the left cerebral hemisphere of 3-week old BALB/c 
mice. At Oh, 12h, 24h, 48h, 72h, 96h, 120h and 144h post-inoculation, 2 mice per virus 
group were killed, their brains removed, homogenized in 0.5ml PBS/calf and sonicated. 
The final volume was measured and recorded, before storing at -70°C. When all samples 
had been collected, they were thawed and progeny virus titrated on BHK21/C13 cells at
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37°C. Final titres were calculated as mean p.f.u./mouse. 
c ) Virus growth properties in vitro
Virus growth experiments in vitro were carried out essentially as described by Brown and 
Harland (1987) and Brown et al (1994a). For multi-cycle growth experiments, confluent 
BHK21/C13 and 3T6 cell monolayers were infected in separate experiments at a 
multiplicity of 0.01 p.f.u./cell of stock viruses. Single-cycle growth experiments were 
carried out by infecting confluent BHK21/C13 monolayers at a multiplicity of 5 
p.f.u./cell. At specific times post-infection, cells were harvested, sonicated and stored at 
-70°C. At the end of the experiments, viruses were titrated on monolayers of BHK21/C13 
cells at 37°C.
d ) Marker rescue
In vitro and the in vivo marker rescue methods was used to restore the neurovirulence 
phenotype of the mutant viruses. DNA (Ipg) from a mutant virus was transfected onto 
BHK21/C13 cells with a 1-, 10- and 100- fold molar excess of a wild-type fragment 
containing the RLl ORF [section 2.2.9]. After 2 days, the monolayer in which c.p.e. was 
most extensive was harvested and sonicated briefly.
For in vitro generation of rescuants, the progeny virus of a transfection mix was titrated 
on confluent 3T6 cells. Large plaques were isolated, purified three times and their DNA 
was analyzed by either in vivo ^^p DNA- labelling [section 2.2.8] or Southern blotting 
[section 2 .2 .2 2 ].
For in vivo marker rescue experiments, 10"  ^and 10”^  dilutions of a transfection mix were 
prepared in PBS/calf serum and 25|il aliquots of each were injected intracerebrally into 3- 
week old BALB/c mice. Deaths from encephalitis were scored up to 21 days post 
inoculation. Mice which showed signs of encephalitis were put down according to the 
regulations for conducting animal experiments. Brains were removed, homogenised in 
PBS/calf serum, and the resultant viruses were titrated on 3T6 cells. Single large plaques 
were isolated, purified once and their genomes analysed to identify wild-type rescuants
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before growing a virus stock.
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CHAPTER 3: RESULTS 
3.1 Strategy
The strategy employed to achieve the objectives of this project was:
1. Construction of RLl recombinant phagemids which have been used in mutagenesis 
experiments to generate RLl mutant phagemids.
2. Isolation of RLl mutant viruses by individual recombination of the mutated phagemids 
with the wild-type genome.
3. Evaluation of the virulence of the mutant viruses compared with the parental wild-type 
HG52.
4. Confirmation of the virulence phenotype of the mutant viruses by isolating wild-type 
rescuants.
5. In vivo and in vitro characterisation of the mutant viruses compared to the parental wild- 
type HG52. The characterization involved determination of :
a) the growth patterns in brains of 3-week old female Balb/c mice over a period of seven 
days.
b) the growth patterns in BHK21/C13 cells and in 3T6 mouse embryo fibroblast cells.
c) the sensitivity to various temperatures (31°C, 37°C and 38.5°C).
6 . In vitro characterisation of the wild-type rescuants in 3T6 mouse embryo fibroblast ceUs.
7. cDNA-PCR of the mRNA flanking the proposed RLl intron in an attempt to provide 
evidence that the mature mRNA of the gene is spliced.
The construction of each recombinant phagemid, mutant virus, wild-type rescuant and the in 
vitro and in vivo characterisation of mutants are described in the following sections of this 
chapter.
3.2. Construction of RLl containing recombinant phagemids
All RLl recombinant phagemids were constructed using pGEM3zf(-) which contains a 
bacteriophage fl DNA replication origin to allow rescue of ssDNA for site-directed
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mutagenesis and (if required) for sequencing. The starting plasmid was pAT153 containing 
the BarniHlg fragment (0.81-0.85 m.u.) (Davison, 1981) of HG52. This fragment (n.p. 
10592-16449) contains the IR l copy of RLl (n.p. 13179-12243) (McGeoch et al, 1991). 
The recombinant plasmid pAT153-5amHIg was digested in separate experiments by Sphl 
and Xhol restriction enzymes [section 2.2.17] and run on a 0.6% agarose gel. The RLl 
containing Sphl and Xhol fragments were cut out and purified as described in section 
2 . 2 . 20 .
A 1.62Kb Sphl fragment of pAT153-RamHI^ was cloned into pGEM3zf(-) at the Sphl site 
of the multicloning region [section 2.2.12.(a)]. The resulting construct was designated pSB 
(Fig. 3.1) and was analysed with various restriction endonucleases (data not shown). pSB 
was used: (i) to delete the proposed intron [section 3.3.3.] and (ii) to insert separate stop 
codons in exon I, within the intron and within the conserved region of exon II [section
3.3.1.]. However, pSB was not suitable for insertion of a stop codon at the start of RLl as 
there is insufficient sequence upstream of the RLl initiation codon for homologous 
recombination to occur (Fig. 3.1). Therefore, a second phagemid, designated pXB, 
containing a 3.343Kb Xhol sub-fragment of pAT 153-RamHIg was constructed. The Xhol 
fragment was cloned into pGEM3zf(-) at the Smal site (Fig. 3.2) after blunting with the 
Klenow fragment of DNA polymerase I [section 2.2.12(b)]. The recombinant pXB was 
used to introduce a stop codon 9bp downstream of the RLl initiation codon [section 3.3.2] 
and to isolate wild-type rescuants in marker rescue experiments [sections 3.7 & 3.9].
3.3. Construction of RLl mutant phagemids
Six mutant phagemids were constructed using the recombinant phagemids pSB and pXB: 
one in which the putative RLl intron has been deleted and five in which stop codons were 
inserted at different sites in the predicted ORF of RLl. Three were used to generate 
individual mutant viruses by recombination with the wild-type genome.The construction of 
the mutant phagemids is described in the following sections:
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Figure 3.1. Construction of the RLl-recombinant pSB phagemid
A 1.620 Kb Sphl (S) fragment containing the HG52 RLl gene was cut from the recombinant 
plasmid pAT 153-BamHI^ and cloned into the Sphl restriction enzyme site in the multicloning 
site of pGEM-3zf(-) to generate the phagemid pSB. The position of the Sphl restriction 
enzyme sites, the location of the HG52 RLl gene within the Sphl fragment and the positions 
of RLl initiation and stop codons are marked. The nucleotide numbers described here 
represent the numbering system of the HG52 DNA sequence reported by McGeoch et al 
(1991).
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Figure 3.2. Construction of the RLl-recombinant pXB phagemid
A 3.343 Kb Xhol (X) fragment containing the HG52 RLl gene was cut from the plasmid 
pAT153-RflwHIg. The termini of this fragment was blunted with the Klenow fragment of 
DNA polymerase and cloned into the Smal site, in the multicloning region of pGEM3zf(-) to 
generate the phagemid pXB. The position of the Xhol restriction enzyme sites and the 
location of the RLl gene are illustrated. The nucleotide numbers described here represent the 
numbering system of the HG52 DNA sequence reported by McGeoch et al (1991).
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3.3.1. Construction of individual RLl mutant phagemids with stop codons 
in exon I, in the intron and within the conserved region of exon II
To determine the functional domains of RLl, it was decided to generate HSV-2 HG52 
variants that produce truncated versions of ICP34.5. Translational stop codons were 
introduced at unique restriction enzyme sites in the RLl gene of pSB. In exon I at the Fspl 
site, in exonll within the conserved region at the P/ZMI and P^rll sites. The positions of 
these sites are illustrated in Figure 3.3. As an alternative to intron deletion, it was decided to 
introduce a stop codon into the intron at the Drdl site (Fig. 3.3). If the predicted ORF is 
correct and this is a true intron, it will be spliced out and the inserted stop codon should not 
affect the gene function.
Initially, linker-insertion mutagenesis [section 2.2.24] was carried out using the 24-mer 
linker (5LTCTAG*ACTAGCTAGCTAGTCTAGA-3 )^. This linker contains the stop codon 
TAG in all six frames in addition to two Xbal restriction sites which facilitate detection of 
mutant phagemids and viruses. To insert the ds-linker into RLl, the recombinant phagemid 
pSB was linearised in separate experiments with Fspl, Drdl, PfJMl and PjrII restriction 
enzymes in the presence of CIP. Fspl is a blunt-cutting enzyme which generates linear pSB 
with blunt-ended termini. The resulting 5' overhangs of pSB linearised with Rsrll were 
filled in with the Klenow fragment of DNA polymerase I [section 2.2.12(b)]. The 3' 
overhangs of pSB linearised with PflM I and Drdl were excised with T4 DNA polymerase 
[section 2.2.12(c)].
Insertional mutagenesis was unsuccessful except at the Rsr n  site (Fig. 3.3). The mutant 
pSB containing the above linker at the Rsr II site (the stop codon in the predicted RLl frame 
is marked *) was analysed by Xbal and other restriction endonucleases (data not shown). 
Before recombination back into wüd type HG52 DNA, the mutation was confirmed by DNA 
sequence analysis. For this purpose, the blunt-ended Rsal-Smal fragment (344bp) (Fig. 
3.4) of the mutated pSB was cloned into the Smal site of M13mpl8 [section 2.2.26] and 
sequenced using the universal M13 primer [section 2.2.29]. As shown in Figure 3.5, the 
sequence confirms insertion of the linker within the conserved region and the stop codon is 
in the predicted RLl frame. This mutated pSB was used to generate the mutant virus 2620
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Figure 3.3. Location of translational stop codons in the ORF of the RLl gene
A. A schematic diagram of the HSV-2 genome with the inverted regions depicted as open 
boxes.
B. An enlargement of the BamYllg fragment at the L-S junction. The positions of the Xhol 
(X) and the Sphl (S) restriction enzyme sites are marked.
C. An expansion of the RLl gene. The intron is indicated by dashed lines, exons by solid lines 
and the conserved region by a solid box. The positions of the inserted stop codons in the pSB 
and pXB phagemids are illustrated. The nucleotide numbers described here represent the 
numbering system of the HG52 DNA sequence reported by McGeoch etal (1991).
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Figure 3.4.The location and the size of RLl DNA fragments used in DNA sequencing 
and Southern blotting
This figure illustrates the location and the size of RLl DNA fragments generated from 
digestion with Smal (S) and (R) restriction enzymes. These fragments were used in DNA 
sequencing to confirm the appropriate mutations in pSB and pXB phagemids. Also the 345bp 
DNA fragment was ^^P-labelled and used as a probe in Southern blotting. The deleted intron 
in the 263bp fragment is indicated by a dashed line. This size refers to the fragment seen in 
the intronless pSB.
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Figure 3.5. DNA sequence of the mutated pSB phagemid in the conserved region of the
RLl gene
A 345 bp RsaVSmal subfragment of the mutated pSB phagemid was cloned into M13mpl8 
and sequenced. The DNA sequence of the non-coding strand of the RLl gene in the 
conserved region is illustrated. The stop codon, TAG (ATC) in 6  reading frames within the 
inserted 24-mer linker is indicated by an open box. The dot (•) represents insertion of 3 bases 
into the RLl sequence downstream of the stop codons, due to blunting of the pSB termini.
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[section 3.4.1] which was used to study the role of the conserved region in the virulence of 
HG52.
Since this approach was unsuccessful for insertion of the 24-mer linker at the other sites of 
RLl, single-stranded site-directed mutagenesis [section 2.2.25] was adopted using the 
oligonucleotides shown in Table 3.1. The oligonucleotides were individually used with the 
ssDNA of pSB in separate attempts to isolate the mutant phagemids. This technique was 
successful in inserting the stop codons in a single frame at the Fspl, Drd I and PjTMl sites 
(Fig. 3.3). Following demonstration of the avirulent phenotype of the mutant virus 2620 
[section 3.5], the mutated pSB phagemids with stop codons at these sites were not used to 
generate HSV-2 HG52 variants.
3.3.2. Construction of a mutant phagemid containing a stop codon at the 
start of RLl
To provide evidence that HG52 encodes ICP34.5, the RLl gene in pXB was mutated by 
introducing in a single frame, the translational stop codon TAG, 9bp downstream of the 
initiation codon (Fig. 3.3). The 44-mer oligonucleotide (5 -CAG CCG CGC GCC ATG 
TCC CGC CTC TAG AGC CGG GGT CCC CGC CG-3') which was used for single­
stranded site-directed mutagenesis is equivalent to part of the RLl sequence of HG52 plus a 
6 bp insert representing an Xbal site (TCTAGA) for generation of mutant phagemid and 
virus. Positive clones were identified by restriction enzyme analysis (data not shown).
The mutation in pXB was confirmed by DNA sequencing of the region around the RLl 
initiation codon. The blunt-ended Rsal-Smal fragment (279bp) (Fig. 3.4) of the mutated 
pXB was cloned into the Smal site of M13mpl8 [section 2.2.26] and sequenced [section 
2.2.29]. The sequence of the coding strand of RLl at the start of the gene is shown in 
Figure 3.6. It confirms the correct position of the stop codon TAG with respect to the RLl 
initiation codon ATG. In addition, it shows deletion of two bases downstream of the stop 
codon, which has arisen during site-directed mutagenesis and which puts RLl out of frame. 
This deletion is probably due to a defect in the synthesised oligonucleotide.
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Figure 3.6. DNA sequence of the mutated pXB phagemid in the region of the RLl ATG 
initiation codon
A 279bp RsaVSmal subfragment of the mutated pXB phagemid with a stop codon at the start 
of the RLl gene was cloned into the Sma I site of M13mpl8. It was sequenced using a M13 
universal primer to confirm insertion of the stop codon, TAG, 9 bp downstream of the ATG 
initiation codon. Products were fractionated by electrophoresis in a 6 % polyacrylamide gel 
containing 9M-urea. Both ATG and TAG are indicated by open boxes. The (•) represents 
deletion of two bases of the RLl sequence which has occurred during site-directed 
mutagenesis. Otherwise, the sequence was identical to the wild-type sequence published by 
McGeoch etal (1991).
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3.3.3. Construction of a RLl intronless phagemid
An intronless phagemid was constructed to investigate the role of the putative intron in 
expression of RLl. The intron was deleted precisely to preserve the translational reading 
frame across the predicted splice junctions. The ss-DNA of the pSB phagemid was used in 
site-directed mutagenesis [section 2.2.25] in the presence of a 52-mer oligonucleotide (5'- 
CGC CCG CGG ACG CGC CGC GCG GGA AGG TGT GCT TCT CGC CGC GCG 
TGC AGG T-33. This oligonucleotide corresponds to the DNA sequence across the intron 
junctions (Fig. 3.7). The deletion within the pSB phagemid was confirmed by restriction 
enzyme analysis (data not shown) and DNA sequencing [section 2.2.29] of the Rsal-Smal 
fragment (263bp) (Fig. 3.4) spanning the deletion. As shown in Figure 3.8, the DNA 
sequencing confirmed the precise deletion of the intron at the splicing sites predicted by 
McGeoch et al (1991).
3.4. Isolation of HSV-2 HG52 mutant viruses
To generate mutant viruses, the mutated phagemids were linearised with HindlTl which cuts 
once in the multicloning site of pGEM3zf(-). Following phenol-chloroform extraction 
[section 2.2.18], the linearised phagemids were cotransfected in separate experiments with 
intact HSV-2 strain HG52 DNA as described in section 2.2.9. When extensive cytopathic 
effect was observed, the transfection plates were harvested and the progeny virus titrated on 
BHK21/C13 cells. Single virus plaques [section 2.2.10] were picked and mutant viruses 
were identified either by ^^P-DNA labelling [section 2.2.8] or Southern blotting [section 
2.2.22]. Mutants with the desired genotype were plaque purified three times before growing 
a stock. Isolation of the mutant viruses is described in the following sections:
3.4.1. Isolation of the mutant virus 2620 with a stop codon within the 
conserved region of exon H
Comparative sequence analysis of the long repeat regions of HSV-1 /HSV-2 showed that 
HG52 possesses a counterpart of the HSV-1 RLl gene (McGeoch etal., 1991). DNA 
sequence analysis of the RLl ORF revealed that the C-terminus of the predicted ICP34.5 of
73
Figure 3.7. A schematic diagram of the RLl gene of HSV-2 strain HG52 and the 
oligonucleotide used to delete the predicted intron
This diagram illustrates the sequence and the location of the two components of the 
oligonucleotide used to delete the intron. The intron of RLl is indicated by dashed lines and 
exons by solid lines. The nucleotide numbers represents the numbering system of the HG52 
DNA sequence reported by McGeoch et al. (1991).
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Figure 3.8. DNA sequence of the intronless pSB phagemid
A 263 bp RsaUSmal subfragment of the intronless pSB phagemid was cloned into M13mpl8 
and sequenced. The DNA sequence confirmed deletion of the intron at the indicated splicing 
sites predicted by McGeoch et a/ (1991).
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One hundred and twenty plaques were picked and the DNA was digested with Xbal
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HG52 is 83% homologous to that of HSV-1 and approximately 50% to the C-terminus of 
the mouse protein MyDl 16 (McGeoch and Barnett, 1991). On this basis, it was important to 
study the role of the conserved region in the virulence of HSV-2 strain HG52. Therefore, 
the mutant virus 2620 was constructed. This mutant was selected by Xbal digestion of 32p- 
labelled DNA of 192 plaques isolated from cotransfection of HG52 DNA and the pSB phagemid 
containing a stop codon in all six open reading frames at the /?5rII site within the conserved 
region (Fig. 3.3) [section 3.3.1]. Each inserted oligonucleotide (in T R l and IR l) contains 
two Xbal sites. On digestion of the recombinant virus, each pair will give the profile of one 
extra Xbal site. One site is 1122bp from the L terminus and the second, 1122bp from the L- 
S junction (Fig. 3.9). Therefore, on digestion of 2620 DNA with Xbal (Fig. 3.10), 
digestion also occurs at the novel Xbal sites. This results in digestion of the normally 0.5M 
terminal c and g fragments of the wild-type, to IM bands, c'and g 'that are 1122bp smaller, 
plus two new 1 M bands of 1122bp that cannot be seen on the gel. Correspondingly, the 
0.25M L-S junction fragments a, b, e an d /o f the wild type disappear from their normal 
positions to be replaced by two 0.5M novel bands running above the i and h bands. These 
were designated /'and A'and are 1122bp bigger than the i and h fragments. The relevant 
Xbal restriction maps for HG52 and 2620 are shown in Figure 3.9.
3.4.2 Isolation of the RLl null mutant virus 2621
Previous studies demonstrated that the HSV-1 RLl gene is responsible for the virulence 
phenotype. Hence, insertion of translational stop codons at the beginning of the coding 
sequence abolished the virulence of HSV-1 strains F and 17"*" (Chou et a i, 1990; McKie et 
ai, 1994). To validate the HG52 RLl sequence analysis, it was decided to generate the RLl 
null mutant virus 2621 using the pXB phagemid containing a stop codon in a single frame
i *
9bp downstream of the RLl initiation codon (Fig. 3.3) [section 3.3.2]. On digestion of 
2621 DNA with Xbal, the profile was essentially the same as 2620. In this case, novel 
bands / "and h ' are 195bp bigger than the corresponding / and A. The g ' and c ' bands are 
195bp smaller than g and c of the wild type (Fig. 3.11).
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Figure 3.9. Position of the Xbal restriction enzyme sites in HSV-2 strain HG52 and the 
mutant virus 2620 genomes in the prototype orientation
The wild-type restriction enzyme sites are marked (Cortini and Wilkie, 1978) and the two stop 
codons (TAG) which have been introduced into the 2620 genome are underlined. The dashed 
vertical line indicates the position of the L-S junction.
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Figure 3.10. Xbal restriction enzyme profiles of HSV-2 strain HG52, the mutant virus 
2620 and the résonant R2620
Autoradiographs of Xbal digests of viral DNA ^^P-labelled in vivo. 2620 contains two 
detectable extra novel Xbal sites 1122bp from the L-terminus and from the L-S junction. 
Missing bands are indicated by an arrow head {< ). Novel bands are indicated by a dot (•) and 
are designated by the letter of the band from which they were derived plus a prime symbol (•). 
The DNA profile of R2620 is identical to that of the wild-type. Lane 1, 2620; Lane 2, HG52; 
Lane 3, R2620.
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Figure 3.11. Xbal restriction enzyme profiles of the DNA of HSV-2 strain HG52, the 
mutant virus 2621 and the rescuant R2621
Autoradiograph of Xbal digests of viral DNA ^^P-labelled in vivo. 2621 contains two no /el 
Xbal sites 195bp from the L-terminus and from the L-S junction. Missing bands are indicated 
by an arrow head (< ). Novel bands are indicated by a dot (•) and are designated by the letter 
of the band from which they were derived plus a prime symbol ('). The DNA profile of R2621 
is identical to that of HG52. Lane 1, 2621; Lane 2, HG52; Lane 3, R2621.
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3.4.3. Isolation of the potential intronless RLl mutant virus 2622
It was predicted from the sequence analysis that the ORF of HG52 RLl gene is interrupted 
by an intron which does not exist in the RLl gene of the sequenced HSV-1 strains ( Chou 
and Roizman, 1990; McGeoch et al, 1991). It was therefore important to provide evidence 
that the mRNA of RLl is spliced. As described in section 3.17 we tried to use PGR to 
amplify the reverse-transcribed cDNA product of the HG52 mRNA.
In parallel it was decided to delete the predicted intron at the proposed splicing sites to study 
its role in the expression of RLl. The mutant 2622 was generated by cotransfection of 
BHK21/C13 cells with intact HSV-2 HG52 DNA and the DNA of the intronless pSB 
phagemid (Fig. 3.7) [section 3.3.3.]. Single 393 plaques were isolated and their 32p- 
labelled DNA subjected to BamWl digestion (data not shown). Because the deletion was 
small (154bp), it was difficult to observe any alteration in the size of the BarnHlg fragment, 
therefore analysis was carried out by double restriction enzyme digestion and Southern 
blotting [section 2.2.22] using the ^^P-labelled Rsal-Smal fragment (344bp) (Fig. 3.4) as a 
probe [section 2.2.21]. As shown in Figure 3.12, digestion of 2622 DNA with Smal and 
Sad  apparently generated an 802bp fragment spanning the deletion compared to the 957bp 
wild-type fragment.
3.5. The virulence of RLl mutant viruses
The virulence of the mutants was determined by calculating the LD50 values in Balb/c mice 
following intracerebral inoculation. The LD50 values were compared to those of the parental 
wild-type HG52 and the RLl deletion mutant 2604. The genotype of 2604 was described in 
detail by Harland and Brown (1985) and Taha et al (1989b). Essentially it has a 1488bp 
deletion in both copies of BamHlv which is located between 0-0.02 and 0.81-0.83 m.u. of 
T R l and IR l, respectively. As it is avirulent on intracerebral inoculation of mice (Taha et 
al., 1989a), it was used as a negative control.
Separate groups of 3-week old Balb/c mice were intracerebrally inoculated [section 
2.2.36(a)] with HG52 and RLl mutant viruses. As the LD50S of HG52 and 2604 were 
known from previous studies (Taha et al., 1989a,b), mice were inoculated with these
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Figure 3.12. Southern blot of a SacVSmal restriction enzyme digest of the DNA of HSV- 
2 strain HG52, the mutant virus 2622 and the rescuant R2622
The genomes of HG52, 2622 and R2622 were digested with Smal and S a d  restriction 
enzymes. The intron sequence was detected using the 344bp SmaURsal fragment of pSB (Fig 
3.4). HG52 and R2622 produced a 957bp fragment while 2622 apparently produced a 802bp 
fragment. Fragments were separated on a 1% agarose gel. Lane 1, size marker; Lane 2, HG52; 
Lane 3, R2622, Lane 4, 2622.
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viruses at doses of 10^-10^ and 10^-10^ p.f.u./mouse, respectively. Since the virulence of 
the constructed mutant viruses could not be anticipated, mice were injected with a range of 
doses, 2620 10^-10^ p.f.u./mouse while 2621 and 2622 10^-10^ p.f.u./mouse. Mice were 
monitored for 21 days and their clinical state recorded. Those which showed neurological 
dysfunction and signs of encephalitis were put down. The symptoms included: ruffled fur, 
hunched back, reluctance to move, tendency to be isolated, lack of interest in food and rarely 
limb paralysis. The results are shown in Table 3.2. It can be seen that HG52 and 2604 had 
LD50S of <10^ p.f.u./mouse and 3.16x10^ p.f.u./mouse, respectively. These values are 
comparable to those determined previously (Taha etal., 1989a,b). The 1CP34.5 null mutant 
2621 was avirulent with a LD50 value > 10^ p.f.u./mouse, thus this mutant was at least 1 0 ^- 
fold less virulent than HG52. This result indicates that loss of HG52 virulence is due to 
lack of ICP34.5 expression and confirms the existence of the HG52 RLl ORF predicted by 
McGeoch etal (1991).
The intronless variant 2622 had an intermediate LD50 value of 10^p.f.u./mouse indicating 
that either (i) the predicted intron in HG52 is functional and required for full expression of 
RLl (ii) the proposed splicing sites of the intron are not correct (iii) the deleted DNA 
sequence is not an intron but a functional domain of RLl, suggesting a sequencing error in 
the predicted ORF of HG52 RLl (iv) there is an undetected secondary mutation in the gene. 
Insertion of a stop codon at the RsrU site within the conserved region abolished the virulence 
phenotype of HG52. The mutant 2620 was avirulent with a LD5 0  of 2.37x10^ 
p.f.u./mouse. This result indicates that the conserved region and/or the C-terminal domain of 
ICP34.5 are essential for gene function. This is supported by the recent finding of Chou and 
Roizman (1994) who demonstrated that the conserved carboxyl terminal domain of the 
HSV-1 RLl gene is necessary to preclude the total shutoff of protein synthesis in the 
neuroblastoma cell Une SK-N-SH.
Due to the avirulent phenotype of 2620, construction of mutant viruses with stop codons 
upstream of the Rjrll site was not pursued. This included those with stop codons inserted at 
the PflM 1, Drd 1 and Fspl restriction sites described in section 3.3.1. Instead, it was 
decided to try to construct a mutant virus with a stop codon precisely at the terminus of the
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Table 3.2. The LD50 values of HSV-2 strain HG52, 2604, 2621, 2622 
and the rescuants following intracerebral inoculation of 
3-week old Balb/c mice.
LDso m utant/ 
LDso rescuant
LDso
p.f.u./mouse
ose
Virus
4 /4 4 /4HG52 ND ND ND ND
3.16X1^2604 ND 0 /4 0 /4 4 /4ND ND
2.37X1^2620 0 /5 0/5 0 /5 0 /5 1/5 ND
2621 0 /4 0 /4 0 /4 0 /4 0 /4 0 /4
2622 0 /4 0 /4 0 /4 2 /4 4 /4 4 /4
R2620 0 /4 1/4 1/4 2.15x10ND ND 1.1x1ND
.62X1J .78x1 âR2621 0 /3 0 /3 2 /3 ND ND ND
3.16X1 JR2622 0 /4 1 /4 3 /4 31.6ND ND ND
ND = not done
* = number of deaths/num ber of animals inoculated
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conserved region. This virus would have confirmed the role of the conserved region in 
function of HG52 ICP34.5. However, despite trying several conditions of single-stranded 
site-directed mutagenesis, all were unsuccessful and the mutant phagemid was not obtained.
3.6. In vivo growth of HG52 and RLl mutants in mouse brain
It has been shown previously that the HG52 variant 2604 is avirulent following intracerebral 
inoculation of mice, due to its inability to replicate in brain tissue (Taha et al., 1989a). 
Similar results were observed with the HSV-1 strain 17+ variants 1716 and 1771 (MacLean, 
A et al., 1991; McKie et a l, 1994). Therefore, it was likely that the differences in the LD50 
values (Table 3.2) between the RLl mutants (2620, 2621,2622) and the parental wild type 
HG52 pi. 17 were also due to differential abilities to replicate in mouse brain. Separate 
groups of 3-week old female Balb/c mice were intracerebrally inoculated with HG52 at an 
input dose of 10^ p.f.u./mouse and with 10^ p.f.u./mouse of each of the RLl mutants 
2604, 2620, 2621 and 2622. At various times post-inoculation, two mice per virus were put 
down, their brains removed, homogenised, sonicated in PBS/calf serum and stored at 
-70°C. The virus progeny in each brain was titrated on BHK/C13 cells at 37°C and the mean 
ated for each virus as p.f.u./mouse (Table 3.2a).The in vivo growth kinetics of HG52 and RLl 
mutant viruses are illustrated in Figure 3.13. As demonstrated previously for HG52 and 
2604 (Taha et a l, 1989a), the wild type grows exponentially reaching a titre of 8x10^ 
p.f.u./mouse by 120h post-inoculation. In contrast, 2604 showed no evidence of 
replication, the titre diminished progressively with time and the virus was cleared by 96h 
post-inoculation. Similarly, the mutants 2620 and 2621 showed no growth. The growth of 
the mutant 2622 was intermediate between HG52 and 2604 and there was no detectable 
virus by 120h post-inoculation. The differential abilities of HG52 and the RLl mutants to 
replicate in mouse brains is consistent with their LD50 values (Table 3.2).
3.7. In vitro marker rescue of the mutant viruses 2620, 2621 and 2622
To confirm that the virulence phenotypes of the mutant viruses were due solely to the RLl 
mutations, wild-type rescuants R2620, R2621 and R2622 were constructed. The differential
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Figure 3.13. In vivo growth kinetics of HG52 and RLl mutant viruses
The in vivo growth kinetics of HG52, 2604, 2620, 2621 and 2622 were determined by 
injection of viruses into the left cerebral hemispheres of 3 week old Balb/c mice. The input 
dose was 10^ p.f.u./mouse for HG52 and 10^ p.f.u./mouse for mutant viruses. At the 
indicated times post inoculation (X-axis), two mice for each time point were sacrificed, their 
brains homogenised, sonicated and progeny virus titrated on BHK21/C13 cells at 37°C. The 
titres are given as p.f.u./mouse (Y-axis).
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Table 3.2 a. Titer of virus in individual mouse brain following 
intracranial inoculation.
Virus
Mouse 1 
(p.f.u./mouse)
Mouse 2 
(p.f.u./mouse)
Mean 
(p.f.u./mouse)
Time post 
inoculation (h)
HG52
2604
26za
2621
2622
2.2x1i
1 2x1 I
1.9x1(j
2.7x lii
1.6x
JLZx
2,7x
1-4x
_LBx
0
HG52
26Q4.
262Q.
2621
2 6 2 2
1.4x1I
8x1Z
1.4x1
1,9x10
1 2 x
1.4x
12 x
2 2 x
1 6x
1-4x
2 . Q 5 X
2-85x I
24
HG52
2 6 0 4
2620
2621
2622
1,7x1
2,0x1
2.0x1 I
2 0x1 I
1.9x1
l,2x
JLÛX
2 2 x
1,4x
2 ^ 2
2 . 0 5 X
48
HG52
2604
2620
2621
2622
4.2x1
2.0x1
7,0x1
2.0x1
1.0x1
1 2 k
l i k
2JÎX I
4 6x
2 -6 x
1 2 x
1 2 x 2
I
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I
1 ^
0.
0.
0.
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HGS2
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3 8x10
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growth of the wild type and RLl negative mutants in 3T6 (Brown et at., 1994a) was used to 
isolate rescuants. Mutants in RLl which fail to express ICP34.5 form minute abortive 
plaques in confluent 3T6 cells while wild-type virus forms normal sized plaques.
Rescuants were generated in separate experiments [section 2.2.36(d)] following transfection 
of BHK/C13 cells with intact mutant DNA and the pXB phagemid linearized with HindlJl. 
The RLl recombinant pXB phagemid [section 3.2] was used in transfection because the 
Xhol fragment is small (3.3Kb) thus minimising the chances of correcting a secondary 
mutation that might exist outwith the RLl gene. Progeny virus was titrated on confluent 3T6 
mouse embryo fibroblast cells. Differentiation was based on size and morphology of plaques 
and individual large plaques were isolated and screened. Viruses with a wild type genotype 
were identified using the same technique previously described for isolation of the mutant 
viruses [section 3.4]. The Xbal profiles of the DNA of the rescuants R2620 and R2621 are 
shown in Figures 3.10 and Figure 3.11, respectively. In both rescuants, the Xbal a, b, e , f  
fragments reappeared and the g and c fragments returned to their wild-type position. The 
DNA profile of R2622 digested with Smal and Sad  restriction enzymes and hybridised to 
the ^^P-labelled probe (344bp) (Fig. 3.4) is indistinguishable from that of HG52 (Fig. 
3.12). All rescuants were plaque purified three times before growing stock virus.
3.8. The virulence of the rescuants generated by in vitro marker rescue
The virulence of the three times plaque purified rescuants generated by in vitro marker rescue 
was evaluated by calculating the LD50 values following intracerebral inoculation of Balb/c 
mice [section 2.2.36(a)]. Groups of 3-week old mice were inoculated separately with the 
rescuants at doses of 10^-10^ p.f.u./mouse. The LD50 values of the rescuants compared to 
the mutants, parental wild-type HG52 and 2604 are shown in Table 3.2. It can be seen that 
the rescuants demonstrated an intermediate level of virulence with their LD50 values ranging 
from 3.16x10^ to 5.62x10^ p.f.u./mouse. R2620 demonstrated about a 110 fold increase in 
virulence over 2620. R2621 demonstrated more than a 1.78x10^ fold increase over the 
virulence of 2621 and R2622 about a 31 fold increase over the virulence of 2622.
The failure of rescuants to regain the virulence of the wild-type HG52 suggested the
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following possibilities: (i) a mutation in the pXB Xhol fragment used in the marker rescue 
experiments or (ii) a secondary mutation in either the RLl gene or elsewhere in the genome 
of the mutant viruses and/or the genome of the rescuants due to either heterogeneity in the 
HG52 stock or in passage of the viruses during the 3 rounds of purification. These 
possibilities were analysed further.
3.9. In vivo marker rescue of the mutant viruses
As the rescuants generated by in vitro marker rescue did not return to the wild-type 
phenotype, it was decided to reisolate them by in vivo marker rescue following intracerebral 
inoculation of groups of mice with: (i) the same transfection mix as used for the in vitro 
marker rescue experiments [section 3.7] (ii) a transfection mix of mutant DNA plus the pAT 
BamHlg plasmid (Fig. 3.1] and (iii) a transfection mix of mutant DNA plus the BamHlg 
fragment, purified from digested HG52 DNA. The fragment BamHlg was used because it 
has been shown previously to restore virulence to 2604 (Taha et al., 1989b). The in vivo 
system should select rescuants generated from recombination of the wild-type DNA 
fragment with a mutant genome having no additional defects. Using a different wild-type 
DNA fragment should determine if there was a secondary mutation in the Xhol fragment of 
pXB. Separate transfections were carried out as described in section 2.2.9 using a 10-fold 
molar excess of either pXB or pAT-BamHI^ plasmids and 1:1 ratio of the HSV-BamHI^ 
fragment. Before animal inoculation, the presence of rescuant viruses with the wild-type 
profile in the transfection mixes was first tested by titration on 3T6 mouse embryo fibroblast 
cells. The DNA of large plaques was confirmed by either ^^P-DNA labelling or Southern 
blotting. As we expected a low frequency of revenants in the HSV-BamHI^ transfection 
mixes, 3-week old Balb/c mice were injected intracerebrally with 25pl of a neat and 10" 1 
dilution of each transfection mix (Table 3.3). As a higher frequency of revertants was 
expected in other transfection mixes with the pXB and pAT-BamHI^ plasmids, mice in this 
case were inoculated with 10"! and 10"2 dilutions (Table 3.3). Mice were monitored for 10 
days and their clinical state recorded. All mice inoculated with neat HSV-BamHI^ 
transfection mixes showed early signs of neurological dysfunction and were put down 24-
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Table 3.3. In vivo marker rescue.
Plasmid/^Xs. Dose 
DNA rescuant^x . 
fragment
N i d r d Putative rescuant
pXB ND 0/2 0 /2
R2620pAT-BamHIg ND 0/2 0 /2
HSV-BamHIg 2/2 0 /2 ND
pXB ND 2/2 1/2
R2621pAT-BamHIg ND 2/2 0 /2
HSV-BamHIg 2/2 0 /2 ND
pXB ND 2/2 0 /2
R2622pAT-BamHIg ND 2/2 0 /2
HSV-BamHIg 2 /2 2 /2 ND
N = neat 
ND = not done
* = number of deaths/ number of animals inoculated
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30h post inoculation. It was considered that the early illness of these mice was due to a high 
dose of input virus from the transfection mixes.
In the case of R2620, apart from mice put down 30h post inoculation, none showed signs of 
illness indicating that R2620 with a wild-type phenotype had not been generated. Therefore, 
R2620 detected in the transfection mixes is likely to contain a defect which modulates 
virulence. To confirm this, it was decided to isolate a rescuant from the brain of a mouse, 
put down 30h post inoculation of the HSV-BamHIg transfection mix (neat).
In the case of R262I, mice especially those inoculated with lO'l of either pXB or the pAT- 
BamHVg transfection mixes (Table 3.3) began to show signs of neurological dysfunction 3-7 
days post inoculation indicating probable generation of wild type revertants. At this point the 
mice were put down, their brains removed and stored at -70°C. Similar findings were 
observed for R2622 (Table 3.3) in mice inoculated with 10"! of either pXB or BarriHig.
The wild-type rescuants R2621 and R2622 were isolated from the brains of mice which 
were put down 3-7 days post inoculation. This time point was based on the growth patterns 
of HG52 and the RLl mutant viruses in mouse brain [section 3.6]. It was obvious that the 
avirulent variants of HG52 can not be detected by day 4 post inoculation and the intermediate 
variant, day 5 post inoculation (Fig. 3.13). Therefore, neurological symptoms observed 
before this time (Table 3.3) might be due to either the growth of rescuants or the high dose 
of input virus.
Two putative R2621 rescuants were isolated from brains of mice which were put down day 
6  post inoculation. One from a brain inoculated with the pAT-BamHIg transfection mix and 
the other from a brain inoculated with the pXB transfection mix (Table 3.4). Similarly, three 
putative R2622 rescuants were isolated, one from brain of a mouse which was put down 4 
days post inoculation of the HSY-BamHlg transfection mix and two from the brain of a 
mouse which was put down 5 days post inoculation of the pXB transfection mix (Table 
3.4).
Brains were homogenised in 500|il PBS/calf serum, progeny virus titrated on 3T6 cells and 
single large plaques were isolated and tested as previously described for isolation of mutants 
[section 3.4]. One isolate with a wild-type restriction enzyme profile was selected from each
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brain (data not shown) and grown into a virus stock. Following one round of purification, 
the LD5 0  values [section 3.10] of these rescuants were determined. The rounds of 
purification were minimized to avoid a reduction in the virulence of the rescuants. The three 
rounds of purification of mutant viruses and rescuants generated in vitro, involved seven 
passages in BHK21/C13 cells.
3.10. Virulence of the rescuants R2620, R2621 and R2622 generated by in  
vivo marker rescue
The virulence of the rescuants R2620, R2621 and R2622 generated by in vivo marker rescue 
was evaluated to determine if their wild-type phenotype had been restored. The LD50 values 
were determined for groups of four Balb/c mice as described in section 2.2.36(a). Mice were 
intracerebrally inoculated with HG52 at doses of 10^-10^ p.f.u./mouse and with mutants 
(2620, 2621 and 2622) at doses of 10^-10^p.f.u./mouse. The doses were based on the 
known virulence phenotype of HG52 and the mutant viruses (Table 3.2). The rescuants 
were injected at doses of 1 0 ^-1 0 ^p.f.u./mouse, as it was anticipated that the rescuants 
would be as virulent as HG52 or 10-200 fold less virulent. The LD50 values of the rescuants 
compared to HG52 and the mutant viruses are shown in Table 3.4. For this experiment, the 
commercial supplier of mice had changed which could account for the slight increase in the 
LD50S of HG52 and the mutants. HG52 was highly virulent giving a LD50 of 2.15x10^ 
p.f.u/mouse. No significant difference was seen between the LD50S of 2620, 2621 and 2622 
and those observed previously (Table 3.2). As expected, the R2620 isolated using the 
BamHlg fragment did not return to the wild-type and had a LD50  value of 1.77x10^ 
p.f.u./mouse. This was only slightly more than a 5 fold increase in virulence compared to 
2620. The two isolates of R2621 regained the wild-type level of virulence and had a LD50 
values of <10^ p.f.u./mouse. This was a >10^ increase in virulence compared to 2621. In 
the case of R2622, one isolate (R2622/C) demonstrated a full virulence phenotype and had a 
LD50 of 3.16x10^ p.f.u./mouse and others behaved intermediately and had LD50S of 10^ 
and 10^ p.f.u./mouse (Table 3.4).
The results from the in vivo marker rescue experiments (i) confirmed the avirulent phenotype
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of the mutant 2621 and the intermediate phenotype of the mutant 2622 (ii) indicated a 
secondary mutation in the genome of the mutant 2620 which requires to be reconstructed (iii) 
ruled out the possibility of a mutation in the pXB Xhol fragment.
3.11. Virulence heterogeneity of individual plaque isolates within the HG52 
plaque 17 stock
Heterogeneity in virulence among individual plaque isolates of the elite stock of HSV-2 
strain HG52 has been demonstrated previously (Taha et al., 1988). At that time, one plaque 
stock, number 17 was shown to be of high virulence and has subsequently been used as our 
parental virus for all virulence experiments. In this study, all rescuants generated in vitro 
(Table 3.2) and R2620, R2622/A and R2622/B generated in vivo (Table 3.4) did not regain 
the wild-type level of virulence. This could be attributed to heterogeneity of the parental 
wild-type HG52 pi. 17 and possibly heterogeneity of the mutants. Therefore it was decided 
to assess heterogeneity within the pi. 17 stock. The plaque 17 stock was diluted, plated out 
on BHK21/C13 cells and 6 well separated individual plaques were picked and subjected to 
three rounds of purification before growing stock virus and injecting into mice. Separate 
groups of 3-week old female Balb/c mice were intracerebrally inoculated with the 6 stock 
viruses at doses of 10^-10"  ^p.f.u./mouse. The LD50 values of the stocks compared to the 
parental pi. 17 are illustrated in Table 3.5. The stocks were assigned to one of 3 classes 
depending on the LD50 values: (i) Class I of high virulence (LD50 ^  10^ p.f.u./mouse) 
contains plaque stocks 2, 5 and 6 (ii) Class II of intermediate virulence (LD50  = 
lO^p.f.u./mouse) contains plaque stock 1. (ii) Class III of low virulence (LD5 0  > 
10^p.f.u./mouse) contains plaque stocks 3 and 4. It can be seen that again heterogeneity is 
demonstrable with LD50 values ranging from <10^ to >10^.f.u7mouse.
It has been shown previously that the elite stock of HG52 contains variants with detectable 
genomic deletions at a frequency of 24% (Harland and Brown, 1985). To investigate the 
possibility that there were gross sequence alteration, the genomes of the 6 individual plaques 
of HG52 pi. 17 were analysed by BamUl restriction enzyme digestion. The analysis revealed 
no obvious deletion in the DNA of any plaque regardless of its virulence phenotype (Fig.
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Table 3 .5 . LD50 values after intracerebral inoculation of individual 
HG52 pl. 17 plaques following 3 rounds of purification.
^ X ^ o s e
V ir u s '^ .
LDso
p.f.u./mouse
Virulence
class
HG52 
Dl. 17
*
1/4 4 /4 ND 2.15X1 a High
pi. 1 0 /4 1/4 2 /4 Intermediate
pi. 2 2 /4 4 /4 4 /4 High
pi. 3 0 /4 0 /4 0 /4 > 1# Low
pi. 4 0 /4 0 /4 0 /4 > 1^ Low
pi. 5 4 /4 4 /4 4 /4 <^è High
pi. 6 4 /4 4 /4 4 /4 <^§ High
ND = not done
* = number of deaths/number of animals inoculated
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3.14). Variation was observed in the size of BamYil z and a\ the known variable fragments, 
which span the jinctions between Us and TRs/IRs (Davison and Wilkie, 1981). Variation 
was also observed in the size of BamHlg and x fragments, the former due to variation in the 
number of the ‘a ’ sequences. The relevant BamHl restriction map for HSV-2 strain HG52 is 
shown in Figure 3.15. It is possible that a mutation which is undetectable e.g. a point 
mutation or a deletion/insertion of <l(X)bp has occurred either somewhere else in the genome 
or in the RLl gene The latter possibility was subsequently ruled out (section 3.16).
3.12. Virus growth properties in vitro
The replication efficiencies of RLl mutant viruses relative to the parental wild-type HG52 
and 2604 were examined in both BHK21/C13 cells and 3T6 mouse embryo fibroblast cells. 
Confluent cells were infected with either 0.01p.f.u./cell (multi-cycle growth experiment) or 
5p.f.u./cell (single cycle growth experiment), at various times post-infection, plates were 
harvested, cells jonicated and the progeny virus titrated on BHK21/C13 cells. In 
BHK21/C13 cells it both low multiplicity of infection (0.01p.f.u./cell) and high multiplicity 
of infection (5p.fj./cell), the mutants 2604, 2620, 2621 and 2622 grew well and their 
growth patterns were similar to that of the wild type virus (Fig. 3.16; Fig. 3.17). Differential 
growth was obsened at low m.o.i. (0.01 p.f.uVcell) in 3T6 cells. This multicycle growth 
experiment was caiied out to test whether the growth differential in confluent 3T6 cells seen 
between HSV-1 srain 17"*" and the RLl negative mutant 1716 (Brown et al., 1994a) is 
mimicked by type2 mutant virus. It can be seen in Figure 3.18 that HG52 showed a 10^ 
fold increase in tire by 72h post-infection compared to impaired growth of the deletion 
mutant 2604. The nutant 2620 with the stop codon in the conserved region was similarly 
impaired. The nul mutant 2621 showed some evidence of replication by 24h but no 
subsequent increase in titre. Compared to HG52 and 2604, the mutant 2622 showed 
intermediate growti with a 10  ^fold increase in titre by 72h post infection. These phenotypes 
in confluent 3T6 cdls are consistent with the growth patterns of HG52 and the RLl mutants 
in mouse brain (Fij. 3.13) and their LD50 values (Table 3.2).
In 3T6 cells, virues were also differentiated based on size and morphology of plaques.
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Figure 3.14. BaniW. restriction enzyme profiles of the DNA of the individual plaques of 
HG52 pl.l7
The genotypes of the individual plaques of HG52 pi. 17 were analysed by BamUl restriction 
enzyme digestion. Cleavage of the genomes of each of the plaques generated fragments of 
equivalent sizes. Lane 1, HG52 pi. 17; Lane 2, pi. 1; Lane 3, pi. 2; Lane 4, pi. 3; Lane 5, pi. 4; 
Lane 6, pi. 5, Lane 7, pl.6.
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Figure 3.15. Position of the BamW. restriction enzyme sites in the HSV-2 strain HG52 
genome
The position of BarnUl sites in the HG52 genome in the prototype orientation is illustrated 
(Wilkie et aL, 1978). The dashed vertical line indicates the position of the L-S junction.
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Figure 3.16. Multi-cycle growth kinetics of HG52 and RLl mutant viruses in 
BHK21/C13 cells
The multi-cycle growth kinetics of 2604, 2620, 2621 and 2622 were compared to HG52 in 
BHK21/C13 cells. Confluent cells were infected at a m.o.i. of 0.01 p.f.u./cell. At indicated 
times post-infection (X-axis), cells were harvested, sonicated and progeny virus titrated on 
BHK21/C13 cells at 37°C. The titres are given as p.f.u./lO^ cells (Y-axis).
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Figure 3.17. Single-cycle growth kinetics of HG52 and RLl mutant viruses in 
BHK21/C13 cells
The single-cycle growth characteristics of 2604, 2620, 2621 and 2622 were compared to the 
wild-type strain HG52 in BHK21/C13 cells. Confluent cells were infected at a m.o.i. of 5 
p.f.u./celL At indicated times post-infection (X-axis), cells were harvested, sonicated and 
progeny virus titrated on BHK21/C13 cells at 37°C. The titres are given as p.f.u./10^ cells (Y- 
axis).
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Figure 3.18. Multi-cyde growth kinetics of HG52 and RLl mutant viruses in 3T6 cells
The multi-cycle growth kinetics of 2620, 2621 and 2622 were compared to HG52 and 2604 in 
3T6 cells. Confluent cells were infected at a m.o.i. of 0.01 p.f.u./cell. Cells were harvested at 
0, 12, 24, 48, 72 and 96h post-infection. The progeny virus was titrated on BHK21/C13 cells 
at 37°C. The titres are given as p.f.u./10^ cells (Y-axis).
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HG52 produced large plaques, 2622 produced intermediate plaques, the RLl negative 
viruses 2604, 2620, 2621 produced small abortive plaques. In addition to the small plaques, 
2621 produced a few large plaques. This was not due to a mixed population of 2621 and 
HG52, as the Xbal genomic profile of the large plaques was identical to that of the small 
plaques of 2621 (Fig. 3.19). This phenotypic property of 2621 is reflected in its growth 
pattern and accounts for the one log difference relative to the growth of 2604 (Fig. 3.18). 
The multicycle growth experiment was repeated several times, the large plaques were 
observed each time and the same growth pattern of 2621 was obtained. To confirm the 
plaque morphology of 2621, the virus was reisolated and when the new mutant, N2621 was 
plated on 3T6 cells, a few large plaques were again observed among the small plaques. The 
Xhal profile of the large plaques of N2621 was identical to that of the small plaques (data 
not shown).
3. 13. In vitro virus growth properties of large and small plaques of the 
mutant 2621
To determine whether the small and large plaques of 2621 retain their morphology following 
3 rounds of purification in 3T6 cells, an aliquot (lOOpl) of 2621 stock virus (1x10^ 
p.f.u./ml) was titrated; 6 small and 6 large well isolated plaques were picked and each was 
transferred to 300|lQ PBS, sonicated and retitrated on 3T6 cells. Following 48h incubation at 
37°C, 2 plaques from each group were picked and subjected to 2 further rounds of 
purification. After picking plaques, the monolayers were stained to determine the ratio 
between the large and small plaques on each plate. The large plaques segregated to give an 
equal proportion of the two plaque sizes. The small plaques gave rise to large plaques at a 
frequency of 3-18%. Virus stocks of 3 times purified large and small plaques were prepared 
to determine their replication efficiency in BHK21/C13 and 3T6 cells. The growth patterns 
of these plaques in 3T6 cells compared to the parental 2621 virus stock, 2604, 2622 and 
HG52 pi. 17 are illustrated in Figure 3.20. Growth of the small plaque stock was more 
efficient than that of the parental 2621 stock and comparable to 2622 by 48h post-infection, 
possibly due to adaptation to growth in 3T6 cells. The growth of the large plaque stock of
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Figure 3.19. Xbal restriction enzyme profiles of the DNA of the small and large plaques 
of 2621
Autoradiograph of an Xba I digest of viral DNA ^^P-labelled in vivo. Cleavage of the DNA of 
the small and large plaques of 2621 with Xbal generated fragments of equivalent sizes. Lane 
1, small plaque of 2621; Lane 2, large plaque of 2621; Lane 3, large plaque of 2621.
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Figure 3.20. Multi-cyde growth kinetics of the small and large plaque stocks of the 
mutant 2621 in 3T6 cells
The multi-cycle growth characteristics of the small and large plaque stocks of the mutant 
2621 were compared to the parental stock 2621, 2604, 2622 and HG52 in 3T6 cells. 
Confluent cells were infected at a m.o.i. of 0.01 p.f.u./cell. Following absorption at 37°C for 
Ih, the monolayers were washed twice with PBS/foetal calf serum, overlaid with Dulbecco’s 
modified Eagle’s medium and incubation continued at 37°C. Plates were harvested at 0, 12, 
24, 48 and 72h post-infection. The progeny virus was titrated on BHK21/C13 cells at 37°C. 
The titres are given as p.f.u./10^ cells (Y-axis).
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2621 was comparable to that of HG52 pi. 17. Since the virulence phenotype in vivo is 
usually mimicked in vitro in 3T6 cells, it was decided to study the virulence efficiency of 
these individual plaques by intracerebral inoculation of mice [section 3.14]. No differential 
growth was observed between the small and large plaques stocks of 2621 and the parental 
2621 virus stock in BHK21/C13 cells (Fig. 3.21).
3.14. Virulence of the large and small plaques of the mutant 2621
To evaluate the virulence of these plaques, mice were intracerebrally inoculated with HG52 
at doses of 10^-10^ p.f.u./mouse. The mutants 2604 and 2621 were injected at doses of 1 0 ^ 
p.f.u./mouse while the mutant 2622 was injected at doses of 10^-10^ p.f.u./mouse. The 
large (2621/L) and the small (2621/S) plaques of 2621 were injected at doses of 10^-10^ 
p.f.u./mouse. The LD50  values of these viruses are shown in Table 3.6. No significant 
difference was seen between the LD50 of HG52, 2621 and 2622 and those observed 
previously (Tables 3.2; 3.4). The 2621/S virus was avirulent and had a LD50 value of 1 0 ^ 
p.f.u./mouse. The 2621/L virus demonstrated an intermediate level of virulence and had a 
LD50 value of 2.15x1 q4 p.f.u./mouse which is within the range of individual plaques of 
HG52 pi. 17.
3.15. Temperature sensitivity
This study showed that the growth of RLl mutant viruses is identical to that of HG52 in 
BHK21/C13 cells at 37°C in both single and multicycle growth experiments [section 3.13]. 
A previous study in our laboratory showed that the variant 2604 is no more impaired in 
BHK21/C13 cells at 38.5°C than the parental HG52 (Harland and Brown, 1985). 
Therefore, it was decided to test whether the RLl mutant viruses 2620, 2621 and 2622 
exhibited a ts phenotype. The growth of the mutant viruses in BHK21/C13 cells relative to 
the parental wild-type HG52 and 2604 was compared at 31°C, 37°C and 38.5°C (section 
2.2.6). At 24h post-infection, cells were harvested, sonicated and the progeny virus titrated 
on BHK21/C13 cells. It can be seen in Figure 3.22 that the yield of the mutant viruses were 
not significantly different from wild-type HG52 and hence do not display ts phenotypes.
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Figure 3.21. Multi-cycle growth kinetics of the small and large plaque stocks of 2621 in 
BHK21/C13 cells
Multi-cycle growth experiments of the small and large plaque stocks of 2621 were carried out 
in BHK21/C13 cells. Cells were infected at m.o.i. of 0.01 p.f.u./cell. Following absorption at 
37°C for Ih, the monolayers were washed with PBS/calf serum, overlaid with ETC 10 and 
incubation continued at 37°C. Plates were harvested at 0, 24, 48 and 72h post-infection and 
titrated on BHK21/C13 cells. The titres are given as p.f.u./lO^ cells (Y-axis). The growth 
kinetics of these plaques were compared with those of 2621, 2622, 2604 and HG52.
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Table 3.6. The LD50 values of the large (L) and the small (S) 
plaques of 2621 following intracerebral inoculation 
of 3-week old Balb/c mice compared to 2621, HG52 
and 2604.
^ s ^ D o s e
V i r u s X ^ i 5 1§
LDso
p.f.u./mouse
HG52
*
0 /4 4 /4 ND ND ND 3.16x1 a
2604 ND ND ND ND 0 /4 >^s
2621 ND ND ND ND 0 /4 >1(5
2622 ND ND ND 0 /4 4 /4 3.16x1(J
2621/L 0 /4 0 /4 1/4 4 /4 4 /4 2.15x1(3
2621/S 0 /4 0 /4 0 /4 0 /4 2 /4 1§
ND = not done
* = number of deaths/number of animals inoculated
Figure 3.22. Temperature sensitivity of the mutant viruses
The temperature sensitivity of 2620, 2621 and 2622 was tested on BHK21/C13 cells and 
compared with HG52 and 2604. Cells were infected at a m.o.i. of 5 p.f.u./cell. Following 24h 
incubation at 31°C, 37°C and 38.5°C (X-axis), the monolayers were harvested, sonicated and 
the progeny virus titrated on BHK21/C13 at 37°C. The titres are given as p.f.u./10^ cells (Y- 
axis).
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The highest virus titres for HG52 and the mutant viruses were observed at 31°C. The titres 
dropped by 1 log and 3.5 logs with temperatures of 37°C and 38.5°C, respectively.
3.16. In vitro growth properties of the rescuants and the individual plaques 
of HG52 pl.l7
The rescuants generated in vitro (Table 3.2) and the rescuants R2620, R2622/B generated in 
vivo (Table 3.4) did not regain the wild-type level of virulence. To test their phenotype in 
vitro, multicycle growth experiments (m.o.i. 0 .0 1  p.f.u./cell) were carried out in 3T6 cells 
over a period of 72h and their growth patterns were compared to those of HG52 pi. 17 and 
2604. The growth patterns of the R2620 rescuants are illustrated in Figure 3.23. As 
observed previously (Fig. 3.18), the growth of both 2604 and 2620 is impaired in 3T6 cells. 
The growth patterns of the intermediate virulence R2620 rescuants generated in vitro and in 
vivo were identical to that of HG52. Similarly, as can be seen in Figure 3.24, the growth of 
the intermediate virulence R2621 generated in vitro was identical to that of the wild-type and 
to the highly virulent rescuant R2621/A generated in vivo. The growth of the intermediate 
rescuant R2622 generated in vitro was similar to that of the wild-type and to the virulent 
rescuant R2622 generated in vivo (Fig. 3.25). These results rule out a possible
mutation in the RLl gene of rescuants generated in vitro.
To evaluate the replication efficiency of the individual plaques of HG52 pi. 17 in 3T6 cells , 
plaque 1 was chosen as a low virulence plaque, while plaques 3 and 5 were chosen as 
intermediate and high virulence plaques, respectively. It can be seen in Figure 3.26, that the 
growth patterns of all selected plaque stocks were identical to that of the parental HG52 
plaque 17. In comparison, the RLl-deletion mutant 2604 showed some evidence of 
replication by 48h with no subsequent increase in titre. Using this system as an assay of 
ICP34.5 expression, the ability of these individual plaques to grow as well as the HG52 
pi. 17 stock rules out mutations in the RLl gene which could have accounted for the
heterogeneity within the HG52 pi. 17 stock as regards LD50 values (Table 3.5).
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Figure 3.23. Multi-cycle growth kinetics of the 2620 rescuants (R2620) in 3T6 cells
The multi-cycle growth characteristics of R2620 generated in vitro and in vivo were compared 
with those of 2620 and HG52 in 3T6 cells. Confluent cells were infected at a m.o.i. of 0.01 
p.f.u./cell. After absorption at 37°C for Ih, cells were washed, overlaid with Dulbecco’s 
modified Eagle’s medium and incubated at 37°C. At various times post-infection (X-axis), 
cells were harvested, virus released by sonication and titrated on BHK21/C13 cells at 37°C. 
The titres are given as p.f.u./10^ cells (Y-axis).
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Figure 3.24. Multi-cycle growth kinetics of the 2621 rescuants (R2621) in 3T6 cells
The multi-cycle growth kinetics of R2621 generated in vitro and in vivo were compared with 
those of 2621 and HG52 in 3T6 cells. Cells were infected at a m.o.i. of 0.01 p.f.u./cell and 
incubated at 37°C for Ih. Cells were washed, overlaid with medium and incubated at 37°C. At 
various times post-infection (X-axis), cells were harvested, sonicated and progeny virus 
titrated on BHK21/C13 cells at 37°. The titres are given as p.f.u./10^ cells (Y-axis).
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Figure 3.25. Multi-cycle growth kinetics of the 2622 rescuants (R2622) in 3T6 cells
The multi-cycle growth experiment of R2622 generated in vitro and in vivo was carried out in 
3T6 cells. Cells were infected at a m.o.i. of 0.01 p.f.u./cell and incubated at 37°C for Ih. Cells 
were washed, overlaid with medium and incubated at 37°C. At various times post-infection 
(X-axis), cells were harvested, sonicated and progeny titrated on BHK21/C13 cells at 37°C. 
The titres are given as p.f.u./10^ cells (Y-axis). The growth kinetics of the rescuants were 
compared with those of 2622 and HG52.
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Figure 3.26. Multi-cycle growth kinetics of 3 individual plaque stocks of HG52 pi. 17 in
3T6 cells
The growth characteristics of plaques 1, 3 and 5 of HG52 pi. 17 were compared with the 
parental stock and with 2604 in 3T6 cells. Cells were infected at a m.o.i. of 0.01 p.f.u./cell. 
Following absorption at 37°C for Ih, the monolayers were washed with PBS/foetal calf, 
overlaid with Dulbecco’s modified Eagle’s medium and incubated at 37°C. At the indicated 
times post-infection (X-axis), plates were harvested and progeny virus titrated on BHK21/C13 
cells at 37°C. The titres are given as p.f.u./10^ cells (Y-axis).
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3.17. cDNA-PCR of RLl mRNA flanking the predicted intron
To provide evidence that the mRNA of RLl is spliced, PCR was employed to try to amplify 
a cDNA product from the HG52 RLl mRNA, using primers flanking the predicted intron 
[section 2.2.35(b,c)]. Total RNA and cytoplasmic poly (A)+RNA were prepared as 
described in sections 2.2.32-34. Three pairs of primers complementary to the DNA 
sequence flanking the intron (Fig. 3.27; Table 3.7) were designed for reverse transcription 
and PCR reactions. The fu*st pair of primers (A, B) was selected by the computer program 
(Oligo; MedProbe A.A); the second (C, D) and the third (E, F) were designed according to 
the criteria outlined by Dutton et al (1993) for amplification of templates with a high G+C 
content [section 2.2.35(a)]. Each primer pair should produce PCR products of different 
sizes (Table 3.7). The size of the PCR product would determine whether the reiterated 
sequence interrupting the predicted RLl ORE is an intron. An intron would be spliced out 
and DNA sequencing of the PCR product would determine whether the proposed splicing 
sites are correct. If there is not an intron, DNA sequencing would define any possible errors 
in the reiterated sequence or in the flanking regions.
Synthesis of cDNA was carried out as described in section 2.2.35(b) using the antisense 
primer (B), AMV reverse transcriptase (RT) and total RNA extracted from BHK21/C13 cells 
infected separately with HG52 and the intronless mutant virus 2622. Amplification was 
performed with Taq DNA polymerase under the conditions described in section 2.2.35(c). 
Appropriate positive intron PCR controls (pSB, HG52-DNA), negative intron controls 
(intronless pSB) and negative controls (mock cells, reagents only) were included in each 
PCR run. To determine if the desired fragment had been amplified, one-tenth of the PCR 
product was analysed on a 3% NuSieve agarose gel. As no amplified product was observed, 
the cDNA/PCR experiment was repeated several times using a new total RNA preparation, 
primer (B) or random hexanucleotide primer (Promega), AMV-RT or MuLV-RT and Taq 
DNA Polymerase. Amplification was performed under various conditions. An appropriate 
fragment could not be detected, possibly due to unsuccessful cDNA synthesis and/or 
unsuccessful amplification due to the high G+C content of the template. Therefore, it was 
decided to carry out the cDNA/PCR reactions at higher temperatures in the presence of
8 7
Figure 3.27. The location of the primers used to amplify the cDNA product of HG52 
mRNA flanking the predicted intron
A schematic diagram of the RLl gene of HSV-2 strain HG52 illustrating the locations of the 
primers used in the cDNA/PCR reactions. The nucleotide numbers are from McGeoch et a l, 
1991.
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thermostable enzymes. It was thought that the high G+C (hGC) PCR protocol reported by 
Dutton et al (1993) would be the best choice for amplification of the cDNA product. This 
protocol requires a very heat stable thermal DNA polymerase and primers of Wallace 
temperatures >80°C [4°Cx(G+C)+2°Cx(A+T)]. The second and the third pairs of primers 
(CD,EF) with high Wallace temperatures (Table 3.7) were used separately in cDNA/PCR 
reactions. These reactions were carried out in the presence of the thermostable Retrotherm- 
RT, antisense primer, Vent DNA Polymerase and cytoplasmic poly (A)+RNA. To ensure 
use of intact mRNA in the cDNA reaction, oligo (dT)25 dynabeads were used as a rapid 
method to extract the poly (A)+ RNA [section 2.2.34] from BHK21/C13 cells infected 
separately with HG52 and 2622. The hGC-PCR amplification protocol was used as 
described in section 2.2.35(c). Multiple non-specific fragments were seen in the gels. 
Several attempts were made to optimise the PCR conditions using the positive (pSB) and the 
negative (intronless pSB) controls but unfortunately all were unsuccessful.
In parallel, another approach (nested PCR) was employed to amplify the target sequence in 
the positive and the negative PCR controls. The primers (C,D) were used as outer primers in 
the first round of nested PCR. The amplification was performed with Vent DNA polymerase 
under the conditions described in section 2.2.35(b). A small aliquot (5pl) of the product was 
subjected to a second round of amplification under the same conditions in the presence of the 
inner pair of primers (A,B). Nested PCR was also unsuccessful in obtaining specific 
amplification.
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ADDENDUM
While the text for this thesis was at the final stage of editing, the following results were 
obtained by Dr. J. Harland:
1. By cDNA-PCR of poly(A+) RNA using primers on either side of the proposed intron, 
a cDNA clone corresponding exactly to the predicted spliced mRNA was amplified.
2. During PCR analysis, 2622 RNA was used as a control. Results indicated that the 
intron was present in non-poly(A+) RNA. Therefore, 2622 DNA was digested with a 
range of restriction enzymes in various combinations. Using the pSB plasmid to generate 
a random primed probe. Southern blot analysis rendered that 2622 had an approximately 
150bp deletion partly in RLl between np. 13037 and np. 13317 and was not deleted 
between the intron splice sites.
The discussion has thus been written to take account of these findings.
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CHAPTER 4
DISCUSSION
CHAPTER 4: DISCUSSION
During the past decade, the pathogenicity of HSV has attracted attention because of the 
increased incidence of chronically recurring genital disease, neonatal transmission and 
the severity of symptoms in immunocompromised individuals. An understanding of the 
molecular basis of HSV pathogenicity is important in intervention therapy such as 
development of HSV vaccines, anti virais and gene therapy. Several genes have been 
implicated in HSV virulence [see section 1.7]. A defined virulence gene, designated 
Yl34.5 or RLl has been identified in the long repeat regions of HSV-1 between RL2 
and the ‘a’ sequence (Chou and Roizman, 1986; Dolan et al., 1992). Its location was 
consistent with findings which associated virulence following intracerebral inoculation 
of mice with mutations in sequences located at or near the termini of the long repeat 
region of the genome (Thompson et al, 1983, 1985, 1986; Javier et al., 1988a; Oakes et 
al., 1986; Taha et al., 1989a,b; MacLean, A et al., 1991). RLl is a diploid gene 
encoding the protein ICP34.5, a 43.5K polypeptide of 263 amino acids in HSV-1 strain 
F infected cells (Ackermann et al., 1986; Chou and Roizman 1986, 1990). An 
equivalent polypepetide (37K) of 248 amino acids was also identified in HSV-1 strain 
17+ infected cells (Mckay et al., 1993). The latter group found that the HSV-l(F) 
polypeptide migrated with a Mr of 39K due to use of different gel systems (McKay et 
al, 1993).
In our laboratory, the R l region of the HSV-2 strain HG52 genome between 0-0.02 and 
0.81-0.83 m.u. had been found to encode virulence determining sequences. The 
variants, 2604 and 2616 with 1488bp and 786bp deletions respectively within this 
region were shown to be a virulent on intracerebral inoculation of Balb/c mice (Taha et 
a l, 1989a,b; Harland and Brown, 1991). Sequence analysis of the long repeat region of 
HSV-2 strain HG52 indicated that HG52 possesses a RLl gene equivalent to that of 
HSV-1. The coding sequence of HG52 RLl is interrupted by a proposed intron 
composed of a repeat element of six complete and one partial copy of 19 nucleotides. 
Each copy contains a stop codon thus all three forward reading frames are blocked.
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Removal of the proposed intron should result in the second exon containing an 189bp 
HSV-l/HSV-2 conserved region, being in frame. RLl of HG52 is predicted to encode a 
protein of 261 amino acids. Eighty three percent of a 63 amino acid domain at the C- 
terminus of the protein is homologous to that of HSV-1 (McGeoch et al., 1991). 
ICP34.5 has not yet been detected in cells infected with HG52. The majority of HSV 
genes are unspliced, RLl of HG52 is unusual in that the predicted splice appears to be 
serotype specific. Because of these observations it became important to:
(i) confirm the predicted ORE of RLl in HSV-2 strain HG52 and its role in the 
virulence of HG52.
(ii) characterise the functional domains of RLl in HG52 and study the role of the 189bp 
conserved region in virulence by making truncated versions of ICP34.5.
(iii) determine experimentally whether RLl of HG52 is spliced.
To confirm the predicted ORE of RLl in HSV-2 strain HG52, an ICP34.5 null mutant 
2621 was constructed with a translational stop codon TAG, 9bp downstream of the RLl 
initiation codon ATG [sections 3.3.2+3.4.2]. The stop codon was inserted in a single 
frame to avoid disrupting any overlapping reading frames and to verify that loss of 
ICP34.5 alone is responsible for the phenotype of 2621. Unfortunately, two bases 
downstream of the inserted stop codon were deleted during site-directed mutagenesis 
which puts RLl out of frame and disrupts any overlapping reading frame which might 
exist antisense to the gene. Time constraints did not allow isolation of another ICP34.5 
null mutant virus. When this study began, apart from LAT (Zwaagstra et al., 1989), 
there was no evidence of an antisense gene to RLl. Recently, two transcription units 
designated GRP P and ORE O were described by Lagunoff and Roizman (1994) 
antisense to RLl. These transcription units will be mentioned in detail later.
The ICP34.5 null mutant, 2621 was avirulent in mice with in vivo and in vitro 
characteristics comparable to those of 2604. On intracerebral inoculation of 3-week old 
Balb/c mice, 2621 had a LD50 >10^ p.f.u./mouse compared to 3.16x10^ p.f.u./mouse 
for 2604 and 10^ p.f.u./mouse for HG52 (Table 3.2). Similar results have been obtained
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when stop codons were inserted at the beginning of the HSV-1 strains 17+ and F, RLl 
genes. The variant 1771 with a single-frame stop codon, 9bp downstream of the RLl 
initiation codon was avirulent with a LD50  >1 0^ p.f.u./mouse compared to < 1 0  
p.f.u./mouse for the wild-type HSV-1 strain 17+ (McKie et al., 1994). A mutant virus 
of strain F carrying a six-frame stop codon about 90bp from the initiating ATG had a 
LD50 >107 p.f.u./mouse compared to 420 p.f.u./mouse for the wild-type (Chou et al.,
1990).
The ability of the rescuant R2621 generated by in vivo marker rescue to fully restore the 
wild-type phenotype (Table 3.4) indicated unambiguously that RLl exists and that it is 
a virulence determinant of HSV-2 strain HG52. The mechanism by which lack of 
expression of ICP34.5 results in failure of virus mplication in the nervous system is not 
clear. Infection of cells of neuronal origin (human neuroblastoma SK-N^SH) by HSV-1 
mutants incapable of expressing ICP34.5 results in shutoff of cellular protein synthesis. 
From these studies it was concluded that ICP34.5 is important in precluding shutoff of 
cellular protein synthesis in order to sustain production of infectious progeny virus 
(Chou and Roizman, 1992). Similar findings in SK-N-SH cells have been shown for the 
HSV-1(17+) mutant 1716 and for the HSV-2 mutant 2604 which grow 2-3 log poorer 
than their parental-wild types at both high and low multiplicities of infection and 
shutoff cellular protein synthesis (Dr. A. MacLean, personal communication). This 
however is not the universal role of ICP34.5 in all non permissive cell types e.g. in 
confluent 3T6 cells RLl negative virus fails to grow due to a defect in virus maturation 
(Brown et al., 1994b). The precise mechanism by which ICP34.5 enables HSV to grow 
in the central and peripheral nervous systems in vivo is not known.
Having confirmed the existence of a HSV-2 RLl gene and its role in virulence, it 
became important to determine the functional domains of the gene. Translational stop 
codons were introduced at unique restriction enzyme sites in exoni at the Fspl site, in 
the proposed intron at the Drdi site and in exonll at the PflMl and Rsrll sites within the 
conserved region (Fig. 3.3). The mutant 2620 with a six-frame stop codon at the RjrII 
site was isolated first and its phenotype determined. Insertion of a stop codon at the
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Rsrll site, 46 codons upstream from the end of RLl and 13 codons upstream of the 3' 
end of the conserved region, would result in most of the protein being expressed. It was 
expected that this mutation might result in a non-functional protein due to disturbance 
of the 63-residue region conserved between HSV-2(HG52) and HSV-1(17+). A 
correponding domain is found in the mouse protein, MyD116 (McGeoch and Barnett,
1991) which was first identified in a myeloid leukaemic cell line induced to 
differentiate by interleukin 6 (Lord et ai, 1990). The conserved domain is also present 
in the hamster GADD34 gene induced by growth arrest signals and DNA damaging 
agents (Fomace et al., 1989). A gene with similar homology, LMW23-NL has been 
identified in African Swine Fever virus. In the conserved domain at the carboxy 
terminus, LMN23-NL and MyD116, show 78% overall conservation, whereas 
LMW223-NL and ICP34.5 have 55% overall conservation (Sussman et al., 1992). The 
conservation of one region within different proteins from diverse sources (Fig. 4.1) 
suggested that it may represent an important functional domain. On this basis it was 
expected that disruption of the conserved region at the C-terminus might reduce or 
abolish the virulence of HG52.
On intracerebral inoculation of 3-week old Balb/c mice, 2620 was as avirulent as 2604 
and the null mutant 2621, with a LD50 of 2.37x10^ p.f.u/mouse (Table 3.2). This result 
indicated that the conserved region and/or the C-terminal domain are essential for 
ICP34.5 function. It is possible that the 46 amino acids remaining between the inserted 
stop codon and the 3' end of RLl are important in the secondary structure and stability 
of ICP34.5 and therefore the truncated version of the protein might be degraded directly 
after its expression. As there is no available antibody which detects HG52 ICP34.5, it 
has not been possible to analyse this possibility.
Based on this data, the construction of mutant viruses with stop codons in RLl 
upstream of the RsrU site (Fig. 3.3) was not pursued. It was decided to rescue the 2620 
mutant and also to construct a mutant with a stop codon at the terminus of the 
conserved region to precisely confirm its role in virulence of HG52. If only the 
conserved region in exonll plays a role in HG52 virulence, it would be expected that
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the mutant would be as virulent as the wild-type. Single-stranded site-directed 
mutagenesis was used to try to insert at the end of the conserved region the Xbal site 
TCTAGA containing the stop codon TAG. Under various reaction conditions, this was 
unsuccessful although site-directed mutagenesis had been successful in other regions of 
RLl in the presence of G+C rich mutagenic oligonucleotides (Table 3.1). This could be 
attributed to variations in the G+C content of the regions under mutation.
Interpretation of the degree of attenuation of the mutant 2620 has been complicated by 
failure to rescue revenants with a wild-type phenotype (Tables 3.2; 3.4). The LD50 
value of 2620 is 200 fold higher than that of R2620 isolated by in vitro marker rescue 
(Table 3.2) indicating at least a 200 fold attenuation in virulence of 2620. The mutant 
has been reisolated (N2620) and partially purified.
Recently, Chou and Roizman (1994) mapped the sequence which precludes the total 
shutoff of protein synthesis in SK-N-SH cells to the carboxyl terminus of RLl of HSV- 
1(F). Protein synthesis was shutoff in cells infected with a mutant containing a stop 
codon at the DraUl site within the conserved region, 11 codons downstream of the last 
PAT repeat. A similar result was obtained when cells were infected with the mutant 
R3616 from which 1Kb of the coding sequence of RLl had been deleted. Protein 
synthesis at levels comparable to those observed in the wild-type infected cells took 
place in cells infected with all other deletion or insertion mutations in the amino- 
terminus upstream of the PAT domain
It was predicted from the sequence analysis that the ORF of RLl is interrupted by an 
intron flanked by splicing sites and composed of a reiterated sequence with stop codons 
blocking all 3 forward reading frames (McGeoch et al., 1991). The presence of an 
intron in RLl is unusual as the majority of HSV genes are unspliced (McGeoch et al., 
1988a) and those which are spliced are conserved between HSV-1 and HSV-2. Five 
spliced genes have been identified in HSV, these are the immediate early gene RL2 
(McGeoch et al., 1988a), USl and US12 (Watson et al., 1981; Murchie and McGeoch, 
1982; Rixon and Clements, 1982) in addition to the latency transcript LAT (Farell et 
al., 1991; McGeoch et al., 1991) and UL15 (Costa et al., 1985; Dolan et a l, 1991).
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Some of the HSV spliced genes possess homologues in other herpesviruses. Both the 
organization and the amino acid sequence of the HSV-1 UL15 gene are highly 
conserved in varicella-zoster virus (Davison and Scott, 1986), human cytomegalovirus 
(Chee et al., 1990), human herpesvirus 6 (Lawrence et al, 1990), Epstein-Barr virus 
(Baer e ta l, 1984; Costa eta l, 1985) and channel catfish virus (Davison, 1992).
A novel promoter upstream and in the opposite orientation to the RL2(aO) promoter 
within the LAT region of the HSV-1 genome was identified by Bohenzky etal (1993). 
Two transcripts of 0.9Kb and 4Kb, antisense to RLl have been detected by Nothem 
blotting. The 5' ends of these transcripts have not been mapped, but they are present in 
cells infected with HSV-1 mutants lacking the LAT promoter and are therefore not 
processed forms of LAT. Moreover, a family of five L/S junction-spanning transcripts 
(L/STs), antisense to RLl, ranging in size from 2.3 to > 9.5Kb has been reported by 
Yeh and Schaffer (1993). L/STs are 5' coterminal transcripts expressed in abundance in 
cells of neural and non-neural origin infected only with Vmwl75 null mutant virus. 
Their expression is regulated by the bidirectional RL2 (aO) promoter described by 
Bohenzky et al (1993). Recently, Lagunoff and Roizman (1994) reported the presence 
of two ORFs, O and P with 173 and 248 codons respectively, antisense to RLl of HSV- 
1 strain F. ORF P is quasi-totally antisense to RLl with only 8 codons not antisense and 
23 codons of RLl not antisense to ORF P. The sequence of ORF P is well conserved 
among HSV-1 strains F, 17+, CVG and MGHIO. The number of the triplet Ala-Gly-Val 
(AGV) repeats, corresponding to the Ala-Thr-Pro repeats of RLl, is variable among 
strains. ORF P is expressed and encodes a protein with a Mr of 30,000 which is in 
agreement with its predicted Mr of 28,000. An equivalent to ORF P has not been 
identified yet in HSV-2(HG52). No protein product corresponding to ORF O has yet 
been identified. In a subsequent study, Bohenzky et al (1995) reported that the novel 
antisense promoter can be divided into two a  X (an IE) and p X (an early) promoters, 
ORF P is driven by aX  promoter while the ORF O is driven by pX promoter. 
Alignment of the ORF P sequence in HSV-1(F) to that of HG52 RLl shows little or no 
homology except in the first amino acids of ORF P which correspond to the RLl
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conserved region (Lagunoff and Roizman, 1994). Downstream sequences beginning 
with the repeat triplet AGV in HSV-1 showed little or no homology to the published 
HG52 sequence (McGeoch et a i, 1991). It was suggested that the homology of the P 
protein could be improved by assuming a HG52 RLl sequencing error resulting in 
frame shifts. It was important therefore to provide evidence that RLl is spliced and if 
spliced, to determine whether the intron is functional. The strategy employed to achieve 
this objective was: (i) amplification of a reverse-transcribed cDNA product of RLl 
mRNA using primers flanking the predicted intron [section 3.17]. (ii) deletion of the 
predicted intron at the proposed splicing sites to study its role in virulence [section 
3.4.3]. (iii) it was also intended to insert a stop codon in the intron and to this end a stop 
codon was inserted at the Drdi site within the proposed intron in the pSB phagemid 
(Fig. 3.3).
To amplify the cDNA product for RLl mRNA, PCR was carried out on either the total 
or cytoplasmic poly (A)+RNA with three pairs of primers flanking the predicted intron 
(Table 3.7, Fig. 3.27). This approach was unsuccessful possibly due to poor quality of 
RNA obtained from infected cells or to unsuccessful cDNA synthesis.
Construction of the 2622 mutant using the intronless pSB phagemid made it 
unnecessary to construct a mutant with a stop codon at the Drdi site. Intracerebral 
inoculation of 2622 resulted in intermediate virulence for mice with a LD50  of 1 0  ^
p.f.u./mouse compared to <10% p.f.u./mouse for HG52 and 3.16x10^ p.f.u./mouse for 
2604 (Table 3.2). Restoring wild-type virulence by in vivo marker rescue (R2622/C) 
(Table 3.5) confirmed the 2622 phenotype. It was concluded that either: (i) The 
predicted intron in HG52 is functional and required for full expression of RLl. (ii) The 
proposed splicing sites of the intron are not correct, (iii) The deleted DNA sequence 
was not an intron but a functional domain of RLl. (iv) There was a secondary mutation 
in RLl.
While this thesis was being written. Dr. A. MacLean (personal communication) re­
sequenced the predicted intron and the flanking region of RLl and ruled out an error in 
the published sequence (McGeoch et a l, 1991). Subsequently, cDNA-PCR was
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employed by Dr. J. Harland (personal communication) and the size of the PCR product 
demonstrated that RLl is spliced and sequence analysis confirmed that the proposed 
splicing sites are correct. Reanalysis of 2622 subsequently revealed a deletion within 
RLl which did not encompass the intron (Dr. J. Harland, personal communication). The 
intron was precisely deleted in the plasmid and hence reisolation of an intronless 
mutant is now underway. The role of the RLl intron in vivo and in vitro in 3T6 cells 
will require to be reassessed.
To confirm the phenotype of the mutants 2620, 2621 and 2622, wild-type rescuants 
were constructed in vitro and in vivo. Rescuants were generated in vitro by transfection 
of BHK/C13 cells with intact mutant DNA and the linearised pXB phagemid. The same 
transfection mix was used for the in vivo marker rescue experiments. In addition two 
other transfection mixes containing the BamHlg fragment derived either from the pAT- 
BamHlg plasmid or from HG52 DNA were used (Table 3.3). Signs of encephalitis were 
an indication of growth and spread of wild-type rescuants in mouse brains which were 
then removed and rescuants isolated and purified. The virulence of rescuants generated 
in vitro and in vivo was compared to HG52 following intracerebral inoculation of 
Balb/c mice. The rescuants were injected at doses of 10^-10^ p.f.u./mouse, as it was 
anticipated that the rescuants would be as virulent as HG52 or 10-2(X) fold less virulent. 
Virulence differences between rescuants and wild-type virus have been shown 
previously e.g. the LD50 values of ts 1207 rescuants were 60-200 fold higher than that 
of the parental wild-type virus (Cameron et a i, 1988) and those of the intertypic 
recombinant RE6 were 50 fold less virulent than the wild type parents (Thompson et 
al, 1983b).
Apart from R2620, rescuants generated by in vivo marker rescue regained wild-type 
virulence (Table 3.4). It was concluded that the virulence phenotype of the mutants 
2621 and 2622 was due to the specific RLl mutations. The R2622 rescuants regained 
virulence with LD50 values ranging from 3.16x10^-10^ p.f.u./mouse. These LD50 
values are within the range of the individual plaque stocks of HG52 pi. 17 (Table 3.5). 
Rescuants generated by in vitro marker rescue failed to return to the wild-type HG52
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phenotype and demonstrated an intermediate level of virulence (Table 3.2). The 
possibility that a mutation in the pXB Xhol fragment might be responsible for the 
intermediate phenotype was ruled out as this fragment restored virulence to the 
rescuants of 2621 and 2622 (R2622/C) generated by in vivo marker rescue (Table 3.4).
A secondary mutation in the genome of the rescuants generated in vitro is the most 
likely explanation. Virulence is multigenically controlled both in HSV [section 1.7] and 
other viruses e.g. pseudorabies virus (Lomniczi etal., 1984), myxoviruses (Rott, 1979) 
and bunyaviruses (Rozhon et al., 1981). A secondary mutation could be attributed to 
inherent heterogeneity in the parental stock and/or passage of the viruses during three 
rounds of purification. Heterogeneity in this context means that viruses arising from 
individual genomes have different virulence potentials. Taha et al (1989a) transfected 
BHK21/C13 cells with a DNA stock of HG52 pi. 17 and isolated 5 well separated 
progeny plaques. The virus stocks from the 5 plaques were intracerebrally inoculated 
into mice and their LD50 values ranged from 10^ to > lO'  ^p.f.u./mouse. It was found 
that individual plaques derived from high virulence stocks demonstrated either a high or 
intermediate level of virulence. Individual plaques derived from intermediate and low 
virulence stocks remained stable as low or intermediate virulence. The basis of this 
virulence variation is not clear, although Stroop et al (1994) attributed the avirulent 
phenotype of one of these individual plaques to deficiency in TK, a gene involved in 
HSV virulence [section 1.7.2.1].
In this study, six individual plaques of pi. 17 were picked randomly and subjected to 
three rounds of purification which included seven passages in BHK21/C13 cells at 
37°C. The individual plaques demonstrated a range of LD5 0  values and were 
categorised as: virulent with a LD50 <1 0^ p.f.u./mouse, intermediate with a LD50 = 10^ 
p.f.u./mouse and avirulent with a LD50 >10^ p.f.u./mouse (Table 3.5). Serial passage 
could have an effect on the stability of the virulence phenotype of these individual 
plaques. It could be concluded that the highly virulent individual plaques No. 2, 5, 6  
with LD50S ^lO^p.f.u/mouse originated from a pi. 17 genome with a high virulence 
capacity. The avirulent phenotype of plaques No. 3 and 4 (LD50S > lO'^p.f.u/mouse)
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may be due to a secondary mutation in other virulence genes arising during passage The 
same applies to the intermediate virulence plaque No. 1 with a LD5 0  of 
lO'^p.f.u./mouse. Assigning phenotype to a specific mutation in RLl requires rescuants 
which return to full virulence.
It is noteworthy that heterogeneity and virulence attenuation by passage is not restricted 
to HG52. Recently it has been observed in HSV-1 strain 17+ (Dr. A. MacLean, 
personal communication). Moreover, it is known that both virulent and avirulent stocks 
of HSV-1 strain KGS exist (Dix et al, 1983). The effect of passage in tissue culture on 
HSV virulence is similar to findings reported for poliovirus. The three attenuated 
strains of poliovirus which are used as oral vaccines were derived from wild-type 
virulent strains by extensive passage in monkey tissue (Sabin, 1955). Point mutations 
were observed scattered over the entire length of the genome of the attenuated strains, 
but those in the 5' non-coding region of the genomic RNA contributed to the attenuation 
of the parental strain (Skinner etal., 1989; Kawamura eta l, 1989 )
In contrast, Thompson and Stevens (1983a) reported that the capacity of HG52 isolates 
to replicate in mouse brain is increased following serial passage at 37.5°C. The 
Glasgow elite stock of HG52 showed a LD5 0  of 10^ p.f.uVmouse following 7 serial 
passages in rabbit skin monolayers at 31°C. Passage at 37.5°C resulted in at least a 
10,000 fold increase in virulence. Five isolates of the elite stock of HG52 were purified 
twice at 31°C and the progeny serially passaged 4-5 times at 31°C or 37.5°C. 
Following intracranial inoculation of 4-6 week-old Swiss Webster mice, it was found 
that all five isolates passaged at 31°C retained the avirulent phenotype, while those 
passaged at 37.5°C became virulent. Possibly passage at 37.5°C resembles conditions 
required for in vivo growth. Goodman and Stevens (1986) demonstrated that passage of 
HSV-1 strain 17+ in vitro in chick embryo fibroblasts selected for a virus capable of 
killing chick embryos indicating that in vitro passage of HSV potentiated rather than 
attenuated virulence. The increase in virulence might be due to adaptation to species. 
Multiple brain passage has been shown to increase the virulence of the avirulent HSV- 
l/HSV-2 recombinant R13-1 and the avirulent HSV-1 strain ANG. Javier et al (1988a)
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reported that virulence of R13-1 increased 25-60 fold after two passages through mouse 
brains. This finding was unexpected as the avirulent phenotype of the recombinants 
RE6  (Thompson et al., 1983b) and RS6  (Javier et al., 1987) was extremely stable 
following seven and eight passages, respectively in mouse brains. Kaemer et al (1983) 
reported that HSV-1 ANG is avirulent for DBA/2J mice upon intraperitoneal or 
intravaginal inoculation but virulent upon intracerebral inoculation. The virulent variant 
HSV-1 ANG path was generated following 12-15 serial passages of HSV-1 ANG in 
mouse brain . In mixed infections both the avirulent and the virulent viruses replicate at 
the primary site of infection and spread to various organs, but only HSV-1 ANG path 
could be recovered from the spinal cords and brains of mice. The restriction 
endonuclease pattern of the virulent Ang isolates differed from those of the avirulent 
strain. It was not clear whether these changes were related to the virulence phenotype 
observed.
In this study the rescuants generated in vitro (Table 3.2) and the rescuants R2620, 
R2622/B generated in vivo (Table 3.4) did not return to the wild-type phenotype. This 
may have been due to a point mutation in the RLl gene of these rescuants. A possibility 
which could also apply to the low and the intermediate virulence plaques of HG52 pi. 17 
(Table 3.5). As there is no available antibody which detects HG52 ICP34.5 we were 
unable to look at expression of the protein in these variants. However, the 3T6 mouse 
embryo fibroblast selection system described by Brown et al (1994a) is a good in vitro 
model for distinguishing RLl mutant virus from wild-type. Confluent 3T6 cells are 
permissive for wild-type HSV-1 strain 17+ and non-permissive for the RLl-negative 
mutants 1716 and 1771 (Brown et al., 1994a). The same was observed for HSV-2 
HG52 and the RLl negative mutant viruses 2604 (Brown et a i, 1994a). It has been 
shown for HSV-1 that the inability of 1716 to grow in 3T6 cells is not due to an 
inability to adsorb to and penetrate cells but due to an inability to spread from the 
initially infected cells (Brown et al., 1994b). Analysis by electron microscopy showed 
that 90% of virus particles are confined to the nuclei of 1716 infected cells. It is clear 
therefore that in certain cell types and under certain cell states failure to express
100
Discussion
ICP34.5 results in a defect in virus maturation and egress from infected cells (Brown et 
a l, 1994b).
In 3T6 cells, 2620 and 2621 behaved as 2604 (Fig. 3.18). It would be expected 
therefore that a defect in RLl of the individual plaques of HG52 pi. 17 or the rescuants 
would result in impaired growth in 3T6 cells. Multicycle growth experiments for the 
individual plaques of HG52 and the rescuants were carried out in 3T6 cells (Figs. 3.23, 
3.24, 3.25, 3.26) over a period of 72h. The growth patterns of the selected individual 
plaques of HG52 pi. 17 regardless of their LD50 values (Table 3.5) were identical to that 
of HG52. Similarly, the growth kinetics of the rescuants generated in vitro were 
identical to those of HG52 pi. 17 and the rescuants generated in vivo. This strongly 
suggests that RLl of the individual plaques and the rescuants generated in vitro is intact 
and expressed. As HSV virulence is multigenetically controlled [section 1.7], point 
mutations in any gene involved in HSV virulence might contribute to the intermediate 
phenotype of these variants.
The in vivo characterisation of the RLl mutants involved studying their replication 
capacity in mouse brain. It was found that the parental virus HG52 pi. 17 replicated to 
high titre within 120h (Fig. 3.13). The avirulent mutants 2620 and 2621 replicated 
poorly with kinetics similar to that of 2604. Virus multiplication was blocked and there 
was no detectable virus by 96h post-inoculation. It was concluded that the avirulent 
phenotypes of 2620 and 2621 (Table 3.2) was due to their inability to replicate in 
mouse brain. The expression of viral antigens in brains inoculated with 2620 and 2621 
was not tested as a previous study by Taha et al (1990) showed that following infection 
with 2604, HSV antigens were located only at the site of inoculation, while following 
infection with HG52, HSV antigens were widely distributed in neurons and supporting 
brain cells. It would be expected that 2620 and 2621 would demonstrate a similar result 
in immunohistochemical analysis. Growth of the mutant 2622 was intermediate with 
respect to 2604 and HG52 and the virus was cleared from the brain by 120h post­
inoculation (Fig. 3.13). The growth kinetics of 2622 are consistent with its LD5 0  value 
(Table 3.2).
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All RLl mutants exhibited no temperature sensitivity (Fig. 3.22) greater than that of 
HG52. Similar results were demonstrated by Taha et al (1989a) for HG52 and 2604 at 
38.5°C in single cycle growth experiments using mouse embryo fibroblast 3T3 cells. 
Differential replication of HG52 and the RLl mutants was not observed in BHK21/C13 
cells at either low or high multiplicities of infection (Fig. 3.16, 3.17). A consistent 
finding in our laboratory is that all RLl variants of HSV-1 strain 17'*' (MacLean, A et 
at., 1991) and HSV-2 strain HG52 (Taha et aL, 1989a; Harland and Brown, 1991) are 
not impaired in BHK21/C13 cells. Electron microscopical analysis of BHK21/C13 cells 
infected separately with HSV-1 (17'*') and the avirulent deletion mutant 1716 revealed 
that virus particles were equally distributed between the nucleus and the cytoplasm of 
infected cells. However, delamination of the nuclear membrane and a significant 
number of particles trapped between the nuclear lamellae were observed in 50% of 
BHK21/C13 cells infected with 1716. It appears that lack of ICP34.5 expression may 
result in blockage of one of the two pathways proposed by Rixon (1993) for egress of 
HSV from the nuclei to the extracellular space (Fig. 1.3). Trapping of virus between the 
nuclear lamellae might be due to overloading of one pathway which compensates for 
the other being blocked (Brown et a i, 1994b).
Differential growth was observed at low m.o.i. (0.01 p.f.u./cell) in confluent 3T6 mouse 
embryo fibroblasts (Fig. 3.18) in which the mutants 2604, 2620 and 2621 mimicked the 
in vivo phenotype (Table 3.2 ; Fig. 3.13) by failing to replicate and producing abortive 
plaques; wild-type HG52 is not impaired and produces large plaques. The mutant 2622 
showed intermediate growth and produced intermediate sized plaques.
In 3T6 cells, 2621 produces plaques of two morphologies, small and large. The 
existence of large plaques in the 2621 stock was reflected in its growth pattern relative 
to 2604 (Fig. 3.18). This phenotypic property of 2621 was confirmed by reisolation of a 
new mutant virus N2621 which also predominantly produced small plaques plus a few 
large plaques. The small and large plaques could not be completely segregated 
following three rounds of purification and their Xbal genomic profiles were identical 
(Fig. 3.19). At present, there is no explanation for this property of 2621 especially as it
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has not been observed for the RLl mutants of HSV-1 strain 17"*" and other HG52 
mutants. The large plaques imply expression of ICP34.5 indicating that a second site 
reversion might have occurred which could not be detected by genomic digestion with 
Xbal (Fig. 3.19). Because there is no available antibody which detects HG52 ICP34.5 
we were not able to test this hypothesis. When the replication efficiency of the small 
and large plaques of 2621 was tested in BHK/C13 cells, no differential growth was 
observed (Fig 3.21). Differential growth was observed in 3T6 cells where large plaque 
growth was comparable to HG52 and growth of the small plaques was greater than the 
parental 2621 (Fig. 3.20). Possibly this is due to adaptation of the small plaques to grow 
in 3T6 cells as a result of passage in these cells. In vivo, the small plaque virus of 2621 
was avirulent and had a LD5 0  of 10^. The large plaque virus demonstrated an 
intermediate level of virulence with respect to HG52 (Table 3.6) with a LD50  of 
2.15x10^, at least 100 fold more virulent than the parental 2621. This intermediate 
phenotype might be due to virulence attenuation as a result of passage in 3T6 cells as 
demonstrated before for the parental stock HG52 PI. 17.
The results presented in this thesis demonstrate the existence of an ORF encoding the 
HSV-2(HG52) RLl as predicted by McGeoch et al (1991). Like HSV-1, RLl 
determines HG52 virulence, hence insertion of a stop codon in the predicted ORF, 9bp 
downstream of the initiation codon was shown to abolish the virulence of HG52. It has 
now been shown that the mature mRNA of RLl is spliced. Introduction of a stop codon 
at the R srll site within the conserved region of RLl yielded a virus whose 
characterisation was complicated possibly due to a secondary mutation in the genome 
of the isolated mutant. The LD50 value of this mutant was 200 fold less than that of the 
revertant isolated by in vitro marker rescue. Virulence heterogeneity in HG52 pi. 17 was 
demonstrated in this study with LD50 values ranging from ^ 1 0 ^ to ^ 10 "^  p.f.u./mouse. 
This fact emphasises the necessity of obtaining rescuants with a totally virulent 
phenotype to confirm that the phenotype of mutants is due to a specific mutation. 
Unfortunately the mutant 2622 which was thought to be intronless turned out to have a
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deletion in another part of RLl partly within exon I with the intron remaining intact. 
Not only was this spontaneous deletion approximately the same size as the intron but it 
was in the same fragment chosen for analysis. At the time there was no reason to 
suppose that the deleted sequence was other than the intron. When it became obvious 
from the PCR analysis that 2622 still contained the RLl intron, a range of double 
restriction enzyme digests were carried out. The genotype of 2622 has now been 
resolved and the intronless plasmid which has been sequenced and shown to be correct 
will be used to generate a new mutant. The mutant 2622 has however demonstrated that 
sequences upstream of the intron interfere with RLl function but do not completely 
abolish virulence.
Future prospects:
1. Purification and characterization of the new mutant of 2620 (N2620) with a stop 
codon at the site within the conserved region of RLl to confirm the role of this 
region in HG52 virulence.
2. Insertion of an in-frame stop codon at the end of the conserved region to determine 
the precise role of this region in HG52 virulence.
3. Identification of the HSV-2 RLl encoded protein (ICP34.5). For this purpose, an 
antiserum directed against the HG52 ICP34.5 expressed protein or possibly against the 
HSV-1(17"*") expressed protein could be used. It has been shown previously, that 
anisera raised against synthetic oligonucleotides representing different regions of HSV- 
1(17"*") RLl including the conserved region were in general unsuccessful in identifying 
ICP34.5 in HSV-1 (17+) infected cells and HSV-2 (HG52) infected cells (McKay et aL,
1993). The only successful peptide used to generate an antiserum was the (PAT) 10 
repeat which is not conserved in HG52. A polyclonal antiserum raised against the 
partially purified ICP34.5 of HSV-1 (17+) expressed in the E. coli pET system failed to 
detect HSV-2(HG52) ICP34.5 by either immunoprécipitation or Western blotting. This 
could be due to a low level of ICP34.5 expression and/or low titre of antisera due to low 
purity of ICP34.5 used to generate the polyclonal antibody. A higher level and higher
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purity of ICP34.5 may be required to get a more sensitive antiserum (McKie et a l,
1994). The baculovirus and the glutathione S-transferase-fusion (GST) expression 
systems are currently being used to express the HSV-1(17+) RLl gene.
4. Reisolation of a mutant in which the RLl intron has been deleted and 
characterisation of the mutant in vivo and in vitro.
105
REFERENCES
REFERENCES
ACKERMANN, M., CHOU. J, SARMIENTO, M, LERNER,R.A. and ROIZMAN B. 
(1986). Identification by antibody to a synthetic peptide of a protein specified by a diploid 
gene located in the terminal repeats of the L component of herpes simplex virus genome. 
Journal o f Virology 58, 843-850.
ADDISON, C., RIXON, F.J., PALFREYMAN, J.W., O’HARA, M. AND PRESTON, 
V.G. (1984). Characterisation of a herpes simplex virus type 1 mutant which has a 
temperature-sensitive defect in penetration of cells and assembly of capsids. Virology 138, 
246-259.
ADDISON, C., RIXON, F.J. AND PRESTON, V.G. (1990). Herpes simplex virus type 1 
UL28 gene product is important for the formation of mature capsids. Journal of General 
Virology 71, 2377-2384.
AL-KOBAISI, M.F., RIXON, F.J., McDOUGALL, I. AND PRESTON, V.G. (1991). The 
herpes simplex virus UL33 gene product is required for the assembly of full capsids. 
Virology 180, 380-388.
APRHYS, C.M., CIUFO, D.M., O’NEILL, E.A., KELLY, T.J. AND HAYWARD, G.S.
(1989). Overlapping octamer and TAATGARATmotifs in the VP65-response elements in 
herpes simplex virus immediate-early promoters represent independent binding sites for 
cellular nuclear factor HI. Journal of Virology 63,2798-2812.
ASHER, Y., HELLER, M. AND BECKER, Y. (1969). Incorporation of lipids into herpes 
simplex virus particles. Journal of General Virology 4, 65-76.
ATKINSON, M.A., BARR, S. AND TIMBURY, M.C. (1978). The fine structure of cells 
infected with temperature sensitive mutants of herpes simplex virus type 2. Journal of 
General Virology 40, 103-119.
BACCHETTI, S., EVELEGH, M.J. AND MUIRHEAD, B. (1986). Identification and 
separation of the two subunits of herpes simplex virus ribonucleotide reductase. Journal of 
Virology 57, 1177-1181.
BAER, R., BANKIER, AT., BIGGIN, M.D., DEININGER, P.L., FARRELL, P.J., 
GIBSON, T.J., HATFULL, G., HUDSON, G.S., SATCHWELL., S.C., SEGUIN, C., 
TUFFNELL, P S. AND BARRELL, B.G. (1984). DNA sequence and expression of the 
B95-8 Epstein-Barr genome. Nature 310, 207-211.
References
BAINES, J.D. AND ROIZMAN, B. (1991). The open reading frames UL3, UL4, ULIO, 
and UL16 are dispensible for the replication of herpes simplex virus 1 in cell culture. 
Journal o f Virology 65,938-944.
BAINES, J.D. AND ROIZMAN, B. (1992). The U L ll gene of herpes simplex virus 1 
encodes a function that facilitates nucleocapsid envelopment and egress from cells. 
Journal of Virology 6 6 , 5168-5174.
BAINES, J.D. AND ROIZMAN, B. (1993). The ULIO gene of herpes simplex virus 
encodes a novel viral glycoprotein, gM, which is present in the virion and in the plasma 
membrane of infected cells. Journal of Virology 67, 1441-1452.
BAINES, J.D., WARD, P.L., CAMPADELLI-FLUME AND ROIZMAN, B. (1991). The 
UL20 gene of herpes simplex virus 1 encodes a function necessary for viral egress. 
Journal of Virology 65, 6414-6424.
BAINES, J.D., POON, A.P.W., ROVNAK, J. AND ROIZMAN, B. (1994). The herpes 
simplex virus 1 UL15 gene encodes two proteins and is required for cleavage of genomic 
viral DNA. Journal o f Virology 6 8 , 8118-8124.
BAINES, J.D., JACOB R.J., SIMMERMAN, L. AND ROIZMAN, B. (1995). The herpes 
simplex virus 1 U Lll proteins are associated with cytoplasmic and nuclear membranes 
and with nuclear bodies of infected cells. Journal of Virology 69, 825-833.
BALAN, P., DAVIS-POYNTER, N., BELL, S., ATKINSON, H., BROWNE, H. AND 
MINSON, T. (1994). An analysis of the in vitro and in vivo phenotypes of mutants of 
herpes simplex virus type 1 lacking glycoproteins gG, gE, gl or the putative gJ. Journal of 
General Virology 15, 1245-1258.
BARADARAN, K., DABROWSKI, C.E. AND SCHAFFER, P.A. (1994). Transcriptional 
analysis of the region of the herpes simplex virus type 1 genome containing the UL8 , UL9 
and ULIO genes and identification of a novel delayed-early gene product, OB PC. Journal 
of Virology 6 8 , 4251-4261.
BARINGER, J R. (1974). Recovery of herpes simplex virus from human trigeminal 
ganglia. New England Journal of Medicine 291, 828-830.
BARINGER, J R. AND SWOVELAND. (1973). Recovery of herpes simplex virus from 
human trigeminal ganglia. New England Journal of Medicine 288, 648-650.
References
BARKER, D. AND ROIZMAN, B. (1990). Identification of 3 genes nonessential for 
growth in cell culture near the right terminus of the unique sequences of long component 
of herpes simplex virus 1. Virology 177, 684-691.
BARKER, D. AND ROIZMAN, B. (1992). The unique sequence of the herpes simplex 
virus 1 L component contains an additional translated open reading frame designated 
UL49.5. Journal of Virology 6 6 , 562-566.
BARNETT, B.C., DOLAN, A., TELFORD, E.A.R., DAVISON, A.J. AND, McGEOCH, 
D.J. (1992). A novel herpes simplex virus gene (UL49A) encodes a putative membrane 
protein with counterparts in other herpesviruses. Journal o f General Virology 73, 2167- 
2171.
BASTIAN, F.O., RABSON, A S., LEE, C.L. AND TRALKA. T.S. (1972). Herpesvirus 
hominis: isolation from the human trigeminal ganglion. Science 178, 306-307.
BATCHELOR, AH. AND O’HARE, P. (1990). Regulation and cell-type-specific activity 
of a promoter located upstream of the latency-associated transcript of herpes simplex virus 
type 1. Journal of Virology 64, 3269-3279.
BATTERSON, W. AND ROIZMAN, B. (1983). Characterisation of the herpes simplex 
virion-associated factor responsible for the induction of a  genes. Journal of Virology 46, 
371-377.
BATTERSON, W., FURLONG, D. AND ROIZMAN, B. (1983). Molecular genetics of 
herpes simplex virus. VIII. Further characterisation of a temperature-sensitive mutant 
defective in release of viral DNA and in other stages of the viral reproductive cycle. 
Journal of Virology 45, 397-407.
BECKER, Y., DYM, H. AND SAROV, I. (1968). Herpes simplex virus DNA. Virology 
36, 184-192.
BECKER, Y., HADAR, J., TABOR, E., BEN-HUR, T., RAIBSTEIN, I., ROSEN, A. 
AND DARAI, G. (1986). A sequence in Hpal-P fragment of herpes simplex virus 1 DNA 
determines intraperitoneal virulence in mice. Virology 149, 255-259.
BEN-HUR, T., HADAR, J., SHTRAM, Y., GILDEN, D.H. AND BECKER, Y. (1983). 
Neurovirulence of herpes simplex virus type 1 depends on age in mice and thymidine 
kinase expression. Archives of Virology 78, 303-308.
References
BEN-HUR, T., ASHER,Y., TABOR, E., DARAI, G. AND BECKER, Y. (1987). HSV-1 
virulence for mice by the intracerebral route is encoded by the BamHl-L DNA fragment 
containing the cell fusion gene. Archives o f Virology 96, 117-122.
BEN-PORAT, T. AND TOKAZEWSKI, A. (1977). Replication of herpesvirus DNA. II. 
Sedimentation characteriatics of newly synthesized DNA. Virology 79, 292-301.
BINDER, P S. (1977). Herpes simplex keratitis. Survey of Ophthamology 21, 313-330.
BIRNBOIM, H.C. AND DOLY, J. (1978). A rapid alkaline extraction procedure for 
screening recombinant plasmid DNA. Nucleic Acids Research 7, 1513-1523.
BLOCK, T.M., SPIVACK, J.G., STEINER, I., DESHMANE, S., McINTOSH, M.T., 
LIRETTE, M.R.P. AND FRASER, N.W. (1990). A herpes simplex virus type 1 latency- 
associated transcript mutant reactivates with normal kinetics from latent infection. Journal 
of Virology 64, 3417-3426.
BLOOM, D C. AND STEVENS, J.C. (1994). Neuron-specific restriction of a herpes 
simplex virus recombinant maps to the UL5 gene. Journal of Virology 6 8 , 3761-3772.
BOHENZKY, R.A., PAPAVASSILION, A.G., GELMAN, I.H. AND SILVERSTEIN, S. 
(1993). Identification of a promoter mapping within the reiterated sequences that flank the 
herpes simplex virus type 1 U l region. Journal of Virology 67, 632-642.
BOHENZKY, R.A., LAGUNOFF, M., ROIZMAN, B., WAGNER, E.K. AND 
SILVERSTEIN, S. (1995). Two overlapping transcription units which extend across the L- 
S junction of herpes simplex virus type 1. Journal of Virology 69, 2889-2897.
BOLOVAN, C.A., SAWTELL, N.M. AND THOMPSON, R.L. (1994). ICP34.5 mutants 
of herpes simplex virus type 1 strain 17syn+ are attenuated for virulence in mice and for 
replication in confluent primary mouse embryo cell cultures. Journal o f Virology 6 8 , 48- 
55.
BRANDT, C.R., KINTER, R.L., PUMFREY, A M., VISALLI, R.J. AND GRAU, D R. 
(1991). The herpes simplex virus ribonucleotide reductase is required for ocular virulence. 
Journal of General Virology 72, 2043-2049.
BRAUN, D.K., ROIZMAN, B. AND PEREIRA, L. (1984a). Characterisation of 
posttranscriptional products of herpes simplex virus gene 35 proteins binding to the 
surface of full but not empty capsids. Journal o f Virology 49, 142-153.
References
BRAUN, D.K., BATTERSON, W. AND ROIZMAN, B. (1984b). Identification and 
genetic mapping of a herpes simplex virus capsid potein which binds DNA. Journal o f 
Virology 50, 645-648.
BROWN, S.M. AND HARLAND, J. (1987). Three mutants of herpes simplex virus type 
2: one lacking the genes US 10, 11 and 12 and two in which Rg has been extended by 6 kb 
to 0.91 map units with a loss of Ug sequences between 0.94 and the Us/TRs junction. 
Journal o f General Virology 68, 1-18.
BROWN, S.M., RITCHIE, D.A. AND SUBAK-SHARPE, J.H. (1973). Genetic studies 
with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their 
arrangement into complementation groups and recombination analysis leading to a linkage 
map. Journal of General Virology 18, 329-346.
BROWN, S.M., HARLAND, J. AND SUBAK-SHARPE, J.H. (1984). Isolation of 
restriction endonuclease site deletion mutants of herpes simplex virus. Journal o f General 
Virology 65, 1053-1068.
BROWN, S.M., MACLEAN, A.R., HARLAND, J., PODIECH, J. AND CLEMENTS, J.B. 
(1994a). Cell type and cell state determine differential in vitro growth of non-virulent 
ICP34.5 negative herpes simplex virus. Journal of General Virology 75, 2367-2377.
BROWN, S.M., MACLEAN, A.R., AITKEN, J.D. AND HARLAND, J. (1994b). ICP34.5 
influences herpes simplex virus type 1 maturation and egress from infected cells in vitro. 
Journal of General Virology 75, 3679-3686.
BUCHMAN, T.G., SIMPSON, T., NOSAL, C., ROIZMAN, B. AND NAHMIAS, A.J. 
(1981). The structure of herpes simplex virus DNA and its application to molecular 
epidemiology. Annals New York of the Academy of Sciences 345, 279-290.
BUCKMASTER, E.A., COMPELS, U. AND MINSON, A. (1984). Characterization and 
physical mapping of an HSV-1 glycoprotein of approximately 115 x 10^ molecular 
weight. Virology 139, 408-413.
BUSBY, D.W.G., HOUSE, W. and MACDONALD, JR . (1964). In “Viriological 
techniques’”. Churchill, London.
CAI, W., GU, B. AND PERSON, S. (1988). Role of glycoprotein B of herpes simplex 
virus type 1 in viral entry and cell fusion. Journal of Virology 62, 2596-2604.
References
C ALDER, J.M. AND STOW, N.D. (1990). Herpes simplex virus helic ase-primase : the 
UL8  protein is not required for DNA-dependent ATPase and DNA helicase activities. 
Nucleic Acids Research 18, 3573-3578.
CALDER, J.M., STOW, E.C. AND STOW, N.D. (1992). On the cellular localization of 
the components of the herpes simplex virus type 1 helicase-primase and the viral origin- 
binding protein. Journal o f General Virology 73, 531-538.
CAMERON, J.M., MCDOUGALL, I., MARSDEN, H.S., PRESTON, V.G., RYAN, D.M. 
AND SUBAK-SHARPE, J.H. (1988). Ribonucleotide reductase encoded by herpes 
simplex virus is a determinant of the pathogenicity of the virus in mice and a valid 
antiviral target. Journal of General Virology 69: 2607-2612.
CAMPBELL, M.E.M., PALFREYMAN, J.W. AND PRESTON, C M. (1984). 
Identification of herpes simplex virus DNA sequences which encode a rra/zj-activating 
polypeptide responsible for stimulation of immediate early transcription. Journal o f 
Molecular Biology 180, 1-19.
CAR ADONNA, S.J. AND CHEUNG, Y.C. (1981). Induction of uracil-DNA glycosylase 
and dUTP nucleotidyltransferase activity in herpes simplex virus infected human cells. 
Journal o f Biological Chemistry 256, 9834-9837.
CARTER, P. (1991). Mutagenesis facilitated by the removal or introduction of unique 
restriction sites. In: M.J. Mcpherson (Ed), Directed Mutagenesis, pp. 1-25. Oxford 
University Press, Oxford.
CASPARY, L., SCHINDLING, B., DUNDAROV, S. AND FALKE, D. (1980). Infections 
of susceptible and resistant mouse strains with herpes simplex virus type 1 and 2. Archives 
of Virology 65, 219-227.
CHALLBERG, M.D. (1986). A method for identifying the viral genes required for 
herpesvirus DNA replication. Proceedings o f the National Academy of Sciences USA. 83, 
9094-9098.
CHANG, Y.E. AND ROIZMAN, B. (1993). The product of the UL31 gene of herpes 
simplex virus 1 is a nuclear phosphoprotein which partitions with the nuclear matrix. 
Journal of Virology 67, 6348-6356.
CHEE, M.S., BANKIER, A T., Beck, S., BOHNI, D R., BROWN, C M., CERNY, R., 
HORSNELL, T., HUTCHISON III, C.A., KOUZARIDES, T., MARTINGNETTI, A.J., 
FREDDIE, E., SATCHWELL, S.C., TOMLINSON, P., WESTON, K.M. AND 
BARRELL, B.G. (1990). Analysis of the protein-coding content of the sequence of human
References
cytomegalovirus strain AD 169. In: J.K. McDougall (Ed), Current Topics in Microbiology 
and Immunology, Vol 154, pp. 125-169. Springer-Verlag, Berlin.
CHOMCZYNSKI, P. AND SACCHI, N. (1987). Single-step method of RNA isolation by 
acid guanidinium thiocyanate-phenol-chloroform extraction. Annals of Biochemistry 162, 
156-159.
CHOU, J. AND ROIZMAN, B. (1985). Isomérisation of herpes simplex virus 1 genome: 
Identification of cw-acting and recombination sites within the domain of the ‘a’ sequence. 
Cell 41, 803-811.
CHOU, J. AND ROIZMAN, B. (1986). The terminal ‘a’ sequence of the herpes simplex 
virus genome contains the promoter of a gene located in the repeat sequences of the L 
component. Journal of Virology 57, 629-637.
CHOU, J. AND ROIZMAN, B. (1989). Characterisation of DNA sequence-common and 
sequence-specific proteins binding to c/5-acting sites for cleavage of the terminal a 
sequence of the herpes simplex virus 1 genome. Journal of Virology 63,1059-1068.
CHOU, J. AND ROIZMAN, B. (1990). The herpes simplex virus 1 gene for ICP34.5 
which maps in inverted repeats , is conserved in several limited-passage isolates but not in 
strain 17 syn+. Journal of Virology 64, 1014-1020.
CHOU, J. AND ROIZMAN, B. (1992). The 7^34.5 gene of herpes simplex virus 1 
precludes neuroblastoma cells from triggering total shutoff of protein synthesis 
characteristic of programmed cell death in neuronal cells. Proceedings o f the National 
Academy o f Sciences USA. 89, 3266-3270.
CHOU, J. AND ROIZMAN, B. (1994). Herpes simplex virus 34.5 gene function, which 
blocks the host response to infection, maps in the homologous domain of the genes 
expressed during growth arrest and DNA damage. Proceedings of the National Academy of 
Sciences USA. 91, 5247-5251.
CHOU, J., KERN, E.R., WHITLEY, R.J. AND ROIZMAN, B. (1990). Mapping of herpes 
simplex virus-1 neurovirulence to yi34.5, a gene nonessential for growth in culture.
Science 250, 1262-1265.
CHUNG, C.T. AND MILLER, R.H. (1988). A rapid and convenient method for the 
preparation and storage of competent cells. Nucleic Acids Research 16, 3580.
References
CLEMENTS, G.B. AND STOW, N.D. (1989). A herpes simplex virus type 1 mutant 
containing a deletion within immediate early gene 1 is latency competent. Journal o f 
General Virology 70, 2501-2506.
CLEMENTS, J.B., CORTINI, R. AND WILKIE, N.M. (1976). Analysis of herpesvirus 
substructure by restriction endonucleases. Journal of General Virology 30, 243-256.
CLEMENTS, J.B., WATSON, R.J. AND WILKIE, N.M. (1977). Temporal regulation of 
herpes simplex 1 transcription: location of transcripts on the viral genome. Cell 12, 275- 
285.
CLEMENTS, J.B., McLAUCHLAN, J. AND McGEOCH, D.J. (1979). Orientation of 
herpes simplex virus type 1 immediate-early RNAs. Nucleic Acids Research 7, 77-91.
COEN, D M., ASCHMAN, D.P., GELEP, P.T., RETONDO, M.J., WELLER, S.K. AND 
SCHAFFER, P.A. (1984). Fine mapping and molecular cloning of mutations in the herpes 
simplex virus DNA polymerase locus. Journal of Virology 49, 236-257.
COEN, D M., KOSZ-VNENCHAK, M., JACOBSON, J.G., LEIB, D.A., BOGART, C.L., 
SCHAFFER, P.A., TYLER, K.L. AND KNIPE, D.M. (1989). Thymidine kinase-negative 
herpes simplex virus mutants establish latency in mouse trigeminal ganglia but do not 
reactivate. Procedings of the National Academy of Sciences, USA. 8 6 , 4736-4740.
COHEN, E.A., CHARRON, J., PERRET, J. AND LANGELIER, Y. (1985). Herpes 
simplex virus ribonucleotide reductase induced in infected BHK-21/C13 cells: 
Biochemical evidence for the existence of two non-identical subunits, HI and H2. Journal 
of General Virology 6 6 ,733-745.
COOK, M.L. AND STEVENS, J.G. (1973). Pathogenesis of herpetic neuritis and 
ganglionitis in mice: evidence for intra-axonal transport of infection. Infection and 
Immunity 7, 272-288.
CORTINI, R. AND WILKIE, N. M. (1978). Physical maps for HSV type 2 DNA with five 
restriction endonucleases. Journal o f General Virolology 39, 259-280.
COSTA, R.H., DEVI, B.G., ANDERSON, K.P., GAYLORD, B.H. AND WAGNER, E.K. 
(1981). Characterisation of a major late herpes simplex type 1 mRNA. Journal of Virology 
38, 483-496.
COSTA, R.H., COHEN, G., EISENBERG, R., LONG, D. AND WAGNER, E. (1984) 
Direct demonstration that the abundant 6 -kilobase herpes simplex virus type 1 mRNA
References
mapping between 0.23 and 0.27 map units encodes the major capsid protein VP5. Journal 
of Virology 49, 287-292.
COSTA, R.H., DRAPER, K.G., KELLY, T.J. AND WAGNER, E.K. (1985). An unusual 
spliced herpes simplex virus type 1 transcript with sequence homology tc^  Epstein -Barr 
virus DNA. Journal of Virology 54, 317-328.
CROEN, K.D., OSTROVE, J.M., DRAGUVIC, L.J., SMIALEK, J.E. AND STRAUS,
S.E. (1987). Latent herpes simplex virus in human trigeminal ganglia. Detection of an 
immediate-early gene antisense transcript by in situ hybridisation. New England Journal of 
Medicine 317, 1427-1432.
CRUTE, J.J. AND LEHMAN, I.R. (1989). Herpes simplex-1 DNA polymerase. 
Identification of an intrinsic 5 -3 ' exonuclease with ribonuclease H activity. Journal of 
Biological Chemistry 264, 19266-19270.
CRUTE, J.J., TSURUMI, T., ZHU, L., WELLER, S.K., OLIVO, P.D., CHALLBERG, 
M.D., MOCARSKI, E.S. AND LEHMAN, I.R. (1989). Herpes simplex virus 1 helicase- 
primase: a complex of three herpes-encoded gene products. Proceedings of the National 
Academy of Sciences, USA. 8 6 , 2186-2189.
DARGAN, D.J. (1986). The structure and assembly of herpesviruses. In J.R.Harris and 
R.W.Home (Eds.), Electron microscopy of proteins; viral structure. Vol. 5, pp. 359-437. 
Academic Press, Orlando & London.
DARLINGTON, R.W. AND MOSS, L.H. (1968). Herpesvirus envelopment. Journal of 
Virology 2, 48-55.
DAVISON, A.J. (1981). Detailed structural aspects of the herpes simplex virus genome. 
Ph.D thesis. University of Glasgow.
DAVISON, A.J. (1992). Channel catfish virus: A new type of herpesvirus. Virology 186, 
9-14.
DAVISON, A.J AND SCOTT, J.E. (1986). The complete DNA sequence of varicella- 
zoster virus. Journal OF General Virology 67, 1759-1816.
DAVISON A.J. AND WILKIE, N.M. (1981). Nucleotide sequence of the joint between 
the L and S segments of herpes simplex virus types 1 and 2. Journal o f General Virolology 
55,315-331.
References
DAVISON, A.J. AND WILKIE, N.M. (1983). Inversion of the 2 segments of the herpes 
simplex virus genome in intertypic recombinants. Journal o f General Virology 64, 1-18.
DAY, S.P., LAUSCH, R.N. AND OAKES, J.E. (1988). Evidence that the gene for herpes 
simplex virus type 1 DNA polymerase accounts for the capacity of an intertypic 
recombinant to spread from eye to central nervous system. Virology 163, 166-173.
DEATLY, A.M., SPIVACK, J.G., LAVI, E. AND FRASER, N.W. (1987). RNA from an 
immediate early region of the type 1 herpes simplex virus genome is present in the 
trigeminal ganglia of latently infected mice. Proceedings o f the National Academy of 
Sciences, USA. 84, 3204-3208.
DEB, S. AND DOELBERG, M. (1988). A 67-Base-pair segment from the OriS region of 
herpes simplex virus type 1 encodes origin function. Journal o f Virology 62, 2516-2519.
DEBROY, C., PEDERSON, N. AND PRESTON, S. (1985). Nucleotide sequence of a 
herpes simplex virus type 1 gene that causes cell fusion. Virology 145, 36-48.
DEISS, L.P. AND FRENKEL, N. (1986). Herpes simplex virus amplicon: Cleavage of 
concatemeric DNA is linked to packaging and involves amplification of the terminally 
reiterated a sequence. Journal of Virology 57, 933-941.
DEISS, L.P., CHOU, J. AND FRENKEL, N. (1986) Functional domains within the ‘a’ 
sequence involved in the cleavage-packaging of herpes simplex virus DNA. Journal o f 
Virology 59, 605-615.
DELUCA, N.A., McCARTHY, A. AND SCHAFFER, P.A. (1985). Isolation and 
characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding 
immediate-early regulatory protein ICP4. Journal of Virology 56, 558-570.
DESAI, P., DELUCA, N.A., GLORIOSO, J.C. AND PERSON, S. (1993). Mutations in 
herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and 
cleavage of replicated DNA. Journal of Virology 67, 1357-1364.
DESHMANE, S.L. AND FRASER, N.W. (1989). During latency, herpes simplex virus 
type 1 DNA is associated with nucleosome in a chromatin structure. Journal o f Virology 
63, 943-947.
DEVI-RAO, G.B., GOODART, S.A., HECHT, L.M., ROCHFORD, R., RICE, M.K. AND 
WAGNER, E.K. (1991). Relationships between polyadenylated and nonpolyadenylated 
herpes virus type 1 latency-associated transcripts. Journal of Virology 65, 2179-2190.
References
DEVI-RAO, G.B., BLOOM, D C., STEVENS, J.G. AND WAGNER, E.K. (1994). Herpes 
simplex virus type 1 DNA replication and gene expression during explant-induced 
reactivation of latently infected murine sensory ganglia. Journal o f Virology 6'^, 1271- 
1282.
DiDONATO, J.A., SPITZER, J R. AND MULLER, M.T. (1991). A predictve model for 
DNA recogntion by herpes simplex virus protein ICP4. Journal of Molecular Biology 219, 
451-470.
DIX, R.D., McKENDALL, R.R. AND BARINGEN, JR . (1983). Comparative 
neurovirulence of herpes simplex virus type 1 strains after peripheral or intracerebral 
inoculation of BALB/c mice. Infection and Immunity 40, 103-112.
DOBSON, A T., SEDERATI, P., DEVI-RAO, G., FLANAGAN, W.M., FARRELL, M.J., 
STEVENS, J.G., WAGNER, E.K. AND FELDMAN, L.T. (1989). Identification of the 
latency-associated transcript promoter by expression of rabbit beta-globin mRNA in 
mouse sensory nerve ganglia latently infected with a recombinant herpes simplex virus. 
Journal of Virology 63, 3844-3851.
DOBSON, A T., MARGOLIS, F., SEDERATI, F., STEVENS, J.G. AND FIELDMAN, 
L.T. (1990). A latent, nonpathogenic HSV-1 derived vector stably expressed P- 
galactosidase in mouse neurons. Neuron 5, 353-360.
DODSON, M.S. AND LEHMAN, I.R. (1991). Association of DNA helicase and primase 
activities with a subassembly of the herpes simplex virus 1 helicase-primase composed of 
the UL5 and UL52 gene products. Proceedings of the National Academy of Sciences, USA. 
8 8 , 1105-1109.
DOERIGE, C., PIZER, L.I. AND WILCOX, C.L. (1991). An antigen encoded by the 
latency-associated transcript in neuronal cell cultures latently infected with herpes simplex 
virus type 1. Journal of Virology 65, 2724-2727.
DOLAN, A., ARBUCKLE, M. AND MCGEOCH, D.J. (1991). Sequence analysis of the 
splice junction in the transcript of herpes simplex virus type 1 gene UL15. Virus Research 
20, 97-104.
DOLAN, A., MCKIE, E., MACLEAN, A.R. AND MCGEOCH, D.J. (1992). Status of the 
ICP34.5 gene in herpes simplex virus type 1 strain 17. Journal o f General Virology 73, 
971-973.
References
DOUVILLE, P., HAGMANN, M., GEORGIEV, O. AND SCHAFFNER, W. (1995). 
Positive and negative regulation at the herpes simplex virus ICP4 and ICPO TAATGARAT 
motifs. Virology 2Q1, 107-116.
DRESSLER, G.R., ROCK, D.L. AND FRASER, N.W. (1987). Latent herpes simplex 
virus type 1 DNA is not extensively methylated in vivo. Journal of General Virology 6 8 , 
1761-1765.
DUBBS, D. R. AND KIT, S. (1964). Mutant strains of herpes simplex deficient in 
thymidine kinase-inducing ability. Virology 22, 493-502.
DUTTON, C M., PAYNTON, C. AND SOMMER, S. (1993). General method for 
amplifying regions of very high G+C content. Nucleic Acids Research 21, 2953-2954.
EFSTATHIOU, S., MINSON, A C., FIELD, H.J., ANDERSON, J R. AND WILDY, P. 
(1986). Detection of herpes simplex virus-specific DNA sequences in latently infected 
mice and in humans. Journal o f Virology 57, 446-455.
EFSTATHIOU, S., KEMP, S., DARBY, G. AND MINSON, A C. (1989). The role of 
herpes simplex virus thymidine kinase in pathogenesis. Journal of General Virology 70, 
869-879.
ELIAS, P. AND LEHMAN, I.R. (1988). Interaction of origin binding protein with an 
origin of replication of herpes simplex virus 1. Proceedings o f the National Academy of 
Sciences USA. 85, 2959-2963.
ELIAS, P., O’DONNELL, M E., MOCARSKI, E.S. AND LEHMAN, I.R. (1986). A DNA 
binding protein specific for an origin of replication of herpes simplex type 1. Proceedings 
of the National Academy of Sciences USA. 83, 6322-6326.
ELIAS, P., GUSTAFSSON, C M. AND HAMMARSTEN, O. (1990). The origin binding 
protein of herpes simplex virus 1 binds cooperatively to the viral origin of replication. 
Journal o f Biological Chemistry 265, 17167-17173.
ELION, G.B., FURMAN, P.A., FYFE, J.A., MIRANDA, P., BEAUCHAMP, L. AND 
ACHAEFFER, H.J. (1977). Selectivity of action of an ) antiherpetic agent, 9-(2- 
hydroxyethoxymethy) guanine. Proceedings o f the National Academy of Sciences USA. 74, 
5716-5720.
ELLIOT, G.D. AND MEREDITH, D.M. (1992). The herpes simplex virus type 1 
tegument protein VP22 is encoded by gene UL49. Journal of General Virology 73, 723- 
726.
References
EVERETT, R.D. (1984). Transactivation of transcription by herpes virus products: 
requirement for two HSV-1 immediate-early polypeptides for maximum activity. EMBO J  
3,3135-3141.
EVERETT, R.D. (1986). The products of herpes simplex virus type 1 (HSV-1) immediate 
early genes 1, 2 and 3 can activate HSV-1 gene expression in trans. Journal o f General 
Virology 67, 2507-2513.
FARELL, M., DOBSON, A T. AND FELDMAN, L.T. (1991). Herpes simplex virus 
latency-associated transcript is a stable intron. Proceedings o f the National Academy of 
Sciences, USA. 88,790-794.
FENWICK, M.L. (1984). The effects of herpesviruses on cellular macromolecular 
synthesis, p.359-3390. In: H. Fraenkel-Conrat and R.R. Wagner (Eds.), Comprehensive 
Virology, Vol. 19, Plenum Publishing Corp., New York.
FENWICK, M.L. AND EVERETT, R.D. (1990a). Transfer of UL41, the gene controlling 
virion-associated host cell shut-off, between different strains of herpes simplex virus. 
Journal o f General Virology 71,411-418.
FENWICK, M.L. AND EVERETT, R.D. (1990b.) Inactivation of the shut-off gene 
(UL41) of herpes simplex virus types 1 and 2. Journal of General Virology 71, 2961-2967.
FIELD, K.J. AND COEN, D.M. (1986). Pathogenicity of herpes simplex virus mutants 
containing drug resistant mutations in the viral DNA polymerase gene. Journal of Virology 
60: 286-289.
FIELD, H.J. AND WILDY. (1978). The pathogenicity of thymidine kinase-deficient 
mutants of herpes simplex virus in mice. Journal of Hygiene 81, 267-277.
FIELD, H.J., DARBY, G. AND WILDY, P. (1980). Isolation and characterization of 
acyclovir-resistant mutants of herpes simplex virus. Journal of General Virology 49, 115- 
124.
FISHER, F.B. AND PRESTON, V.G. (1986). Isolation and characterisation of herpes 
simplex virus type 1 mutants which fail to induce dUTPase activity. Virology 148, 190- 
197.
FORNACE, A.J., NEBERT, D.W., HOLLANDER, C., LUETHY, J.D., 
PAPATHANASIOU, M., FARNGOLI, J. AND HOLBROOK, N.J. (1989). Mammalian 
genes coordinately regulated by growth arrest signals and DNA-damaging agents. 
Molecular and Cellular Biology 9, 4196-4203.
References
FORRESTER, A.J., FARRELL, H., WILKINSON, G., KAYE, L, POYNTER, N.D. AND 
MINSON, A.C. (1992). Construction and properties of herpes simplex virus 1 with 
glycoprotein H coding sequences deleted. Journal of Virology 6 6 , 341-348.
FRAME, M.C., McGEOCH, D.J., RIXON, F.J., ORR, A.C. AND MARSDEN, H.S. 
(1986). The lOK virion phosphoprotein encoded by gene US9 from herpes simplex virus 
type 1. Virology 150, 321-332.
FRASER, N.W., BLOCK, T.M. AND SPIVACK, J.G. (1992). The latency-associated 
transcripts of herpes simplex virus: RNA in search of function. Virology 191,1-8.
FRESHNEY, R.I. (1994). Culture o f Animal Cells : A Manual of Basic Technique. 3rd Ed. 
Wiley-Liss, New York.
FULLER, A.O. AND LEE, W-C. (1992). Herpes simplex virus type 1 entry through a 
cascade of virus cell interactions requires different roles of gD and gH in penetration. 
Journal o f Virology 6 6 , 5002-5012.
FULLER, A.O. AND SPEAR, P.G. (1985). Specificities of monoclonal and polyclonal 
antibodies that inhibit adsorption of herpes simplex virus to cells and lack of inhibition by 
potent neutralising antibodies. Journal o f Virology 55, 475-482.
FULLER, A.O. AND SPEAR, P.G. (1987). Anti-glycoprotein D antibodies that permit 
adsorption but block infection by herpes simplex virus 1 prevent virion-cell fusion at the 
cell surface. Proceedings of the National Academy of Sciences USA. 84, 5454—5458.
FULLER, A.O., SANTOS, R. AND SPEAR, P.G. (1989) Neutralising antibodies specific 
for glycoprotein H of herpes simplex virus permit viral attachment to cells but prevent 
penetration. Journal of Virology 63, 3435-3443.
FURLONG, G.D., SWIFT, H. AND ROIZMAN, B. (1972). Arrangement of the 
herpesvirus deoxyribonucleic acid in the core. Journal of Virology 10, 1071-1074.
GAFFNEY, D.F., McLAUCHLAN, J., WHITTON, J.L. AND CLEMENTS, J.B. (1985). 
A modular system for the assay of transcription regulatory signals: the sequence 
TAATG ARAT is required for herpes simplex virus immediate early gene activation. 
Nucleic Acid Research 13, 7874-7863.
GALLO, M.L., JACKWOOD, D.H., MURPHY, M., MARSDEN, H.S. AND PARRIS,
D.S. (1988). Purification of the herpes simplex virus type 1 65-kilodalton DNA-binding 
protein: properties of the protein and evidence of its association with the viral encoded 
DNA polymerase. Journal of Virology 62, 2874-2883.
References
GALLOWAY, D.A., FENOGLIO, C M., SHEVCHUK, M. AND McDOUGALL, J.K. 
(1979). Detection of herpes simplex virus RNA in sensory ganglia. Virology 95, 265-268.
GAO, M., MATUSICK-KUMAR, L., HURLBURT, W., DTUSA, S.F., NEWCOMB, 
W.W., BROWN, J.C., McCANN, P.J., DECKMAN, I. AND COLONNO, R.J. (1994). The 
protease of herpes simplex virus type 1 is essential for functional capsid formation and 
viral growth. Journal o f Virology 6 8 , 3702-3712.
GEORGOPOULOU, U., MICHAELIDOU, A., ROIZMAN, B. AND MAVROMARA, P.
(1993). Identification of a new transcriptional unit that yields a gene product within the 
unique sequences of the short component of the herpes simplex virus 1 genome. Journal of 
Virology 67, 3961-3968.
GERSTER, T. AND ROEDER, R.G. (1988). A herpesvirus rran^-activating protein 
interacts with transcription factor OTF-1 and other cellular proteins. Proceedings of the 
National Academy of Sciences USA. 85, 6347-6351.
GIBSON, W. AND ROIZMAN, B. (1972). Proteins specified by herpes simplex virus 
VIII. Characterization and composition of multiple capsid forms of subtypes 1 and 2. 
Journal of Virology 10, 1044—1052.
GOINS, W.F., STERNBERG, L.R., CROEN, K.D., KRAUSE, P R., HENDRICKS, R.L., 
FINK, D.J., STRAUS, S.E., LEVINE, M. AND GLORIOSO, J.C. (1994). A novel 
latency-active promoter is contained within the herpes simplex virus type 1 U l flanking 
repeats. Journal of Virology 6 8 , 2239-2252.
GOLDSTEIN, D.J. AND WELLER, S.K. (1988a). Herpes simplex virus type 1-induced 
ribonucleotide reductase is dispensable for virus growth and DNA synthesis: isolation and 
characterisation of an ICP6  lacZ insertion mutant. Journal o f Virology 62, 196-205.
GOLDSTEIN, D.J. AND WELLER, S.K. (1988b). Factor(s) present in herpes simplex 
virus type-1  infected cells can compensate for the loss of the large subunit of the viral 
ribonucleotide reductase: characterization of an ICP6  deletion mutant. Virology 166, 41-51
GOODMAN, J.L. AND STEVENS, J.G. (1986). Passage of herpes simplex virus type 1 
on chick embryo fibroblasts confers virulence for chick embryos. Virus Research 5, 191- 
200.
GOODRICH, L.D., SCHAFFER, P.A., DORSKY, D.L, CRUMPACKER, C.S. AND 
PARRIS, D.S. (1990). Localisation of the herpes simplex virus type 1 65-Kilodalton 
DNA-binding protein and DNA polymerase in the presence and absence of viral DNA 
synthesis. Journal of Virology 64, 5738-5749.
References
GOUGH J. AND MURRAY, N. (1983). Sequence diversity among related genes for 
recognition of specific targets in DNA molecules. Journal o f Molecular Biology 166, 1-19.
GRAY, C.P. AND KAERNER, H.C. (1984). Sequence of the putative origin of replication 
in the U l region of herpes simplex virus type 1 ANG DNA. Journal o f General Virology 
65,2109-2119.
GREEN, M.T., COURTNEY, R.J. AND DUNKEL, E.C. (1981). Detection of an 
immediate early herpes simplex virus type 1 polypeptide in trigeminal ganglia from 
latently infected animals. Infection and Immunity 34, 987-992.
HAANES, E.J., NELSON, C M., SOULE, C.L. AND GOODMAN, J.L. (1994). The UL45 
gene product is required for herpes simplex virus type 1 glycoprotein B-induced fusion. 
Journal o f Virology 6 8 , 5825-5834.
HALLIBURTON, I.W., HONESS, R.W. AND KILLINGTON, R.A. (1987). Virulence is 
not conserved in recombinants between herpes simplex virus type 1 and 2. Journal of 
General Virology 6% 1435-1440.
HARLAND, J AND BROWN, S.M. (1985). Isolation and characterisation of deletion 
mutants of herpes simplex virus type 2 (strain HG52). Journal o f General Virology 6 6 , 
1305-1321.
HARLAND, J. AND BROWN, S.M. (1991). Abolition of the RL neurovirulence 
phenotype of herpes simplex virus type 2 strain HG52 does not require deletion of the DRl 
element of the ‘a’ sequence. Journal o f General Virology 72, 2777-2779.
HARRIS, R.A., EVERETT, R.D., ZHU, X., SILVERSTEIN, S. AND PRESTON, C M.
(1989). Herpes simplex virus type 1 immediate-early protein VmwllO reactivates latent 
herpes simplex virus type 2 in an in vitro latency system. Journal of Virology 63, 3513- 
3515.
HAYWARD, G.S., JACOB, R.J., WADSWORTH, S.C. AND ROIZMAN, B. (1975). 
Anatomy of herpes simplex virus DNA: evidence for four populations of molecules that 
differ in the relative orientations of their long and short components. Proceedings o f the 
National Academy of Sciences USA. 72, 4243-4247.
HE, X., TREACY, M.N., SIMMONS, D.M., INGRAHAM, H.A., SWANSON, L.W. 
AND ROSENFELD, M.G. (1989). Expression of a large family of POU-domain 
regulatory genes in mammalian brain development. Nature 340, 35-42.
References
HEROLD, B.C., WUDUNN, D., SOLTYS, N. AND SPEAR, P.G. (1991). Glycoprotein C 
of herpes simplex virus type 1 plays a principal role in the adsorption of virus to cells and 
in infectivity. Journal of Virology 65, 1090-1098.
HEROLD, B.C., VISALLI, R.J., SUSMARSKI, N., BRANDT, C.R. AND SPEAR, P.G.
(1994). Glycoprotein C-independent binding of herpes simplex virus to cells requires cell 
surface heparan sulphate and glycoprotein B. Journal o f General Virology 75, 1211-1222.
HIGHLANDER, S.L., SUTHERLAND, S.L., GAGE, P.J., JOHNSON, D C., LEVINE, M. 
AND GLORIOSO, J.C. (1987). Neutralizing monoclonal antibodies specific for herpes 
simplex virus glycoprotein D inhibit virus penetration. Journal of Virology 61, 3356-3364.
HIGHLANDER, S.L., CAI, W., PERSON, S., LEVINE, M. AND GLORIOSO, J.C. 
(1988). Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B 
involved in virus penetration. Journal of Virology 62, 1881-1888.
HILL, T.J. (1985). Herpes simplex virus latency. In: B. Roizman (Ed.), The Herpes 
Viruses, Vol.3, pp. 175-225. Plenum Press, New York.
HILL, T.J., SEDERATI, P., JAVIER, R.T., WAGNER, E.K. AND STEVENS, J.G.
(1990). Herpes simplex virus latent phase transcription facilitates in vivo reactivation. 
Virology 174, 117-125.
HO, D.Y. AND MOCARKI , E.S. (1989). Herpes simplex virus latent RNA (LAT) is not 
required for latent infection in the mouse. Proceedings o f the National Academy o f 
Sciences, USA. 8 6 , 7596-7600.
HOMA, F.L., OTAL, T.M., GLORIOSO, J.C. AND LEVINE, M. (1986). Transcriptional 
control signals of a herpes simplex virus type 1 late (7 2 ) gene lie within bases -34 to +124 
relative to the 5’ terminus of the mRNA. Molecular and Cellular Biology 6 , 3652-3666.
HOMA, F.L., OTAL, T.M., GLORIOSO, J.C. AND LEVINE, M. (1988). A specific 15-bp 
TATA box promoter element is required for expression of a herpes simplex virus type 1 
late gene. Genes and Development 2,40-53.
HONESS, R.W. AND ROIZMAN, B. (1974.) Regulation of herpesvirus macromolecular 
synthesis I. Cascade regulation of the synthesis of three groups of viral proteins. Journal of 
Virology 14, 8-19.
HONESS, R.W. AND ROIZMAN, B. (1975). Regulation of herpesvirus macromolecular 
synthesis: sequential transition of polypeptide synthesis requires functional viral 
polypeptides. Proceedings of the National Academy of Sciences USA. 72,1276-1280.
References
HUTCHINSON, L., BROWNE, H., WARGENT, V., DAVIS-POYNTER, N., 
PRIMORAC, S., GOLDSMTH, K., MINSON, A.C. AND JOHNSON, D C. (1992a). A 
novel herpes simplex virus glycoprotein, gL, forms a complex with glycoprotein H (gH) 
and affects normal folding and surface expression of gH. Journal o f Virology 6 6 , 2240- 
2250.
HUTCHINSON, L., GOLDSMITH, K. SNODDY, D., GHOSH, H., GRAHAM, F.L. 
AND JOHNSON, D.C.(1992b). Identification and characterisation of a novel herpes 
simplex virus glycoprotein, gK, involved in cell fusion. Journal o f Virology 6 6 , 5603- 
5609.
INGEMARSON, R. AND LANKINEN, H. (1987). The herpes simplex virus type 1 
ribonucleotide reductase is a tight complex of the type a2^2 composed of 40K and 140K 
proteins, of which the latter shows multiple forms due to proteolysis. Virology 156, 417- 
422.
IZUMI, K. AND STEVENS, J.G. (1990). Molecular and biological characterization of a 
herpes simplex virus type 1 (HSV-1) neuroinvasiveness gene. Journal o f Experimenal 
Medicine 172, 487-496.
JACOB, R.J. AND ROIZMAN, B. (1977). Anatomy of herpes simplex virus DNA. VIII. 
Properties of the replicating DNA. Journal of Virology 23, 394-411.
JACOB, R.J., MORSE, L.S. AND ROIZMAN, B. (1979) Anatomy of herpes simplex 
virus DNA XII. Accumulation of head-to-tail concatemers in nuclei of infected cells and 
their role in the generation of the four isomeric arrangements of viral DNA. Journal o f 
Virology 29, 448—457.
JACOBSON, J.G., LEIB, D.A., GOLDESTEIN, D.J., BOGART, C.L., SCHAFFER, P.A., 
WELLER, S.K. AND COHEN, D.M. (1989). A herpes simplex virus ribonucleotide 
reductase deletion mutant is defective for productive acute and reactivable latent infections 
of mice and for replication in mouse cells. Virology 173, 276-283.
JAVIER, R.T., THOMPSON, R.L. AND STEVENS, J.G. (1987). Genetic and biological 
analysis of a herpes simplex virus intertypic recombinant reduced specifically for 
neuro virulence. Journal of Virology 61, 1978-1984.
JAVIER, R.T., IZUMI, K.M. AND STEVENS, J.G. (1988a). Localization of a herpes 
simplex virus neurovirulence gene dissociated from high titer virus replication in the brain. 
Journal of Virology 62, 1381-1387.
References
JAVIER, R.T., STEVENS, J.G., DISSETTE, V.B. AND WAGNER, E.K. (1988b). A 
herpes simplex virus transcript abundant in latently infected neurons is dispensable for 
establishment of latent state. Virology 166, 254-257.
JOHNSON, D.C. AND SPEAR, P.G. (1982). Monensin inhibits the processing of herpes 
simplex virus glycoproteins, their transport to the cell surface, and the egress of virions 
from infected cells. Journal o f Virology 43,1102-1112.
JOHNSON, D C., BURKE, R.L. AND GREGORY, T. (1990). Soluble forms of herpes 
simplex virus glycoprotein D bind to a limited number of cell surface receptors and inhibit 
virus entry into cells. Journal of Virology 64, 2569-2576.
JOHNSON, R.E., NAHMIAS, A.J., MAGDER, L.S., LE, F.K., BROOKS, C.A. AND 
SNOWDEN, C.B. (1989). A seroepidemiological survey of the prevalence of herpes 
simplex virus type 2 infection in the United States. New England Journal of Medicine 321, 
7-12.
JONES, K.A. AND TJIAN, R. (1985). SPl binds to promoter sequences and activates 
herpes simplex virus ‘immediate-early’ gene transcription in vitro. Nature 317, 179-182.
JONES, K.A., YAMAMOTO, R. AND TJIAN, R. (1985). Two distinct transcription 
factors bind to the HSV thymidine kinase promoter in vitro. Cell 42, 559-572.
KAERNER, H.C., SCHRODER, C H., OTT-HARTMANN, A., KUMEL, G. AND 
KIRCHNER, H. (1983). Genetic variability of herpes simplex virus: development of a 
pathogenic variant during passaging of a nonpathogenic herpes simplex virus type 1 virus 
strain in mouse brain. Journal of Virology 46: 83-93.
KALINYAK, I.E., LEAGUE, G. AND DOCHERTY, J.J. (1977). Incidence and 
distribution of herpes simplex virus types 1 and 2  from genital lesions in college women. 
Journal of Medical Virology 1, 173.
KATAN, M., HAIG, A., VERRIJZER, C.P., van der VLIET, P C. AND O’HARE, P.
(1990). Characterisation of a cellular factor which interacts functionally with Oct-1 in the 
assembly of a multicomponent transcriptional complex. Nucleic Acids Research 18, 6871- 
6880.
KATZ, J.P., BODIN, E.T. AND COEN, D.M. (1990). Quantitative polymerase chain 
reaction analysis of herpes simplex virus DNA in ganglia of mice infected with 
replication-incompetent mutants. Journal of Virology 64,4288-4295.
References
KAWAMURA, N., KOHARA, M., ABE, S., KOMATSU, T., TAGO, K., ARITA, M. 
AND NOMOTO, A. (1989). Determinants in the 5' non-coding region of poliovirus Sabin 
1 RNA that influence the attenuation phenotype. Journal o f Virology 63, 1302-1309.
KEMP, L.M., DENT, C.L. AND LATCHMAN, D.S. (1990). Octamer motif mediates 
transcriptional repression of HSV immediate-early genes and octamer-containing cellular 
promoters in neuronal cells. Neuron 4, 215-222.
KIEFF, E.D., HOYER, B., BACHENHEIMER, S.L. AND ROIZMAN, B. (1972). Genetic 
relatedness of type 1 and type 2 herpes simplex virus. Journal of Virology 9, 738-745.
KINGHORN, G.R. (1993). Genital herpes: Natural history and treatment of acute episode. 
Journal of Medical Virology 1, 33-38.
KIT, S. AND DUBBS, D R. (1963). Acquisition of thymidine kinase activity by herpes 
simplex virus infected mouse fibroblast cells. Biochemica Biophysica Acta 11, 55-59.
KIT, S. AND DUBBS, D R. (1965). Properties of deoxythymidine kinase partially purified 
from noninfected and virus-infected mouse fibroblast cells. Virology 26, 16-27.
KIT, S., SHEPPARD, M., ICHIMURA, H., NUSINOFF-LEHRMAN, S., ELIS, M.N., 
FYFE, J.A. AND OTSUKA, H. (1987). Nucleotide sequence changes in thymidine kinase 
gene of herpes simplex virus type 2 clones from an isolate of a patient treated with 
acyclovir. Antimicrobial Agents and Chemotherapy 31, 1483-1490.
KLEMPERER, H.G., HAYNES, G.R., SHEDDON, W.I.H. AND WATSON, D.H. (1967). 
A virus-specific thymidine kinase in BHK 21 cells infected with herpes simplex virus. 
Virology 31, 120-128.
KLINEDINST, D.K. AND CHALLBERG, M.D. (1994). Helicase-primase complex of 
herpes simplex virus type 1: a mutation in the UL52 subunit abolishes primase activity. 
Journal of Virology 68, 3693-3701.
KNOPF, C.W., SPIES, B. AND KAERNER, H.C. (1986). The DNA replication origins of 
herpes simplex virus type 1 strain Angelotti. Nucleic Acid Research 14, 8655-8667.
KOCH, H.G., ROSEN, A., ERNST, F., BECKER, Y. AND DARAI, G. (1987). 
Determination of nucleotide sequence flanking the deletion (0.762-0.789 map units) in the 
genome of an intraperitoneally virulent HSV-1 strain HFEM. Virus Research 7, 105-115.
References
KOFF, A. AND TEGTMEYER, P. (1988). Characterisation of major recognition 
sequences for a herpes simplex virus type 1 origin-binding protein. Journal of Virology 62, 
4096-4103.
KOPS, A.B. AND KNDPE, D.M. (1988). Formation of DNA replication structures in 
herpes virus-infected cells requires a viral DNA binding protein Cell 55, 857-868.
KOPS, A.B. AND KNIPE, D.M. (1994). Preexisting nuclear architecture defines the 
intranuclear location of herpesvirus DNA replication structures. Journal o f Virology 68, 
3512-3526.
KOSZ-VNENCHAK, M., COEN, D.M. ANDKN1PE,D.M. (1990). Restricted expression 
of herpes simplex virus lytic genes during establishment of latent infection by thymidine 
kinase-negative mutant viruses. Journal of Virology 64, 5396-5402.
KRAMER, M.F. AND COEN, D.M. (1995). Quantification of transcripts from the ICP4 
and thymidine kinase genes in mouse ganglia latently infected with herpes simplex virus. 
Journal of Virology 69, 1389-1399.
KRISTENSSON, K., LYCKE, E., ROYTTA, M., SVENNERHOLM, B. AND VAHLNE,
A. (1986). Neuritic transport of herpes simplex virus in rat sensory neurons in vitro. 
Effects of substances interacting with microtubular function and axonal flow [Nocodazole, 
Taxol and Erythro-9-3-(2-hydroxynonyl) adenine]. Journal of General Virology 67, 2023- 
2028.
KRISTIE, T.M. AND ROIZMAN, B. (1986). DNA-binding site of major regulatory 
protein a4 specifically associated with promoter regulatory domains of a  genes of herpes 
simplex virus type 1. Proceedings of the National Academy of Sciences USA. 83, 4700- 
4704.
KRISTIE, T.M. AND ROIZMAN, B. (1987). Host cell proteins bind to the cw-acting site 
required for virion-mediated induction of herpes simplex virus 1 a  genes. Proceedings of 
the National Academy of Sciences, U.S.A 84, 71-75.
KRISTIE, T.M, LeBOWITZ, J.H. AND SHARP, P.A. (1989). The octamer-binding 
proteins form multi-protein-DNA complexes with the HSV a-TIF regulatory protein. 
EMBOJ.H,  4229-4238.
KUHN, I.E., KRAMER, M.D., WILLENBACHER, W., WIELAND, U., LORENTZEN,
E.U. AND BRAUN, R.W. (1990). Identification of herpes simplex virus type 1 
glycoproteins interacting with the cell surface. Journal o f Virology 64, 2491-2497.
References
KUMEL, G., KIRCHNER, H., ZAWATZKY, R., ENGLER, H., SCHRODER, C.H. AND 
KAERNER, H.C. (1982). Experimental infection of inbred mice with herpes simplex 
virus. V. Investigation with a virus strain non-lethal after peripheral infection. Journal of 
General Virology 63, 315-323.
KUNKEL, T.A. (1985). Rapid and efficient site-specific mutagenesis without phenotypic 
selection. Proceedings of the National Academy of Sciences. U.SA. 82,488-492.
KUNKEL, T.A., ROBERTS, J.D. AND ZAKOUR, R.A. (1987). Rapid and efficient site- 
specific mutagenesis without phenotypic selection. Methods In Enzymology 154, 367-382.
KWONG, A.D. AND FRENKEL, N. (1987). Herpes simplex virus-infected cells contain a 
function(s) that destabilize both host and viral mRNAs. Proceedings o f the National 
Academy of Sciences. U.S.A 84: 1926-1930.
KWONG, A.D., KRUPER, A.J. AND FRENKEL, N. (1988). Herpes simplex virus virion 
host shutoff function. Journal of Virology 62, 912-921.
LAFFERTY, W.E., COOBS, R.W., BENEDETH, J., CRITCHLOW, C. AND COREY, L. 
(1987). Recurrences after oral and genital herpes simplex virus infection. Influence of site 
of infection and viral type. New England Journal Of Medicine 316, 1444-1449.
LAGUNOFF, M AND ROIZMAN, B. (1994). Expression of a herpes simplex virus 1 
open reading frame antisense to the 7% 34.5 gene and transcribed by an RNA 3' coterminal 
with the unspliced latency-associated transcript. Journal of Virology 68, 6021-6028.
LARDER, B.A., LISLE, J.J. AND DARBY,G. (1986). Restoration of wild-type 
pathogenicity to an attenuated DNA polymerase mutant of herpes simplex virus type 1. 
Journal of General Virology 67, 2501-2506.
LATCHMAN, D.S., DENT, C.L., LILLYCROP, K.A. AND WOOD, J.N. (1992). POU 
family transcription factors in sensory neurons. Biochemical Society Transactions 20, 627- 
631.
LAWRENCE, G.L., CHEE, M., CRAXTON, M.A., COMPELS, U.A., HONESS, R.W. 
AND BARRELL, B.C. (1990). Human herpesvirus 6 is closly related to human 
cytomegalovirus. Journal of Virology 64, 287-299.
LEIB, D.A., COEN, D M., BOGARD, C.L., HICKS, K.A., YAGER, D R., KNIPE, D.M., 
TYLER, K.L. AND SCHAFFER, P.A. (1989a) Immediate-early regulatory gene mutants 
define different stages in the establishment and reactivation of herpes simplex virus 
latency. Journal of Virology 63, 759-768.
References
LEIB, D.A., BOGARD, C.L., KOSZ-VNENCHAK, M., HICKS, K.A., COEN, D.M., 
KNIPE, D.M. AND SCHAFFER, P.A. (1989b). A deletion mutant of the latency- 
associated transcript of herpes simplex virus type 1 reactivates from the latent state with 
reduced frequency. Journal of Virology 63, 2893-2900.
LEIB, D.A., NADEAU, K.C., RUNDLE, S.A. AND SCHAFFER, P.A. (1991). The 
promoter of the latency associated transcripts of herpes simplex virus type 1 contains a 
functional cAMP-response element: Role of the latency associated transcripts and cAMP 
in reactivation of viral latency. Proceedings of the National Academy of Sciences, USA. 88, 
48-52.
LEMASTER, S. AND ROIZMAN, B. (1980). Herpes simplex virus phosphoproteins. II. 
Characterisation of the virion protein kinase and of the polypeptides phosphorylated in the 
virion. Journal of Virology 35, 798-811.
LIESEGANG, T.J. (1988). Ocular herpes simplex infection: Pathogenesis and current 
therapy. Mayo Clinic Proceedings 63, 1092-1105.
LIGAS, M.W., AND JOHNSON, D C. (1988). A herpes simplex virus mutant in which 
glycoprotein D sequences are replaced by P-galactosidase sequences binds to but is unable 
to penetrate into cells. Journal of Virology 62,1486-1494.
LILLYCROP, K.A. AND LATCHMAN, D.S. (1992). Alternative splicing of the Oct-2 
transcription factor RNA is differentially regulated in neuronal cells and B cells and results 
in protein isoforms with opposite effects on the activity of octamer/TAATGARAT- 
containing promoters. Journal of Biological Chemistry 267, 24960-24966.
LILLYCROP, K.A., DENT, C.L., WHEATLEY, S.C., BEECH, M.N., NINKINA, N.N., 
WOOD, J.N. AND LATCHMAN, D.S. (1991). The octamer-binding protein Oct-2 
represses HSV immediate-early genes in cell lines derived from latently infectable sensory 
neurons. Neuron 7, 381-390.
LILLYCROP, K.A., HOWARD, M.K., ESTRIDGE, J.K. AND LATCHMAN, D.S. 
(1994a). Inhibition of herpes simplex virus infection by ectopic expression of neuronal 
splice variants of the Oct-2 transcription factor. Nucleic Acids Research 22, 815-820.
LILLYCROP, K.A., HOWARD, M.K. AND LATCHMAN, D.S. (1994b). Regulation of 
HSV latency by cellular POU proteins. The 19th international herpes virus workshop. 
University of British Columbia, Vancouver-Canada, July 30-August 5.
References
LIU, F. AND ROIZMAN, B. (1991a). The promoter, transcriptional unit, and coding 
sequence of herpes simplex virus 1 family 35 proteins are contained within and in frame 
with the UL26 open reading frame. Journal of Virology 65, 206-212.
LIU, F. AND ROIZMAN, B. (1991b). The herpes simplex virus 1 gene encoding a 
protease also contains within its coding domain the gene encoding the more abundant 
substrate. Journal of Virology 65, 5149-5156.
LOCKSHON, D. AND GALLOWAY, D A. (1986). Cloning and characterisation of 
OriLl, a large palindromic DNA replication origin of herpes simplex virus type 2. Journal 
of Virology 58, 513-521.
LOKENSGARD, J R., BLOOM, D C., DOBSON, A T. AND FELDMAN, L.T. (1994). 
Long-term promoter activity during herpes simplex virus latency. Journal of Virology 68, 
7148-7158.
LOMNICZI, B., WATANABE, S., BEN-PORAT, T. AND KAPLAN, A S. (1984). 
Genetic basis of the neurovirulence of pseudorabies virus. Journal o f Virology 52, 198- 
205.
LONGNECKER, R., CHATTERJEE, S., WHITLEY, R.J. AND ROIZMAN, B. (1987). 
Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster 
dispensible for growth in tissue culture. Proceedings of the National Academy of Sciences 
USA. 84, 4303^307.
LONSDALE, D.M. (1979). A rapid technique for distinguishing herpes simplex virus type 
1 from type 2 by restriction technology. Lancet i: 849-852.
LOPEZ, C. (1985). Natural resistance mechanisms in herpes simplex virus infections. In: 
B.Roizman and C.Lopez (Eds.), The Herpesviruses, Vol. 4, pp. 1-36. Plenum Press, New 
York.
LORD, K.A., HOFFMAN-LIEBERMANN, B. AND LIEBERMANN, D A. (1990). 
Sequence of MyD116 cDNA: a novel myeloid differentiation primary response gene 
induced by IL6. Nucleic Acids Research 18, 2823.
LYCKE, E., JOHANSSON, M., SVENNERHOLM, B. AND LINDAHI, U. (1991). 
Binding of herpes simplex virus to cellular heparan sulphate, an initial step in the 
adsorption process. Journal of General Virology 72, 1131-1137.
McGEOCH, D.J. AND BARNETT, B. (1991). Neurovirulence factor. Nature 353, 609.
References
McGEOCH, D.J., DOLAN, A. AND RDCON, FJ. (1985). Sequence determination and 
genetic content of the short unique region in the genome of herpes simplex virus type 1. 
Journal o f Molecular Biology 181, 1-13.
McGEOCH, D.J., DOLAN, A., DOLAND, S. AND BRAUER, D.H.K. (1986). Complete 
DNA sequence of the short repeat region in the genome of herpes simplex virus type 1. 
Nucleic Acids Research 14, 1727-1745.
McGEOCH, D.J., MOSS, H.W., McNAB, D. AND FRAME, M.C. (1987). DNA sequence 
and genetic content of the HindlW I region in the short unique component of the herpes 
simplex virus type 2 genome: Identification of the gene encoding glycoprotein G and 
evolutionary comparisons. Journal of General Virology 68, 19-38.
McGEOCH, D.J., DALRYMPLE, M.A., DAVISON, A.J., DOLAN, A., FRAME, M.C., 
McNAB, D., PERRY, L.J., SCOTT, I.E. AND TAYLOR, P. (1988a). The complete DNA 
sequence of the long unique region in the genome of herpes simplex virus type 1. Journal 
of General Virology 69: 1531-1574.
McGEOCH, D.J., DALRYMPLE, M.A., DOLAN, A., McNAB, D., PERRY, L.J., 
TAYLOR, P. AND CHALLERG, M.D. (1988b). Structures of herpes simplex virus type 1 
genes required for replication of virus DNA. Journal of Virology 62, 444-453.
McGEOCH, D.J., CUNNINGHAM, C., McINTYRE, G. AND DOLAN, A. (1991). 
Comparative sequence analysis of the long repeat region and adjoining parts of the long 
unique regions in the genomes of herpes simplex viruses types 1 and 2. Journal of General 
Virology 72, 3057-3075.
McGEOCH, D.J., BARNETT, B.C. AND MACLEAN, C.A. (1993). Emerging functions 
of alphaherpesvirus genes. Seminars in Virology 4, 125-134.
McKAY, E.M., McVEY, B., MARSDEN, H.S., BROWN, S. M. AND MACLEAN, A. R. 
(1993). The herpes simplex virus type 1 strain 17"*" open reading frame RLl encodes a 
ploypeptide of apparent Mr 37K equivalent to ICP34.5 of herpes simplex virus type 1 
strain F. Journal of General Virology 74, 2493-2497.
MACKEM, S. AND ROIZMAN, B. (1982). Structural features of the herpes simplex virus 
a  gene: 4,0, and 27 promoter-regulatory sequences which confer a  regulation on chimeric 
thymidine kinase genes. Journal o f Virology 44,939-949.
McKENDALL, R.R., KLASSES, T. AND BARINGER, R. (1979). Host defences in 
herpes simplex virus infections of the nervous system: Effect of antibody on disease and 
viral spread. Infection and Immunity 23, 305-311.
References
McKIE, E.A.E., HOPE, G.R., BROWN, S.M. AND MACLEAN, A.R. (1994). 
Characterization of the herpes simplex virus type 1 strain 17+ neurovirulence gene RLl 
and its expression in a bacterial system. Journal of General Virology 75, 733-741.
Me KNIGHT, S.L. AND KINGSBURY, R. (1982). Transcriptional control signals of a 
eukaryotic protein-coding gene. Science 217, 316-324.
Me KNIGHT, S.L. AND THAN, R. (1986). Transcriptional selectivity of viral genes in 
mammalian cells. Cell 46, 795-805.
McKNIGHT, J.L.C., PELLETT, P.E., JENKINES, F.J. AND ROIZMAN, B. (1987). 
Characterisation and nucleotide sequence of two herpes simplex virus 1 genes whose 
products modulate a  rraw.s-inducing factor dependent activation of a  genes. Journal o f 
Virology 61, 992-1001.
McLAUCHAN, J. AND RIXON, F.J. (1992). Characterisation of enveloped tegument 
structures (L particles) produced by alphaherpesviruses: integrity of the tegument does not 
depend on the presence of capsid or envelop. Journal of General Virology 73, 269-276.
MACLEAN, A.R., FAREED, M.U., ROBERTSON, L., HARLAND, J. AND BROWN, S. 
M. (1991). Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint 
neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 
and the ‘a ’ sequence. Journal of General Virology 72, 631-639.
MACLEAN, C.A., CLARK, B. AND McGEOCH, D.J. (1989). Gene U L ll of herpes 
simplex virus type 1 encodes a virion protein which is myristylated. Journal o f General 
Virology 70, 3147-3157.
MACLEAN, C.A., EFSTATHIOU, S., ELLIOT, M L., JAMIESON, F.E. AND 
McGEOCH, D. (1991). Investigation of herpes simplex virus type 1 genes encoding 
multiply inserted membrane proteins. Journal o f General Virology 72, 897-906.
MACLEAN, C.A., DOLAN, A., JAMIESON, F.E. AND McGEOCH, D.J. (1992). The 
myristylated virion proteins of herpes simplex virus type 1: Investigation of their role in 
the virus life cycle. Journal o f General Virology 73, 539-547.
MACLEAN, C.A., ROBERTSON, L.M. AND JAMIESON, F.E. (1993). Characterization 
of the ULIO gene product of herpes simplex virus type 1 and investigation of its role in 
vivo. Journal of General Virology 74. 975-983.
References
M cL en n an , J.L. a n d  d a r b y ,  G. (1980). Herpes simplex virus latency: the cellular 
location of virus in dorsal root ganglia and the fate of the infected cell following virus 
activation. Journal of General Virology 51, 233-243.
McMAHAN, L. AND SCHAFFER, P.A. (1990). The repressing and enhancing functions 
of the herpes simplex virus regulatory protein ICP27 map to the C-terminal regions and are 
required to modulate viral gene expression very early in infection. Journal o f Virology 64, 
3471-3485.
McNABB, D.S. AND COURTNEY, R.J. (1992). Characterisation of the large tegument 
protein (ICPl/2) of herpes simplex virus type 1. Virology 190, 221-232.
MACPHERSON, I. AND STOKER, M.G. (1962). Polyoma transformation of hamster 
cell clones: an investigation of genetic factors affecting cell competence. Virology 16, 
147-151.
MANNIATIS, T., FRITSCH, E.F. AND SAMBROOK, J. (1982). ^^Molecular Cloning; A 
Laboratory Manual”, N.Y.: Cold Spring Harbour Laboratory.
MARGOLIS, T.P., SEDARATI, F., DOBSON, A T., FELDMAN, L.T. AND STEVENS, 
J.G. (1992). Pathways of viral gene expression during acute neuronal infection with HSV- 
1. Virology 189, 150-1160.
MELLERICK, D.M. AND FRASER, N.W. (1987). Physical state of the latent herpes 
simlex virus genome in a mouse model system: Evidence suggesting an episomal state. 
Virology 158, 265-275
MINAGAWA, H., TANAKA, S., TOH, Y. AND MORI, R. (1994). Detection of herpes 
simplex virus type 1-encoded RNA by polymerase chain reaction: different pattern of viral 
RNA detection in latently infected murine trigeminal ganglia following in vitro or in vivo 
reactivation. Journal of General Virology 75, 647-650.
MITCHELL, W.J., DESHMANE, S.L., DOLAN, A., McGEOCH, D.J. AND FRASER, 
N.W. (1990a). Characterisation of herpes simplex virus type 2 transcription during latent 
infection of mouse trigeminal ganglia. Journal of Virology 64, 5342-5348.
MITCHELL, W.J., LIRETTE, R.P. AND FRASER, N.W. (1990b). Mapping of low 
abundance latency-associated RNA in the trigeminal ganglia of mice latently infected with 
herpes simplex virus type 1. Journal of General Virology 71, 125-132.
MITCHELL, W.J., STEINER, I., BROWN, S.M., MACLEAN, A.R., SUBAK-SHARPE, 
J.H. AND FRASER, N.W. (1990c). A herpes simplex virus type 1 variant, deleted in the
References
promoter region of the latency-associated transcripts, does not produce any detectable 
minor RNA species during latency in the mouse trigeminal ganglion. Journal of General 
Virology 71, 953-957.
MOCARSKI, E.S. AND ROIZMAN, B. (1981). Site-specific inversion sequence of the 
herpes simplex virus genome: Domain and structural features. Proceedings of the National 
Academy of Sciences USA.IS, 7047-7051.
MOCARSKI, E.S. AND ROIZMAN, B. (1982). Structure and role of the herpes simplex 
virus DNA termini in inversion, circularization and generation of virion DNA. Cell 31, 89- 
97.
MOCARSKI, E.S., POST, L. AND ROIZMAN, B. (1980). Molecular engineering of the 
herpes simplex virus genome: insertion of a second L-S junction into the genome causes 
additional genome inversions. Cell 22, 243-255.
MORGAN, C., ROSE, H.M. AND MEDNIS, B. (1968). Electron microscopy of herpes 
simplex virus. I. Entry. Journal of Virology 2, 507-516.
MOYAL, M., BERKOWrrZ, C., ROSEN-WOLFF, A., DARAI, G. AND BECKER, Y. 
(1992). Mutation in the UL53 gene of HSV-1 abolish virus neurovirulence to mice by the 
intracerebral route of infection. Virus Research 26, 99-112.
MURCHIE, M. AND McGEOCH, D.J. (1982). DNA sequence analysis of an immediate- 
early gene region of the herpes simplex virus type 1 genome (map coordinates 0.950- 
0.978). Journal of General Virology 62, 1-15.
NAHMIAS, A.J. AND DOWDLE, W. (1968). Antigenic and biologic differences in 
herpesviruses honinis. Progress in Medical Virology 10, 110-159.
NAHMIAS, A.J., JOREY, W.E., NAIB, Z.M., LUCE, C.L. AND DUFFEY, A. (1970). 
Antibodies to herpesvirus hominis type 1 and 2 in humans. American Journal o f 
Epidemiology 92, 539-546.
NASH, A.A., LEUNG, K.N. AND WILDY, P. (1985). The T-cell mediated immune 
response of mice to herpes simplex virus. In: B. Roizman and C. Lopez (Eds.), The 
Herpesviruses. Plenum Press, N.Y..
NAVARRO, D., PAZ, P. AND PEREIRA, L. (1992). Domains of herpes simplex virus 1 
glycoprotein B that function in virus penetration, cell-to-cell spread and fusion. Virology 
186, 99-112.
References
NEWCOMB, W.W. AND BROWN, J.C. (1989). Use of Ar+ plasma etching to localize 
structural proteins in the capsid of herpes simplex virus type 1. Journal of Virology 63, 
4697-4702.
NEWCOMB, W.W. AND BROWN, J.C. (1991). Structure of the herpes simplex virus 
capsid: effects of extraction with guanidine hydrochloride and partial reconstitution of 
extracted capsids. Journal of Virology 65, 613-620.
NU, S., MORGAN, C. AND ROSE, H.M. (1968). Electron microscopy of herpes simplex 
virus. II. Sequence of development. Journal o f Virology 2, 517-536.
O'HARE, P. AND GODING, C.R. (1988). Herpes simplex virus regulatory elements and 
the immunoglobulin octamer domain bind a common factor and are both targets for virion 
transactivation. Cell 52, 435^445.
O’HARE, P. AND HAYWARD, G.S. (1985). Evidence for a direct role for both the 
175,000 and 110,000- molecular weight immediate early proteins of herpes simplex virus 
in the transactivation of delayed early proteins. Journal of Virology 53, 751-760.
OAKES, J.E., GRAY, W.L. AND LAUSAN, R.N. (1986). Herpes simplex virus type 1 
DNA sequences which direct spread of virus from cornea to central nervous system. 
Virology 150, 513-517.
OLIVO, P.D., NELSON, N.J. AND CHALLBERG, M.D. (1989). Herpes simplex virus 
type 1 gene products required for DNA replication: Identification and overexpression. 
Journal of Virology 63, 196-204.
OROSKAR, A.A. AND READ, S. (1987). A mutant of herpes simplex virus type 1 
exhibits increased stability of immediate-early (alpha) mRNAs. Journal of Virology 61, 
604-606.
OROSKAR, A.A. AND READ, S. (1989). Control of mRNA stability by the virion host 
shutoff function of herpes simplex virus. Journal of Virology 63, 1897-1906.
OVERTON, H., McMILLAN, D., HOPE, L., RITCHIE, A.J. AND WONG-KAI-IN, P. 
(1992). Herpes simplex virus type 1 gene UL13 encodes a phosphoprotein that is a 
component of the virion. Virology 190, 184-192.
OVERTON, H., McMILLAN, D., HOPE, L. AND WONG-KAI-IN, P. (1994). Production 
of host shutoff-defective mutants of herpes simplex virus type 1 by inactivation of the 
UL13 gene. Virology 202, 97-106.
References
PARRIS, D.S., CROSS, A., HAARR, L., ORR, A., FRAME, M.C., MURPHY, M., 
McGEOCH, D.J. AND MARSDEN, H.S. (1988). Identification of the gene encoding the 
65-kilodalton DNA-binding protein of herpes simplex virus type 1. Journal o f Virology 
62:,818-825.
PATEL, A H. AND MACLEAN, J.B. (1995). The product of the UL6 gene of herpes 
simplex virus type 1 is associated with virus capsids. Virology 206,465-478.
PERNG, G-C, DUNKEL, E.C., GEARY, P.A., SLANINA, S.M., GHIASI, H., 
NESBURN, A.B. AND WECHSLER, S.L. (1994). The latency-associated transcript gene 
of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous 
reactivation of HSV-1 from latency. Journal o f Virology 68, 8045-8055.
PERRY, L.J. AND McGEOCH, D.J. (1988). The DNA sequences of the long repeat 
region and adjoining parts of the long unique region in the genome of herpes simplex virus 
type 1. Journal General Virology 69, 2831-2846.
PERTUISET , B., BOCCARA, M., CEBRIAN, J., BERTHELOT, N., CHOUSTERMAN,
S., PUVION-DUTILLEUL, F„ SISMAN, J. AND SHELDRICK, P. (1989). Physical 
mapping and nucleotide sequence of a herpes simplex virus type 1 gene required for capsid 
assembly. Journal of Virology 63, 2169-2179.
POFFENBERGER, K.L., TAB ARES, E. AND ROIZMAN, B. (1983). Characterisation of 
a viable, non-inverting herpes simplex virus 1 genome derived by insertion of sequences at 
the L-S component junction. Proceedings of the National Academy o f Sciences USA. 80, 
2690-2694.
POGUE-GEILE, K.L. AND SPEAR, P.G. (1987). The single base pair substitution 
responsible for the syn phenotype of herpes simplex virus type 1 strain MP. Virology 157, 
67-74.
POWELL, K.L. AND PURIFOY, D.J.M. (1977). Nonstructural proteins of herpes simplex 
virus. I. Purification of the induced DNA polymerase. Journal o f Virology 24, 618-626.
PRESTON, C M., FRAME, M.C. AND CAMPBELL, M.M. (1988). A complex formed 
between cell components and an HSV structural polypeptide binds to a viral immediate 
early gene regulatory DNA sequence. Cell 52, 425-434.
PRESTON, V.G., COATES, J.A.V. AND RIXON, F.J. (1983). Identification and 
characterisation of a herpes simplex virus gene product required for encapsidation of virus 
DNA. Journal of Virology 45, 1056-1064.
References
PURIFOY, D.J.M. AND POWELL, K.L. (1976) DNA-binding proteins induced by herpes 
simplex virus type 2 in HEp-2 cells. Journal o f Virology 19, 717-731.
PURVES, F.C., OGLE, W.O. AND ROIZMAN, B. (1993). Processing of the herpes 
simplex virus regulatory protein a22 mediated by the UL13 protein kinase determines the 
accumulation of a subset of a  and y mRNAs and proteins in infected cells. Proceedings of 
the National Academy of Sciences USA. 90, 6701-6705.
PYLES, R.B., SAWTELL, N. M. AND THOMPSON, R.L. (1992). Herpes simplex virus 
type 1 dUTPase mutants are attenuated for neurovirulence, neuroinvasiveness and 
reactivation from latency. Journal ofViroogy 66, 6706-6713.
QUINLAN, M.P. AND KNIPE, D.M. (1985). Stimulation of expression of a herpes 
simplex virus DNA-binding protein by two viral functions. Molecular and Cellular 
Biology 5,957-963.
QUINLAN, M.P., CHEN, L.B. AND KNIPE, D.M. (1984). The intranuclear location of a 
herpes simplex virus DNA-binding protein is determined by the status of viral DNA 
replication. Cell 36, 857-868.
RAIPH, W.M., CABATINGAN, M.S. AND SCHAFFER, P.A. (1994). Induction of 
herpes simplex virus type 1 immediate-early gene expression by a cellular activity 
expressed in Vero and NB41A3 cells after growth arrest-release. Journal of Virology 68, 
6871-6882.
RAMASWAMY, R. AND HOLLAND, T.C. (1992). In vitro characterisation of the HSV- 
1 UL53 gene product. Virology 186, 579-587.
READ, G.S. AND FRENKEL, N. (1983). Herpes simplex virus mutants defective in the 
virion-associated shutoff of host polypeptide synthesis and exhibiting abnormal synthesis 
of a  (immediate early) viral polypeptides. Journal of Virology 46, 498-512.
REED, L.J. AND MEUNCH, H. (1938). A simple method of estimating fifty percent 
endpoints. American Journal of Hygiene 27, 493-497.
RIGBY, P.W.J., DIECKMAN, M., RHODES, C. AND BERG, P. (1977). Labelling 
deoxyribonucleic acid to a high specific activity in vitro by nick translation with DNA 
polymerase I. Journal of Molecular Biology 113, 237-251
RIVERA-GONZALEZ, R., IMBALZANO, A.N., GU, B. AND DELUCA, N.A. (1994). 
The role of ICP4 repressor activity in temporal expression of the IE-3 and latency- 
associated transcript promoters during HSV-1 infection. Virology 202, 550-564.
References
RIXON, FJ. (1993). Structure and assembly of herpesviruses. Seminars in Virology 4: 
135-144.
RIXON, F.J. AND CLEMENTS J.B. (1982). Detailed structural analysis of 2 spliced 
HSV-1 immediate early RNAs. Nucleic Acids Research 10, 2241-2256.
RIXON, F.J., ATKINSON, M.A. AND HAY, J. (1983). Intranuclear distribution of herpes 
simplex virus type 2 DNA synthesis: examination by light and electron microscopy. 
Journal o f General Virology 64, 2087-2092.
RIXON, F.J., CROSS, A.M., ADDISON, C. AND PRESTON, V.G. (1988). The products 
of herpes simplex virus type 1 gene UL26 which are involved in DNA packaging are 
strongly associated with empty but not with full capsids. Journal o f General Virology 69, 
2879-2891.
ROBERTS, M.S., BOUNDY, A., O'HARE, P., PIZZORNO, M.C., CIUFO, D.M AND 
HAYWARD, G.S. (1988). Direct correlation between a negative autoregulatory response 
element at the cap site of the herpes simplex virus type 1 IE175 (a4) promoter and a 
specific binding site for the IE175 (ICP4) protein. Journal of Virology 62, 4307-4320.
ROBERTSON, L.M., MACLEAN, A.R. AND BROWN, S.M. (1992). Peripheral 
replication and latency reactivation kinetics of the non-neurovirulent herpes simplex virus 
type 1 variant 1716. Journal of General Virology 73,967-970.
ROCK, D.L. AND FRASER, N.W. (1983). Detection of HSV-1 genome in central nervous 
system of latently infected mice. Nature 302, 523-525.
ROCK, D.L. AND FRASER, N.W. (1985). Latent herpes simplex virus type 1 DNA 
contains two copies of the virion DNA joint region. Journal o f Virology 55, 849-852.
ROCK, D.L., NESBURN, A.B., GHIASI, H., ONG, J., LEWIS, T.L., LOKENSGARD, 
J R. AND WECHSLER, S.L. (1987). Detection of latency related viral RNAs in trigeminal 
ganglia of rabbits latently infected with herpes simplex virus type 1. Journal of Virology 
61, 3820-3826.
RODGERS, E.G. (1973). Infection, haemorrhage and death of chick embryos after 
inoculation of herpes simplex virus type 2 on to the chorioallantoic membrane. Journal of 
Virology 21, 187-191.
ROIZMAN, B. (1979). The structure and isomerization of herpes simplex virus genomes. 
Cell 16,48W 94.
References
ROIZMAN, B. AND FURLONG, D. (1974). The replication of herpes-viruses. In: H. 
Fraenkel-Conrat and R.R. Wagner (Eds.), Comprehensive Virology, Vol.3. Plenum Press, 
N.Y. and London.
ROIZMAN, B. AND ROANE, P.R. (1964). The multiplication of herpes simplex virus, n. 
The relation between protein synthesis and the duplication of viral DNA in infected HEp-2 
cells. Virology 22, 262-269.
ROIZMAN, B. AND SEARS, A.E. (1987). An enquiry in to the mechanisms of herpes 
simplex virus latency. Annual Review of Microbiology 41, 543-571.
ROIZMAN, B AND SEARS, A.E. (1990). Herpes simplex virus and their replication. In:
B.N. Fields, D.M. Knipe, R.M. Chanock, M.S. Hirsch, J.L. Melnick, T.P. Monath and B. 
Roizman (Eds.), Virology (2nd ed.), pp.1796-1828. Raven Press, New York.
ROIZMAN, B., AURELIAN, L. AND ROANE, P.R. (1963). The multiplication of herpes 
simplex virus. I. The programming of viral DNA duplication in HEp-2 cells. Virology 21, 
482-498.
ROIZMAN, B., BORMAN, G.S. AND KAMALI-ROUSTA, M. (1965). Macromolecular 
synthesis in cells infected with herpes simplex virus. Nature 206, 1374-1375
ROLLER, R.J. AND ROIZMAN, B. (1992). The herpes simplex virus 1 RNA binding 
protein US 11 is a virion component and associates with ribosomal 60S subunits. Journal 
of Virology 66, 3624-3632.
ROOP, C., HUTCHINSON, L. AND JOHNSON, D C. (1993). A mutant herpes simplex 
virus type 1 unable to express glycoprotein L can not enter cells, and its particles lack 
glycoprotein H. Journal of Virology 67, 2285-2297.
ROSEN, A., GELDERBLOM, H. AND DARAI, G. (1985). Transduction of virulence in 
herpes simplex virus type 1 from a pathogenic to an apathogenic strain by a cloned viral 
DNA fragment. Medical Microbiology and Immunology 173, 257-278.
ROSEN, A., ERNST, F., KOCH, H.G., GELDERBLOM, H., DARAI, G., HADAR, J., 
TABOR, E., BEN-HUR, T. AND BECKER, Y. (1986). Replacement of the deletion in the 
genonme (0.726-0.789mu) of avirulent HSV-1 HFEM using cloned Mlul DNA fragment 
(0.7615-0.769mu) of virulent HSV-1 F leads to generation of virulent intratypic 
reconbinant. Virus Research 5, 157-175.
References
ROSEN-WOLFF, A. AND DARAI, G. (1985). Mapping of the deletion in the genome of 
HSV-1 strain HFEM responsible for its avirulent phenotype. Medical Microbiology and 
Immunology 113, 329-343.
ROSEN-WOLFF, A. AND DARAI, G. (1991). Identification and mapping of the UL56 
gene transcript of herpes simplex virus type 1. Virus Research 19, 115-126.
ROTT, R. (1979). Molecular basis of infectivity and pathogenecity of myxovirus. Archives 
o f Virology 59, 285-298.
ROZHON, E.J., GENSEMER, P., SHOPE, R.E. AND BISHOP, D H L. (1981). 
Attenuation of virulence of a bunyavirus involving an L RNA defect and isolation of 
LAC/SSH/LAC and LAC/SSH/SSH reassortants. Virology 111, 125-138.
RUBENSTEIN, A., GRAVELL, M. AND DAELINGTON, R. (1972). Protein kinase in 
enveloped herpes simplex virions. Virology 50, 287-290.
RUYECHAN, W.T. AND WEIR, A C. (1984). Interaction with nucleic acids and 
stimulation of the viral DNA polymerase by the herpes simplex virus type 1 major DNA- 
binding protein. Journal o f Virology 52,727-733.
SABIN, A.B. (1955). Characteristics of genetic potentialities of experimentally produced 
and naturally occuring variants of poliomyelities virus. Annals o f the New York Acadamy 
of Sciences 61, 924-939.
SACKS, W.R., GREENE, C.C., ASCHMAN, D P. AND SCHAFFER, P.A. (1985). 
Herpes simplex virus type 1 ICP27 is an essential regulatory protein. Journal of Virology 
55,796-805.
SAIKI, R.K., GELFAND, D.H., STOFFEL, S., SCHARE, S.L, HIGUCHI, R. , HORN, 
G.T., MULLIS, K.B. AND ERLICH, H.A. (1988). Primer-directed enzymatic 
amplification of DNA with a thermostable DNA polymerase. Science 239, 487-491.
SAMBROOK,!., FRITSCH, E.F. AND MANIATIS, T. (1989). Molecular Cloning: A 
laboratory Manual. 2nd Ed. Cold Spring Harbor Laboratory Press. U.S.A.
SAWTELL, N.M. AND THOMPSON, R.L. (1992a). Rapid in vivo reactivation of herpes 
simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. 
Journal of Virology 66, 2150-2156.
References
SAWTELL, N.M. AND THOMPSIN, R.L. (1992b). Herpes simplex virus type 1 latency- 
associated transcription unit promotes anatomical site-dependent establishment and 
reactivation from latency. Journal of Virology 66, 2157-2169.
SCHLITT, M., LAKEMAN, A.D., WILSON, E.R., TO, A., ASCOFF, R.W., HARSH, 
G.R. AND WHITLEY, R.J. (1986). A rabbit model of focal herpes simplex encephalitis. 
Journal o f Infectious Diseases 153,732-735.
SCHMITZ, J.B., ALBRIGHT, A.G., KINCHINGTON, P.R. AND JENKINS, F.J. (1995). 
The UL37 protein of herpes simplex virus type 1 is associated with the tegument of 
purified virions. Virology 206,1055-1065.
SCHRAG, J.D., PRASAD, B.V.V., RIXON, F.J. AND CHIU, W. (1989). Three- 
dimensional structure of the HSV-1 nucleocapsid. Cell 56, 651-660.
SCRIBA, M. AND TATZBER, F. (1981). Pathogenesis of herpes simplex virus infections 
in guinea pigs. Infection and Immunity 34,655-661.
SEARS, A.E. AND ROIZMAN, B. (1990). Amplification by host cell factors of a 
sequence contained within the herpes simplex virus 1 genome. Proceedings of the National 
Academy of Sciences, USA. 87, 9441-9444.
SEARS, A.E., HALLIBURTON, I.W., MEIGNIER, B., SILVER, S. AND ROIZMAN, B. 
(1985). Herpes simplex virus 1 mutant deleted in the a22 gene: Growth and gene 
expression in permissive and restricted cells and establishment of latency. Journal of 
Virology 55, 338-346.
SEARS, A.E., HUKKANEN, V., LABOW, M.A., LEVINE, A,J. AND ROIZMAN, B.
(1991). Expression of the herpes simplex virus 1 a  transinducing factor (VP 16) does not 
induce reactivation of latent virus or prevent the establishment of latency in mice. Journal 
of Virology 65, 2929-2935.
SEKULOVICH, R.E., LEARY, K. AND SANDRI-GOLDIN, R.M. (1988). The herpes 
simplex virus type 1 alpha protein ICP27 can act as a trans-repressor or trans-activator in 
combination with ICP4 and ICPO. Journal of Virology 62, 4510-4522.
SHELDRICK, P. AND BERTHELOT, N. (1974). Inverted repetitions in the chromosome 
of herpes simplex virus. Cold Spring Harbor Symposia on Quantitative Biology Vol. 39 
part 2.
SHERMAN, G. AND BACHENHIMER, S.L. (1988). Characterisation of intranuclear 
capsids made by ts morphogenic mutants of HSV-1. Virology 163,471-480.
References
SHIEH, M-T. AND SPEAR, P.G. (1994). Herpesvirus-induced cell fusion that is 
dependent on cell surface heparan sulfate or soluble heparin. Journal of Virology 68, 1224- 
1228.
SHIEH, M-T., WUDUNN, D., MONTGOMERY, R.I., ESKO, J.D. AND SPEAR, P.G.
(1992). Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. 
Journal of Cell Biology 116, 1273-1281.
SKARE, J. AND SUMMERS, W.C. (1977). Structure and function of herpesvirus 
genomes. II. EcoBl, Xbal and HindSi endonuclease cleavage sites on herpes virus type 1 
DNA. Virology 76, 581-595.
SKINNER, M.A., RACANIELLO, V.R., DUNN,G., COOPER,J., MINOR, P.D. AND 
ALMOND, J.W. (1989). New model for the secondary structure of the 5' non-coding RNA 
of poliovirus is supported by biochemical and genetic data that also show that RNA 
secondary structure is important in neurovirulence. Journal of Molecular Biology 261, 
379-392.
SMIBERT, C.A., JOHNSON, D C. AND SMILEY, J.R. (1992). Identification and 
characterisation of the virion-induced host shutoff product of herpes simplex virus gene 
UL41. Journal of General Virology 73, 467—470.
SMIBERT, C.A., POPOVA, B., XIAO, P., CAPONE, J.P. AND SMILEY, J.R. (1994). 
Herpes simplex virus VP 16 forms a complex with the virion host shutoff protein vhs. 
Journal of virology 68, 2339-2346.
SMITH, I.W., PEUTHERER, J.F. AND ROBERTSON, D.H. (1977). Virological studies 
in genital herpes. Lancet 2, 1089.
SMITH, R.L., PIZER, L.I., JOHNSON, E.M. AND WILCOX, C.L. (1992). Activation of 
second-messenger pathways reactivates latent herpes simplex virus in neuronal culture. 
Virology 188, 311-318.
SPAETE, R.R. AND FRENKEL, N. (1982). The herpes simplex virus amplicon: a new 
eucaryotic defective-virus cloning-amplifying vector. Cell 30, 295-304.
SPEAR, P.G. (1976). Membrane proteins specified by herpes simplex viruses. I. 
Identification of four glycoprotein precursors and their products in type 1 infected cells. 
Journal of Virology 17, 991-1008.
References
SPEAR, P.G., KILLER, J.M. AND ROIZMAN, B. (1970). The proteins specified by 
herpes simplex virus. II. Viral glycoproteins associated with cellular membranes. Journal 
of Virology S, 123-131.
SPECK, P.G. AND SIMMONS, A. (1991). Divergent molecular pathways of productive 
and latent infection with a virulent strain of herpes simplex virus type 1. Journal o f 
Virology 65,4001-4005.
SPIVACK, J.G. AND FRASER, N.W. (1987). Detection of herpes simplex virus type 1 
transcripts during latent infection in mice. Journal of Virology 61, 3841-3847.
SPIVACK, J.G., WOODS, G.M. AND FRASER, N.W. (1991). Identification of a novel 
latency-specific splice donor signal within the herpes simplex virus type 1 2.0-kilobase 
latency-associated transcript (LAT): Translation inhibition of LAT open reading frames by 
the intron within the 2.0-kilobase. Journal o f Virology 65,6800-6810.
SPIVACK, J.G., FAREED, M.U, VALY-NAGY, T., NASH, T.C., O’KEEFE, J.S, 
GERSSER, R.M., McKIE, E.A., MACLEAN, A.R., FRASER, N.W. AND BROWN, S.M. 
(1995). Replication, establishment of latent infection, expression of the latency-associated 
transcripts and explant reactivation of herpes simplex virus type yi 34.5 mutants in a 
mouse eye model. Journal of General Virology 76, 321-332.
SPRECHER, E. AND BECKER, Y. (1986). Skin Langerhan’s play an essential role in the 
defence against herpes simplex virus type 1 infection. Archives of Virology 91, 341-349.
SPRECHER, E. AND BECKER, Y. (1987). Herpes simplex virus type 1 pathogenicity in 
footpad and ear skin of mice depends on Langerhan’s cell density, mouse genetics and 
virus strain. Journal o f Virology 61, 2515-2522.
SPRUANCE, S T., OVERALL, J.C. AND KERN, E.R. (1977). The natural history of 
recurrent herpes simplex labialis-implication for antiviral therapy. New England Journal of 
Medicine 297, 69-75.
STANBERRY, L.R., KIT, S. AND MAYERS M.G. (1985). Thymidine kinase-deficient 
herpes simplex virus type 2 genital infection in guinea pigs. Journal of Virology 55, 322- 
328.
STANNARD, L.M., FULLER, A.O. AND SPEAR, P.G. (1987). Herpes simplex virus 
glycoproteins associated with different morphological entities projecting from the virion 
envelope. Journal of General Virology 6S, 715-725.
References
STEINER, L, SPIVSCK, J.G., LIRETTE, R.P., BROWN, S.M., MACLEAN, A.R., 
SUBAK-SHARPE, J.H. AND FRASER, N.W. (1989). Herpes simplex virus latency- 
associated transcripts are evidently not essential for latent infection. EMBO Journal 8, 
505-511.
STEINER, I., SPIVAK, J.G., DESHMANE, S.L., ACE, C.L, PRESTON, C M. AND 
FRASER, N.W.(1990). A herpes simplex virus type 1 mutant containing a non- 
transinducing Vmw65 protein establishes a latent infection in vivo in the absence of viral 
replication and reactivates efficiently from explanted ganglia. Journal of Virology 64, 
1630-1638.
STERN, S., TANAKA, M. AND HERR, W. (1989). The Oct-1 homeodomain directs 
formation of a multiprotein-DNA complex with the HSV transactivator VP 16. Nature 341, 
624-630.
STEVENS, J.G. AND COOK, M L (1971). Latent herpes simplex virus in spinal ganglia 
of mice. Science 173, 843-847.
STEVENS, LG., WAGNER, E.K., DEVI-RAO, G.B., COOK, M L. AND FELDMAN, 
L.T. (1987). RNA complementary to a herpesvirus a  gene mRNA is prominent in latently 
infected neurons. Science 235, 1056-1059.
STOW, N.D. (1982) Localization of an origin of DNA replication within the TRs/IRs 
repeated region of the herpes simplex virus type 1 genome. EMBO J. 1, 863-867.
STOW, N.D. AND McMONAGLE, E C. (1983). Characterization of the TRs/IRs origin of 
DNA replication of herpes simplex virus type 1. Virology 130, 427-438.
STOW, N.D. AND WILKIE, N.M. (1976). An improved technique for obtaining enhanced 
infectivity with herpes simplex virus type 1 DNA. Journal of General Virology 33: 447- 
458.
STROM, T. AND FRENKEL, N. (1987). Effects of herpes simplex virus on mRNA 
stability. Journal of Virology 61, 2198-2207.
STROOP, W.G., BANKS, M.C., QAVI, H., CHODOSH, J. AND BROWN, S.M. (1994). 
A thymidine kinase deficient HSV-2 strain causes acute keratitis and establishes trigeminal 
ganglionic latency, but poorly reactivates in vivo. Journal of Medical Virology 43, 297- 
309.
SU, L. AND KNIPE, D.M. (1989). Herpes simplex virus a protein ICP27 can inhibit or 
augment viral gene transactivation. Virology 170,496-504.
References
SUBURO, A.M., WHEATLEY, S.C., HORN, D.A., GIBSON, S.J., JAHN,, R., 
FISCHER-COLBRIE, R., WOOD, J.N., LATCHMAN, D.S. AND POLAK, J.M. (1992). 
Intracellular redistribution of neuropeptides and secretory proteins during differentiation of 
neuronal cell lines. Neuroscience 46, 881-889.
SULLIVAN, V. AND SMITH, G.L. (1988). The herpes simplex virus type 1 US7 gene 
product is a 66K glycoprotein and is a target for complement-dependent virus 
neutralization. Journal o f General Virology 69, 859-867.
SULLIVAN-BOLYAI, J., HULL, H.F., WILSON, C. AND COREY, L. (1983). Neonatal 
herpes simplex virus infection in King Country, Washington: Increasing incidence and 
epidemiology correlates. Journal of the American Medical Association 250, 3059-3062.
SUSSMAN, M.D., LU, Z., KUTISH,G., ALFONSO, C.L., ROBERTS, P. AND ROCK, 
D.L. (1992). Identification of an African Swine Fever virus gene with similarity to a 
myeloid differentiation primary response gene and a neuro virulence-associated gene of 
herpes simplex virus. Journal of Virology 66: 5586-5589.
SVENNERHOLM, B., JEANSSON, S., VAHLNE, A. AND LYCKE, E. (1991). 
Involvement of glycoprotein C (gC) in adsorption of herpes simplex virus type 1 (HSV-1) 
to the cell. Archives o f Virology 120, 273-279.
SYDISKIS, R.J. AND ROIZMAN, B. (1966). Polysomes and protein synthesis in cells 
infected with a DNA virus. Science 153, 76-78.
TAHA, M.Y., BROWN, S.M. AND CLEMENTS, G.B. (1988). Neurovirulence of 
individual plaque stocks of herpes simplex virus type 2 strain HG52. Archieves o f Virology 
103, 15-25.
TAHA, M.Y., CLEMENTS, G.B. AND BROWN, S.M. (1989a). A variant of herpes 
simplex virus type 2 strain HG52 with a 1.5kb deletion in R l between 0 to 0.02 and 0.81 
to 0.83 map units is non-neurovirulent for mice. Journal of General Virology 70, 705-716.
TAHA, M.Y., CLEMENTS, G.B. AND BROWN, S.M. (1989b). The herpes simplex virus 
type 2 (HG52) variant JH2604 has a 1488bp deletion which eliminates neurovirulence in 
mice. Journal of General Virology 70, 3073-3078.
TAHA, M.Y., BROWN, S.M., CLEMENTS, G.B. AND GRAHAM, D.I. (1990). The 
JH2604 deletion variant of herpes simplex virus type 2 (HG52) fails to produce necrotizing 
encephalitis following intracranial inoculation of mice. Journal of General Virology 71, 
1597-1601.
References
TENSER, R.B. AND DUNSTAN, M E. (1979). Herpes simplex virus thymidine kinase 
expression in an infection of the trigeminal ganglion. Virology 99, 417-422.
TENSER, R.B., MILLER, R.L. AND RAPP, F. (1979). Trigeminal ganglion infection by 
thymidine kinase-negative mutants of herpes simplex virus. Science 205, 915-918.
TENSER, R.B., RESSEL, S. AND DUNSTAN, M E. (1981). Herpes simplex virus 
thymidine kinase expression in trigeminal ganglia: correction of enzyme activity with 
ganglion virus titre and evidence of in vivo correlation complementation. Virology 112, 
328-341.
TENSER, R.B., HAY, K.A. AND EDRIS, W.A. (1989). Latency-associated transcript but 
not reactivable virus is present in sensory ganglion neurons after inoculation of thymidine 
kinase-negative mutants of herpes simplex virus type 1. Journal o f Virology 63, 2861- 
2865.
THELANDER, L. AND REICHARD, P. (1979). Reduction of ribonucleotides. Annual 
Review of Biochemistry 48, 133-158.
THOMPSON, R.L. AND STEVENS, J.G. (1983a). Replication at the body temperature 
selects a neurovirulence herpes simplex virus type 2. Infection and Immunity 41: 855-857.
THOMPSON, R.L. AND STEVENS, J.G. (1983b). Biological characterization of a herpes 
simplex virus intertypic recombinant which is completely and specifically 
nonneurovirulent. Virology 131, 171-179.
THOMPSON, R.L., WAGNER, E.K. AND STEVENS, J.G. (1983). Physical location of a 
herpes simplex virus type 1 function(s) specifically involved with a 10 million fold 
increase in HSV neuro virulence. Virology 131, 180-192.
THOMPSON, R.L., DEVI-RAO, G.B., STEVENS, J.G. AND WAGNER, E.K. (1985). 
Rescue of a herpes simplex virus type 1 neuro virulence function with a cloned DNA 
fragment. Journal of Virology 55, 504-508.
THOMPSON, R.L., COOK, M L., DEVI-RAO, G.B., WAGNER, E.K. AND STEVENS, 
J.G.(1986). Functional and molecular analyses of the avirulent wild-type herpes simplex 
virus type 1 strain KOS. Journal of Virology 58, 203-211.
THOMPSON, R.L., ROGERS, S.K. AND ZERHUSEN, M.A. (1989). Herpes simplex 
virus neurovirulence and productive infection of neuronal cells is associated with a 
function which maps between 0.82 and 0.832 map units on the HSV-1 genome. Virology 
172, 435-450.
References
TIMBURY, M.C. 1971. Temperature-sensitive mutants of herpes simplex virus type 2. 
Journal o f General Virology 13, 373-376.
TODARO, G.J. AND GREEN, H. (1963). Quantitative studies of the growth of mouse 
embryo cells in culture and their development in to established cell lines. Journal of Cell 
Biology 17, 299-313.
TOGNON, M., FURLONG, D., CONLEY, A.J. AND ROIZMAN, B. (1981). Molecular 
genetics of herpes simplex virus. V. Characterisation of a mutant defective in: ability to 
form plaques at low temperatures and in a viral function which prevents accumulation of 
coreless capsids at nuclear pores late in infection. Journal o f Virology 40, 870-880.
TROUSDALE, M.D., STEINER, I., SPIVACK, J.G., DESHMANE, S.L., BROWN, S.M.
MACLEAN, A.R., SUBAK-SHARPE, J.H. AND FRASER, N.W. (1991). In 
vivo and in vitro reactivation impairment of a herpes simplex virus type 1 latency- 
associated transcript variant in a rabbit eye model. Journal of Virology 65, 6989-6993.
TRYBALA, E., BERGSTROM, T., SVENNERHOLM, B., JEANSSON, S., GLORIOSO, 
J.C. AND OLOFSSON, S. (1994). Localisation of a functional site on herpes simplex 
virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. Journal of 
Virology 75, 743-752.
TURK, S R., KIK, N.A., BIRCH, G.M., CHIEGO, D.J. AND SHIPMAN, C. (1989). 
Herpes simplex virus type 1 ribonucleotide reductase Null mutants induce lesions in 
guinea pigs. Virology 173, 733-735.
UNDERWOOD, G.E. AND WEED, S.D. (1974). Recurrent cutaneous herpes simplex in 
hairless mice. Infection and Immunity 10, 471.
VALYI-NAGY, T., DESHMANE, S.L., SPIVACK., J.G., STEINER, I., ACE, C.L, 
PRESTON, C M. AND FRASER, N.W. (1991). Investigation of herpes simplex virus type 
1 (HSV-1) gene expression and DNA synthesis during the establishment of latent infection 
by an HSV-1 mutant, m l814, that does not replicate in mouse trigeminal ganglia. Journal 
of General Virology 72, 641-649.
VARMUZA, S.L. AND SMILEY, J.R. (1985). Signals for site-specific cleavage of HSV 
DNA: maturation involves two separate cleavage events at sites distal to the recognition 
sequences. Cell 41, 793-802.
VLAZNY, D A. AND FRENKEL, N. (1981). Replication of herpes simplex virus DNA: 
Localization of replication recognition signals within defective virus genomes. 
Proceedings o f the National Academy of Sciences, US A.IS, 742-746.
References
VLAZNY, D.A., KWONG, A. AND FRENKEL, N. (1982). Site-specific cleavage 
packaging of herpes simplex virus DNA and the selective maturation of nucleocapsids 
containing full-length viral DNA. Proceedings of the National Academy of Sciences USA. 
79, 1423-1427.
WADSWORTH, S., JACOB, R.J. AND ROIZMAN, B. (1975). Anatomy of herpes 
simplex virus DNA. II. size, composition and arrangement of inverted terminal repetitions. 
Journal of Virology 15, 1487-1497.
WAGNER, E.K. (1985). Individual HSV transcripts. In ‘The Herpesviruses”, Vol. 3, p. 
45-104. Roizman, B. (Ed), Plenum Publishing Corp., New York.
WAGNER, E.K. AND ROIZMAN, B. (1969). RNA synthesis in cells infected with herpes 
simplex virus. I. The patterns of RNA synthesis in productively infected cells. Journal of 
Virology 4, 36-46.
WAGNER, E.K., DEVI-RAO, G.B., FELDMAN, L.T., DOBSON, A T., ZHANG, Y.F., 
FLANAGAN, W.M. AND STEVENS, J.G. (1988). Physical characterisation of the herpes 
simplex virus latency-associated transcript in neurons. Journal o f Virology 62, 1194-1202.
WAGNER, M.J. AND SUMMERS, W.C. (1978). Structure of the joint region and the 
termini of the DNA of herpes simplex virus type 1. Journal of Virology 27, 374-387.
WATSON, R.J., SULLIVAN, M. AND VANDE WOUDE, G.F. (1981). Structures of 2 
spliced herpes simplex virus type 1 immediate early mRNAs which map at the junctions of 
the unique and reiterated regions of the virus DNA S component. Journal o f Virology 37, 
431-444.
WECHSLER, S.L., NESBURN, A.B., ZWAAGSTRA, J. AND GHIASI, H. (1989). 
Sequence of the latency-related gene of herpes simplex virus type 1. Virology 168, 168- 
172.
WELLER, S.K., SPADARO, A., SCHAFFER, J.E., MURRAY, A.W., MAX AM, A. M. 
AND SCHAFFER, P.A. (1985). Cloning, sequencing, and functional analysis of onL, a 
herpes simplex virus type 1 origin of DNA synthesis. Molecular and Cellular Biology 5, 
930-942.
WELLER, S.K., CARMICHAEL, E.P., ASCHMAN, D.P., GOLDSTEIN, D.J. AND 
SCHAFFER, P.A. (1987). Genetic and phenotypic characterisation of mutants in four 
essential genes that map to the left half of HSV-1 UL DNA. Virology 161, 1198-1210.
References
WHEATLEY, S.C., DENT, C.L., WOOD, J.N. AND LATCHMAN, D.S. (1991). A 
cellular factor binding to the TAATGARAAT DNA sequence prevents the expression of 
the HSV immediate-early genes following infection of nonpermissive cell lines derived 
from dorsal root ganglion neurons. Experimental Cell Research 194, 78-82.
WHEATLEY, S.C., DENT, C.L., WOOD, J.N. AND LATCHMAN, D.S. (1992). 
Elevation of cAMP levels in cell lines derived from latently infectable sensory neurons 
increases their permissivity for herpes virus infection by activating the viral im mediate- 
early 1 gene promoter. Molecular Brain Research 12,149-154.
WHITLEY, R.J. (1990). Herpes simplex viruses. In: B.N, Fields, D.M. Knipe, R.m. 
Chanock, M.S. Hirsch, J.L. Melnick, T.P. Monath and B. Roizman ÇEôls.),Virology (2nd 
ed.), pp. 1844-1877. Raven Press, New York.
WHITLEY, R.J., ARVIN, A., PROBER, C., LAWRENCE, C., BUCHETT, S., POLTKIN,
S., STARR, S.E., JACOBS, R.F., POWELL, D.A., NAHMIAS, A.J., SUMAYA, C., 
EDWARDS, C., ALFORD, C., CADDELL, G. AND SOONG, S.J. (1991). Predictors of 
morbidity and mortality in neonates with herpes simplex virus infections. New England 
Journal o f Medicine 324,450-454.
WHITTON, J.L. AND CLEMENTS, J.B. (1984). Replication origins and a sequence 
involved in coordinate induction of the immediate-early gene family are conserved in an 
intergenic region of herpes simplex virus. Nucleic Acids Research 12, 2061-2079.
WIEDBRAUK, D.L. AND JOHNSTON, S.G. (1993). Manual o f Clinical Virology, pp. 
109-120. Raven Press, New York.
WILCOX, C.L. AND JOHNSON, E.M. (1987). Nerve growth factor deprivation results in 
the reactivation of latent herpes simplex virus in vitro. Journal o f Virology 61, 2311-2315.
WILCOX, C.L. AND JOHNSON, E.M. (1988). Characterisation of nerve growth factor- 
dependent herpes simplex virus latency in neurons in vitro. Journal o f Virology 62, 393- 
399.
WILDY, P., RUSSELL, W.C. AND HORNE, R.W. (1960). The morphology of herpes 
virus. Virology 12, 204-222.
WILKIE, N.M. (1973). The synthesis and substructure of herpesvirus DNA. The 
distribution of alkali labile single-strand interruptions in HSV-1 DNA. Journal of General 
Virology 21,453-467.
References
WILKIE, N.M. (1976). Physical maps for herpes simplex virus type 1 DNA for restriction 
endonucleases Hind III, Hpa I, and Xba I Journal of Virology 20, 222-233.
WILKIE, N.M. AND CORTINT, R. (1976). Sequence arrangement in herpes simplex virus 
type 1 DNA: identification of terminal fragments in restriction endonuclease digests and 
evidence for inversions in redundant and unique sequences. Journal o f Virology 20, 211- 
221 .
WILLIAMS, M.V. (1988). Herpes simplex virus induced dUTPase: target site for antiviral 
chemotherapy. Virology 166, 262-264.
WILLIAMS, M.V. AND PARRIS, D.S. (1987). Characterisation of a herpes simplex virus 
type 2 deoxyuridine triphosphate nucleotidohydrolase and mapping of a gene conferring 
type specificity for the enzyme. Virology 156, 282-292.
WIRTH, T., PRIESS, A., ANNWEILER, A., ZWILLING, S. AND OELER, B. (1991). 
Multiple Oct2 isoforms are generated by alternative splicing. Nucleic Acids Research 19, 
43-51.
WOHLRAB*, F. AND FRANCKE, B. (1980). Deoxyribopyrimidine triphosphatase 
activity specific for cells infected with herpes simplex virus type 1. Proceedings o f the 
National Academy of Sciences, USA. 77, 1872-1876.
WOOD, J.N., LILLYCROP, K.A., DENT, C.L., NINKINA, N.N., BEECH, M.M., 
WILLOUGHBY, J.J., WINTER, J. AND LATCHMAN, D.S. (1992). Regulation of 
expression of the neuronal POU protein Oct-2 by nerve growth factor. Journal of 
Biological Chemistry 2^1 ,17787-17791.
WORRAD, D.M. AND CAR ADONNA, S. (1988). Identification of the coding sequence 
for herpes simplex virus uracil-DNA glycosylase. Journal of Virology 62, 4774-4777.
WU, C.A., NELSON, N.J., McGEOCH, D.J. AND CHALLBERG, M.D. (1988). 
Identification of herpes simplex virus type 1 genes required for origin-dependent DNA 
synthesis. Journal of Virology 62,435—443.
WUDUNN, D. AND SPEAR, P.G. (1989). Initial interaction of herpes simplex virus with 
cells is binding to heparan sulfate. Journal of Virology 63, 52-58.
XIAO, P. AND CAPONE, J.P. (1990). A cellular factor binds to the herpes simplex virus 
type 1 transactivator Vmw65 and is required for Vmw65-dependent protein-DNA complex 
assembly with Oct-1. Molecular and cellular Biology 10,4974-4977.
References
YAMADA, Y., KIMURA, H., MORISHIMA, T., DAIKOKU, T., MANO, K. AND 
NISHIYAMA, Y. (1991). The pathogenicity of ribonucleotide reductase-null mutants of 
herpes simplex virus type 1 in mice. Journal o f Infectious Diseases 164, 1091-1097.
Y AO, F. AND COURTNEY, R.J. (1989). A major transcriptional regulatory protein 
(ICP4) of herpes simplex virus type 1 is associated with purified virions. Journal of 
Virology 63, 3338-3344.
Y AO, F. AND Schaffer, P.A. (1994). Physical interaction between the herpes simplex 
virus type 1 immediate-early regulatory proteins ICPO and ICP4. Journal o f Virology 68, 
8158-8168.
YEH, L. AND SCHAFFER, P.A. (1993). A novel class of transcripts expressed with late 
kinetics in the absence of ICP4 spans the junction between the long and short segments of 
the herpes simplex virus type 1 genome. Journal of Virology 67, 7373-7382.
YUHASZ, S.A. AND STEVENS, J.G. (1993). Glycoprotein B is a specific determinant of 
herpes simplex virus type 1 neurovirulence. Journal of Virology 67, 5948-5954.
ZAWATZKY, R., ENGLER, H. AND KIRCHNER, H. (1982). Experimental infection of 
inbred mice with herpes simplex virus. III. Comparison between newborn and adult 
C57BL/6 mice. Journal of General Virology 60, 25-29.
ZHANG, Y., SIRKO, D A. AND McKNIGHT, J.L.C. (1991). Role of the herpes simplex 
virus type 1 UL46 and UL47 in a  TIF-mediated transcriptional induction: Characterisation 
of three viral deletion mutants. Journal of Virology 65, 829-841.
ZHOU, Z.H., PRASAD, B.V.V, JAKANA, J., RIXON, F.J. AND CHIU, W. (1994). 
Protein subunit structures in the herpes simplex virus A-capsid determined from 400K 
spot-scan electron cryomicroscopy. Journal of Molecular Biology 244, 456-469.
ZHU, X., CHEN, J., YOUNG, C.S.H. AND SILVERSTEIN, S. (1990). Reactivation of 
latent herpes simplex virus by adenovirus recombinants encoding mutant IE-0 gene 
products. Journal of Virology 64,4489-4498.
ZWAAGSTRA, J., GHIASI, H., NESBURN, A.B. AND WECHSLER, S.L. (1989). In 
vitro promoter activity associated with the latency-associated transcript gene of herpes 
simplex virus type 1. Journal of General Virology 70, 2163-2169.
ZWAAGSTRA, J., GHIASI, H., SLANINA, S.M., NESBURN, A.B., WHEATLEY, S.C., 
LILLYCROP, K., WOOD, J., LATCHMAN, D.S., PATEL, K., AND WECHSLER, S.L. 
(1990). Activity of herpes simplex virus Type 1 latency-associated transcript (LAT)
References
promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT 
transcript. Journal o f Virology 64, 5019-5028.
ZWAAGSTRA, J.C., GHIASI, H., NESBURN, A.B. AND WECHSLER, S.L. (1991). 
Identification of a major regulatory sequence in the latency associated transcript (LAT) 
promoter of herpes simplex virus type 1 (HSV-1). Virology 182, 287-297.
G L A S G O W
UNr'ERsnr
U B k A k Y
